Datasets:
bio-datasets
/
bigbio-ner-merged

Dataset card Data Studio Files
xet
Community
answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
list
text
stringlengths
5
72.4k
tokens
list
types
list
migraine, flunarizine, acetylsalicylic acid, 30, children between 7 and 17, common or classical migraine, blocker Flunarizine ( Sibelium ), Acetylsalicylic acid ( ASS ), attack frequency and duration, reduction of attack frequency or symptoms, Migraine frequency, Duration, slight body weight gain, abdominal pain, childhood migraine .
75521_task2
Sentence: [ Prevention of migraine with flunarizine and acetylsalicylic acid . A double-blind study ] . UNLABELLED 30 children between 7 and 17 years suffering from at least 2 attacks/month of common or classical migraine since more than 1 year were studied . After clinical exclusion of symptomatic headache 4 weeks were documented by means of a migraine diary . Prophylaxis with Calcium entry blocker Flunarizine ( Sibelium ) or Thromboxane A inhibitor Acetylsalicylic acid ( ASS ) was carried out in a double blind design for 3 months . Medication was given as one dosage in the evening : 2-5 mg/kg KG ASS or 5-10 mg Flunarizine . Documented attack frequency and duration were controlled at monthly physical examinations . Final results showed no differences in significant reduction of attack frequency or symptoms between both different therapeutic principals . 72.4 % ( ASS 73.3 % ; Flunarizine 71.4 % ) of patients were attack-free or had at least a 50 % reduction . Migraine frequency of initially 7-8 was reduced to 1-2 attacks/month . Duration remained constant in both groups ( 1-3 h ) . Side effects were slight body weight gain or abdominal pain after intake , prophylaxis had not to be interrupted therefore . Longtime prognosis is not yet possible because the time of observation is too short so far . CONCLUSION Both substances are definitely useful and have few side effects in childhood migraine . If the response to one is insufficient the other substance should be tried . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Outcome_Mental", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
[ Prevention of migraine with flunarizine and acetylsalicylic acid . A double-blind study ] . UNLABELLED 30 children between 7 and 17 years suffering from at least 2 attacks/month of common or classical migraine since more than 1 year were studied . After clinical exclusion of symptomatic headache 4 weeks were documented by means of a migraine diary . Prophylaxis with Calcium entry blocker Flunarizine ( Sibelium ) or Thromboxane A inhibitor Acetylsalicylic acid ( ASS ) was carried out in a double blind design for 3 months . Medication was given as one dosage in the evening : 2-5 mg/kg KG ASS or 5-10 mg Flunarizine . Documented attack frequency and duration were controlled at monthly physical examinations . Final results showed no differences in significant reduction of attack frequency or symptoms between both different therapeutic principals . 72.4 % ( ASS 73.3 % ; Flunarizine 71.4 % ) of patients were attack-free or had at least a 50 % reduction . Migraine frequency of initially 7-8 was reduced to 1-2 attacks/month . Duration remained constant in both groups ( 1-3 h ) . Side effects were slight body weight gain or abdominal pain after intake , prophylaxis had not to be interrupted therefore . Longtime prognosis is not yet possible because the time of observation is too short so far . CONCLUSION Both substances are definitely useful and have few side effects in childhood migraine . If the response to one is insufficient the other substance should be tried .
[ "[", "Prevention", "of", "migraine", "with", "flunarizine", "and", "acetylsalicylic", "acid", ".", "A", "double", "-", "blind", "study", "]", ".", "UNLABELLED", "30", "children", "between", "7", "and", "17", "years", "suffering", "from", "at", "least", "2", "attacks", "/", "month", "of", "common", "or", "classical", "migraine", "since", "more", "than", "1", "year", "were", "studied", ".", "After", "clinical", "exclusion", "of", "symptomatic", "headache", "4", "weeks", "were", "documented", "by", "means", "of", "a", "migraine", "diary", ".", "Prophylaxis", "with", "Calcium", "entry", "blocker", "Flunarizine", "(", "Sibelium", ")", "or", "Thromboxane", "A", "inhibitor", "Acetylsalicylic", "acid", "(", "ASS", ")", "was", "carried", "out", "in", "a", "double", "blind", "design", "for", "3", "months", ".", "Medication", "was", "given", "as", "one", "dosage", "in", "the", "evening", ":", "2", "-", "5", "mg", "/", "kg", "KG", "ASS", "or", "5", "-", "10", "mg", "Flunarizine", ".", "Documented", "attack", "frequency", "and", "duration", "were", "controlled", "at", "monthly", "physical", "examinations", ".", "Final", "results", "showed", "no", "differences", "in", "significant", "reduction", "of", "attack", "frequency", "or", "symptoms", "between", "both", "different", "therapeutic", "principals", ".", "72.4", "%", "(", "ASS", "73.3", "%", ";", "Flunarizine", "71.4", "%", ")", "of", "patients", "were", "attack", "-", "free", "or", "had", "at", "least", "a", "50", "%", "reduction", ".", "Migraine", "frequency", "of", "initially", "7", "-", "8", "was", "reduced", "to", "1", "-", "2", "attacks", "/", "month", ".", "Duration", "remained", "constant", "in", "both", "groups", "(", "1", "-", "3", "h", ")", ".", "Side", "effects", "were", "slight", "body", "weight", "gain", "or", "abdominal", "pain", "after", "intake", ",", "prophylaxis", "had", "not", "to", "be", "interrupted", "therefore", ".", "Longtime", "prognosis", "is", "not", "yet", "possible", "because", "the", "time", "of", "observation", "is", "too", "short", "so", "far", ".", "CONCLUSION", "Both", "substances", "are", "definitely", "useful", "and", "have", "few", "side", "effects", "in", "childhood", "migraine", ".", "If", "the", "response", "to", "one", "is", "insufficient", "the", "other", "substance", "should", "be", "tried", "." ]
[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Condition", "Participant_Age", "Outcome_Adverse-effects", "Outcome_Other", "Outcome_Mental", "Participant_Sample-size" ]
adenylosuccinate synthetase is a GENE-Y
17929831_task0
Sentence: Kinetic characterization of adenylosuccinate synthetase from the thermophilic archaea Methanocaldococcus jannaschii. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y
[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]
Kinetic characterization of adenylosuccinate synthetase from the thermophilic archaea Methanocaldococcus jannaschii.
[ "Kinetic", "characterization", "of", "adenylosuccinate", "synthetase", "from", "the", "thermophilic", "archaea", "Methanocaldococcus", "jannaschii", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
adenylosuccinate synthetase is a GENE-Y
17929831_task1
Sentence: Kinetic characterization of adenylosuccinate synthetase from the thermophilic archaea Methanocaldococcus jannaschii. Instructions: please typing these entity words according to sentence: adenylosuccinate synthetase Options: GENE-Y
[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]
Kinetic characterization of adenylosuccinate synthetase from the thermophilic archaea Methanocaldococcus jannaschii.
[ "Kinetic", "characterization", "of", "adenylosuccinate", "synthetase", "from", "the", "thermophilic", "archaea", "Methanocaldococcus", "jannaschii", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
adenylosuccinate synthetase
17929831_task2
Sentence: Kinetic characterization of adenylosuccinate synthetase from the thermophilic archaea Methanocaldococcus jannaschii. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]
Kinetic characterization of adenylosuccinate synthetase from the thermophilic archaea Methanocaldococcus jannaschii.
[ "Kinetic", "characterization", "of", "adenylosuccinate", "synthetase", "from", "the", "thermophilic", "archaea", "Methanocaldococcus", "jannaschii", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Leberwerte is an umlsterm, Leberwerte is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Morbiditaet is an umlsterm, Patienten is an umlsterm
DerChirurg.70680763.ger.abstr_task0
Sentence: Zusammenfassung . Erhoehte " Leberwerte " sind ein haeufiges klinisches Problem von unterschiedlicher Signifikanz . Die Entscheidung ueber die Indikation zur weiteren hepatologischen Abklaerung ist im Kontext der klinischen Praesentation und Fragestellung zu sehen . Praeoperativ erhoehte " Leberwerte " sind bei Elektivoperationen Indikation zur weiteren Abklaerung und ggf. Therapie . Symptomatische Patienten mit Hepatopathie haben ein erhoehtes Operationsrisiko . Zur Reduktion der erhoehten Morbiditaet und Letalitaet von Patienten mit akuter oder chronischer Hepatopathie ist ein Verstaendnis der pathophysiologischen Zusammenhaenge fuer die optimale prae- , intra- und postoperative Betreuung von grosser klinischer Relevanz . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Erhoehte " Leberwerte " sind ein haeufiges klinisches Problem von unterschiedlicher Signifikanz . Die Entscheidung ueber die Indikation zur weiteren hepatologischen Abklaerung ist im Kontext der klinischen Praesentation und Fragestellung zu sehen . Praeoperativ erhoehte " Leberwerte " sind bei Elektivoperationen Indikation zur weiteren Abklaerung und ggf. Therapie . Symptomatische Patienten mit Hepatopathie haben ein erhoehtes Operationsrisiko . Zur Reduktion der erhoehten Morbiditaet und Letalitaet von Patienten mit akuter oder chronischer Hepatopathie ist ein Verstaendnis der pathophysiologischen Zusammenhaenge fuer die optimale prae- , intra- und postoperative Betreuung von grosser klinischer Relevanz .
[ "Zusammenfassung", ".", "Erhoehte", "\"", "Leberwerte", "\"", "sind", "ein", "haeufiges", "klinisches", "Problem", "von", "unterschiedlicher", "Signifikanz", ".", "Die", "Entscheidung", "ueber", "die", "Indikation", "zur", "weiteren", "hepatologischen", "Abklaerung", "ist", "im", "Kontext", "der", "klinischen", "Praesentation", "und", "Fragestellung", "zu", "sehen", ".", "Praeoperativ", "erhoehte", "\"", "Leberwerte", "\"", "sind", "bei", "Elektivoperationen", "Indikation", "zur", "weiteren", "Abklaerung", "und", "ggf", ".", "Therapie", ".", "Symptomatische", "Patienten", "mit", "Hepatopathie", "haben", "ein", "erhoehtes", "Operationsrisiko", ".", "Zur", "Reduktion", "der", "erhoehten", "Morbiditaet", "und", "Letalitaet", "von", "Patienten", "mit", "akuter", "oder", "chronischer", "Hepatopathie", "ist", "ein", "Verstaendnis", "der", "pathophysiologischen", "Zusammenhaenge", "fuer", "die", "optimale", "prae-", ",", "intra-", "und", "postoperative", "Betreuung", "von", "grosser", "klinischer", "Relevanz", "." ]
[ "umlsterm" ]
Leberwerte is an umlsterm, Leberwerte is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Morbiditaet is an umlsterm, Patienten is an umlsterm
DerChirurg.70680763.ger.abstr_task1
Sentence: Zusammenfassung . Erhoehte " Leberwerte " sind ein haeufiges klinisches Problem von unterschiedlicher Signifikanz . Die Entscheidung ueber die Indikation zur weiteren hepatologischen Abklaerung ist im Kontext der klinischen Praesentation und Fragestellung zu sehen . Praeoperativ erhoehte " Leberwerte " sind bei Elektivoperationen Indikation zur weiteren Abklaerung und ggf. Therapie . Symptomatische Patienten mit Hepatopathie haben ein erhoehtes Operationsrisiko . Zur Reduktion der erhoehten Morbiditaet und Letalitaet von Patienten mit akuter oder chronischer Hepatopathie ist ein Verstaendnis der pathophysiologischen Zusammenhaenge fuer die optimale prae- , intra- und postoperative Betreuung von grosser klinischer Relevanz . Instructions: please typing these entity words according to sentence: Leberwerte, Leberwerte, Therapie, Patienten, Morbiditaet, Patienten Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Erhoehte " Leberwerte " sind ein haeufiges klinisches Problem von unterschiedlicher Signifikanz . Die Entscheidung ueber die Indikation zur weiteren hepatologischen Abklaerung ist im Kontext der klinischen Praesentation und Fragestellung zu sehen . Praeoperativ erhoehte " Leberwerte " sind bei Elektivoperationen Indikation zur weiteren Abklaerung und ggf. Therapie . Symptomatische Patienten mit Hepatopathie haben ein erhoehtes Operationsrisiko . Zur Reduktion der erhoehten Morbiditaet und Letalitaet von Patienten mit akuter oder chronischer Hepatopathie ist ein Verstaendnis der pathophysiologischen Zusammenhaenge fuer die optimale prae- , intra- und postoperative Betreuung von grosser klinischer Relevanz .
[ "Zusammenfassung", ".", "Erhoehte", "\"", "Leberwerte", "\"", "sind", "ein", "haeufiges", "klinisches", "Problem", "von", "unterschiedlicher", "Signifikanz", ".", "Die", "Entscheidung", "ueber", "die", "Indikation", "zur", "weiteren", "hepatologischen", "Abklaerung", "ist", "im", "Kontext", "der", "klinischen", "Praesentation", "und", "Fragestellung", "zu", "sehen", ".", "Praeoperativ", "erhoehte", "\"", "Leberwerte", "\"", "sind", "bei", "Elektivoperationen", "Indikation", "zur", "weiteren", "Abklaerung", "und", "ggf", ".", "Therapie", ".", "Symptomatische", "Patienten", "mit", "Hepatopathie", "haben", "ein", "erhoehtes", "Operationsrisiko", ".", "Zur", "Reduktion", "der", "erhoehten", "Morbiditaet", "und", "Letalitaet", "von", "Patienten", "mit", "akuter", "oder", "chronischer", "Hepatopathie", "ist", "ein", "Verstaendnis", "der", "pathophysiologischen", "Zusammenhaenge", "fuer", "die", "optimale", "prae-", ",", "intra-", "und", "postoperative", "Betreuung", "von", "grosser", "klinischer", "Relevanz", "." ]
[ "umlsterm" ]
Leberwerte, Leberwerte, Therapie, Patienten, Morbiditaet, Patienten
DerChirurg.70680763.ger.abstr_task2
Sentence: Zusammenfassung . Erhoehte " Leberwerte " sind ein haeufiges klinisches Problem von unterschiedlicher Signifikanz . Die Entscheidung ueber die Indikation zur weiteren hepatologischen Abklaerung ist im Kontext der klinischen Praesentation und Fragestellung zu sehen . Praeoperativ erhoehte " Leberwerte " sind bei Elektivoperationen Indikation zur weiteren Abklaerung und ggf. Therapie . Symptomatische Patienten mit Hepatopathie haben ein erhoehtes Operationsrisiko . Zur Reduktion der erhoehten Morbiditaet und Letalitaet von Patienten mit akuter oder chronischer Hepatopathie ist ein Verstaendnis der pathophysiologischen Zusammenhaenge fuer die optimale prae- , intra- und postoperative Betreuung von grosser klinischer Relevanz . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Erhoehte " Leberwerte " sind ein haeufiges klinisches Problem von unterschiedlicher Signifikanz . Die Entscheidung ueber die Indikation zur weiteren hepatologischen Abklaerung ist im Kontext der klinischen Praesentation und Fragestellung zu sehen . Praeoperativ erhoehte " Leberwerte " sind bei Elektivoperationen Indikation zur weiteren Abklaerung und ggf. Therapie . Symptomatische Patienten mit Hepatopathie haben ein erhoehtes Operationsrisiko . Zur Reduktion der erhoehten Morbiditaet und Letalitaet von Patienten mit akuter oder chronischer Hepatopathie ist ein Verstaendnis der pathophysiologischen Zusammenhaenge fuer die optimale prae- , intra- und postoperative Betreuung von grosser klinischer Relevanz .
[ "Zusammenfassung", ".", "Erhoehte", "\"", "Leberwerte", "\"", "sind", "ein", "haeufiges", "klinisches", "Problem", "von", "unterschiedlicher", "Signifikanz", ".", "Die", "Entscheidung", "ueber", "die", "Indikation", "zur", "weiteren", "hepatologischen", "Abklaerung", "ist", "im", "Kontext", "der", "klinischen", "Praesentation", "und", "Fragestellung", "zu", "sehen", ".", "Praeoperativ", "erhoehte", "\"", "Leberwerte", "\"", "sind", "bei", "Elektivoperationen", "Indikation", "zur", "weiteren", "Abklaerung", "und", "ggf", ".", "Therapie", ".", "Symptomatische", "Patienten", "mit", "Hepatopathie", "haben", "ein", "erhoehtes", "Operationsrisiko", ".", "Zur", "Reduktion", "der", "erhoehten", "Morbiditaet", "und", "Letalitaet", "von", "Patienten", "mit", "akuter", "oder", "chronischer", "Hepatopathie", "ist", "ein", "Verstaendnis", "der", "pathophysiologischen", "Zusammenhaenge", "fuer", "die", "optimale", "prae-", ",", "intra-", "und", "postoperative", "Betreuung", "von", "grosser", "klinischer", "Relevanz", "." ]
[ "umlsterm" ]
diseases is an umlsterm, elastic tissue is an umlsterm, dermatosis is an umlsterm, elastic tissue is an umlsterm, forms is an umlsterm
DerHautarzt.70480045.eng.abstr_task0
Sentence: In recent years there has been increased interest in diseases showing degeneration of dermal elastic tissue . Mid dermal elastolysis is a rare dermatosis , which is histopathologically characterized by mid dermal loss of elastic tissue . Both papular and patchy forms , as well as inflammatory and non- inflammatory variants , have been described . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In recent years there has been increased interest in diseases showing degeneration of dermal elastic tissue . Mid dermal elastolysis is a rare dermatosis , which is histopathologically characterized by mid dermal loss of elastic tissue . Both papular and patchy forms , as well as inflammatory and non- inflammatory variants , have been described .
[ "In", "recent", "years", "there", "has", "been", "increased", "interest", "in", "diseases", "showing", "degeneration", "of", "dermal", "elastic", "tissue", ".", "Mid", "dermal", "elastolysis", "is", "a", "rare", "dermatosis", ",", "which", "is", "histopathologically", "characterized", "by", "mid", "dermal", "loss", "of", "elastic", "tissue", ".", "Both", "papular", "and", "patchy", "forms", ",", "as", "well", "as", "inflammatory", "and", "non-", "inflammatory", "variants", ",", "have", "been", "described", "." ]
[ "umlsterm" ]
diseases is an umlsterm, elastic tissue is an umlsterm, dermatosis is an umlsterm, elastic tissue is an umlsterm, forms is an umlsterm
DerHautarzt.70480045.eng.abstr_task1
Sentence: In recent years there has been increased interest in diseases showing degeneration of dermal elastic tissue . Mid dermal elastolysis is a rare dermatosis , which is histopathologically characterized by mid dermal loss of elastic tissue . Both papular and patchy forms , as well as inflammatory and non- inflammatory variants , have been described . Instructions: please typing these entity words according to sentence: diseases, elastic tissue, dermatosis, elastic tissue, forms Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In recent years there has been increased interest in diseases showing degeneration of dermal elastic tissue . Mid dermal elastolysis is a rare dermatosis , which is histopathologically characterized by mid dermal loss of elastic tissue . Both papular and patchy forms , as well as inflammatory and non- inflammatory variants , have been described .
[ "In", "recent", "years", "there", "has", "been", "increased", "interest", "in", "diseases", "showing", "degeneration", "of", "dermal", "elastic", "tissue", ".", "Mid", "dermal", "elastolysis", "is", "a", "rare", "dermatosis", ",", "which", "is", "histopathologically", "characterized", "by", "mid", "dermal", "loss", "of", "elastic", "tissue", ".", "Both", "papular", "and", "patchy", "forms", ",", "as", "well", "as", "inflammatory", "and", "non-", "inflammatory", "variants", ",", "have", "been", "described", "." ]
[ "umlsterm" ]
diseases, elastic tissue, dermatosis, elastic tissue, forms
DerHautarzt.70480045.eng.abstr_task2
Sentence: In recent years there has been increased interest in diseases showing degeneration of dermal elastic tissue . Mid dermal elastolysis is a rare dermatosis , which is histopathologically characterized by mid dermal loss of elastic tissue . Both papular and patchy forms , as well as inflammatory and non- inflammatory variants , have been described . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In recent years there has been increased interest in diseases showing degeneration of dermal elastic tissue . Mid dermal elastolysis is a rare dermatosis , which is histopathologically characterized by mid dermal loss of elastic tissue . Both papular and patchy forms , as well as inflammatory and non- inflammatory variants , have been described .
[ "In", "recent", "years", "there", "has", "been", "increased", "interest", "in", "diseases", "showing", "degeneration", "of", "dermal", "elastic", "tissue", ".", "Mid", "dermal", "elastolysis", "is", "a", "rare", "dermatosis", ",", "which", "is", "histopathologically", "characterized", "by", "mid", "dermal", "loss", "of", "elastic", "tissue", ".", "Both", "papular", "and", "patchy", "forms", ",", "as", "well", "as", "inflammatory", "and", "non-", "inflammatory", "variants", ",", "have", "been", "described", "." ]
[ "umlsterm" ]
Literatur is an umlsterm, Entwicklungslaendern is an umlsterm, Inzidenz is an umlsterm, Pubertas praecox is an umlsterm, Waisenhaus is an umlsterm, Eltern is an umlsterm, Pubertas praecox is an umlsterm, Therapie is an umlsterm, Pubertaet is an umlsterm
MonatsschriftKinderheilkunde.81460957.ger.abstr_task0
Sentence: Die Abhaengigkeit der zeitlichen Pubertaetsentwicklung von nutritiven Faktoren ist bekannt . In der Literatur zeigt sich bei Maedchen , die aus Entwicklungslaendern in hochindustrialisierte Laender adoptiert wurden , eine erhoehte Inzidenz der Pubertas praecox vera . Wir berichten ueber ein indisches Maedchen , das mit 5 Jahren aus einem suedindischen Waisenhaus von deutschen Eltern adoptiert wurde und mit 6 Jahren eine Pubertas praecox vera zeigte . Unter Therapie mit dem GnRH-Analogon Leuprorelinazetat konnte die Progredienz der Pubertaet aufgehalten werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Die Abhaengigkeit der zeitlichen Pubertaetsentwicklung von nutritiven Faktoren ist bekannt . In der Literatur zeigt sich bei Maedchen , die aus Entwicklungslaendern in hochindustrialisierte Laender adoptiert wurden , eine erhoehte Inzidenz der Pubertas praecox vera . Wir berichten ueber ein indisches Maedchen , das mit 5 Jahren aus einem suedindischen Waisenhaus von deutschen Eltern adoptiert wurde und mit 6 Jahren eine Pubertas praecox vera zeigte . Unter Therapie mit dem GnRH-Analogon Leuprorelinazetat konnte die Progredienz der Pubertaet aufgehalten werden .
[ "Die", "Abhaengigkeit", "der", "zeitlichen", "Pubertaetsentwicklung", "von", "nutritiven", "Faktoren", "ist", "bekannt", ".", "In", "der", "Literatur", "zeigt", "sich", "bei", "Maedchen", ",", "die", "aus", "Entwicklungslaendern", "in", "hochindustrialisierte", "Laender", "adoptiert", "wurden", ",", "eine", "erhoehte", "Inzidenz", "der", "Pubertas", "praecox", "vera", ".", "Wir", "berichten", "ueber", "ein", "indisches", "Maedchen", ",", "das", "mit", "5", "Jahren", "aus", "einem", "suedindischen", "Waisenhaus", "von", "deutschen", "Eltern", "adoptiert", "wurde", "und", "mit", "6", "Jahren", "eine", "Pubertas", "praecox", "vera", "zeigte", ".", "Unter", "Therapie", "mit", "dem", "GnRH", "-", "Analogon", "Leuprorelinazetat", "konnte", "die", "Progredienz", "der", "Pubertaet", "aufgehalten", "werden", "." ]
[ "umlsterm" ]
Literatur is an umlsterm, Entwicklungslaendern is an umlsterm, Inzidenz is an umlsterm, Pubertas praecox is an umlsterm, Waisenhaus is an umlsterm, Eltern is an umlsterm, Pubertas praecox is an umlsterm, Therapie is an umlsterm, Pubertaet is an umlsterm
MonatsschriftKinderheilkunde.81460957.ger.abstr_task1
Sentence: Die Abhaengigkeit der zeitlichen Pubertaetsentwicklung von nutritiven Faktoren ist bekannt . In der Literatur zeigt sich bei Maedchen , die aus Entwicklungslaendern in hochindustrialisierte Laender adoptiert wurden , eine erhoehte Inzidenz der Pubertas praecox vera . Wir berichten ueber ein indisches Maedchen , das mit 5 Jahren aus einem suedindischen Waisenhaus von deutschen Eltern adoptiert wurde und mit 6 Jahren eine Pubertas praecox vera zeigte . Unter Therapie mit dem GnRH-Analogon Leuprorelinazetat konnte die Progredienz der Pubertaet aufgehalten werden . Instructions: please typing these entity words according to sentence: Literatur, Entwicklungslaendern, Inzidenz, Pubertas praecox, Waisenhaus, Eltern, Pubertas praecox, Therapie, Pubertaet Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Die Abhaengigkeit der zeitlichen Pubertaetsentwicklung von nutritiven Faktoren ist bekannt . In der Literatur zeigt sich bei Maedchen , die aus Entwicklungslaendern in hochindustrialisierte Laender adoptiert wurden , eine erhoehte Inzidenz der Pubertas praecox vera . Wir berichten ueber ein indisches Maedchen , das mit 5 Jahren aus einem suedindischen Waisenhaus von deutschen Eltern adoptiert wurde und mit 6 Jahren eine Pubertas praecox vera zeigte . Unter Therapie mit dem GnRH-Analogon Leuprorelinazetat konnte die Progredienz der Pubertaet aufgehalten werden .
[ "Die", "Abhaengigkeit", "der", "zeitlichen", "Pubertaetsentwicklung", "von", "nutritiven", "Faktoren", "ist", "bekannt", ".", "In", "der", "Literatur", "zeigt", "sich", "bei", "Maedchen", ",", "die", "aus", "Entwicklungslaendern", "in", "hochindustrialisierte", "Laender", "adoptiert", "wurden", ",", "eine", "erhoehte", "Inzidenz", "der", "Pubertas", "praecox", "vera", ".", "Wir", "berichten", "ueber", "ein", "indisches", "Maedchen", ",", "das", "mit", "5", "Jahren", "aus", "einem", "suedindischen", "Waisenhaus", "von", "deutschen", "Eltern", "adoptiert", "wurde", "und", "mit", "6", "Jahren", "eine", "Pubertas", "praecox", "vera", "zeigte", ".", "Unter", "Therapie", "mit", "dem", "GnRH", "-", "Analogon", "Leuprorelinazetat", "konnte", "die", "Progredienz", "der", "Pubertaet", "aufgehalten", "werden", "." ]
[ "umlsterm" ]
Literatur, Entwicklungslaendern, Inzidenz, Pubertas praecox, Waisenhaus, Eltern, Pubertas praecox, Therapie, Pubertaet
MonatsschriftKinderheilkunde.81460957.ger.abstr_task2
Sentence: Die Abhaengigkeit der zeitlichen Pubertaetsentwicklung von nutritiven Faktoren ist bekannt . In der Literatur zeigt sich bei Maedchen , die aus Entwicklungslaendern in hochindustrialisierte Laender adoptiert wurden , eine erhoehte Inzidenz der Pubertas praecox vera . Wir berichten ueber ein indisches Maedchen , das mit 5 Jahren aus einem suedindischen Waisenhaus von deutschen Eltern adoptiert wurde und mit 6 Jahren eine Pubertas praecox vera zeigte . Unter Therapie mit dem GnRH-Analogon Leuprorelinazetat konnte die Progredienz der Pubertaet aufgehalten werden . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Die Abhaengigkeit der zeitlichen Pubertaetsentwicklung von nutritiven Faktoren ist bekannt . In der Literatur zeigt sich bei Maedchen , die aus Entwicklungslaendern in hochindustrialisierte Laender adoptiert wurden , eine erhoehte Inzidenz der Pubertas praecox vera . Wir berichten ueber ein indisches Maedchen , das mit 5 Jahren aus einem suedindischen Waisenhaus von deutschen Eltern adoptiert wurde und mit 6 Jahren eine Pubertas praecox vera zeigte . Unter Therapie mit dem GnRH-Analogon Leuprorelinazetat konnte die Progredienz der Pubertaet aufgehalten werden .
[ "Die", "Abhaengigkeit", "der", "zeitlichen", "Pubertaetsentwicklung", "von", "nutritiven", "Faktoren", "ist", "bekannt", ".", "In", "der", "Literatur", "zeigt", "sich", "bei", "Maedchen", ",", "die", "aus", "Entwicklungslaendern", "in", "hochindustrialisierte", "Laender", "adoptiert", "wurden", ",", "eine", "erhoehte", "Inzidenz", "der", "Pubertas", "praecox", "vera", ".", "Wir", "berichten", "ueber", "ein", "indisches", "Maedchen", ",", "das", "mit", "5", "Jahren", "aus", "einem", "suedindischen", "Waisenhaus", "von", "deutschen", "Eltern", "adoptiert", "wurde", "und", "mit", "6", "Jahren", "eine", "Pubertas", "praecox", "vera", "zeigte", ".", "Unter", "Therapie", "mit", "dem", "GnRH", "-", "Analogon", "Leuprorelinazetat", "konnte", "die", "Progredienz", "der", "Pubertaet", "aufgehalten", "werden", "." ]
[ "umlsterm" ]
diagnosis is an umlsterm, lower extremities is an umlsterm, analysis is an umlsterm, leg is an umlsterm, diagnostic is an umlsterm, physical examination is an umlsterm, diagnosis is an umlsterm, physical examination is an umlsterm, deformity is an umlsterm, operative procedure is an umlsterm, diagnosis is an umlsterm, axis is an umlsterm, X - ray is an umlsterm, leg is an umlsterm, knee joints is an umlsterm, deformities is an umlsterm, legs is an umlsterm, gold is an umlsterm, standard is an umlsterm, torsion is an umlsterm, lower extremities is an umlsterm, CT scan is an umlsterm, methods is an umlsterm, measurements is an umlsterm, literature is an umlsterm, method is an umlsterm, choice is an umlsterm, measurement is an umlsterm, physical examination is an umlsterm, literature is an umlsterm, reference values is an umlsterm, Method is an umlsterm, risks is an umlsterm, MRI is an umlsterm, method is an umlsterm, method is an umlsterm, ultrasound is an umlsterm, measurement is an umlsterm, torsion is an umlsterm, lower extremities is an umlsterm, proven is an umlsterm, MRI is an umlsterm, determination is an umlsterm, torsion is an umlsterm, lower extremities is an umlsterm, ultrasound is an umlsterm, role is an umlsterm, diagnosis is an umlsterm, lower extremities is an umlsterm, children is an umlsterm, adolescents is an umlsterm, method is an umlsterm, planning is an umlsterm, leg is an umlsterm, deformities is an umlsterm, adults is an umlsterm
DerChirurg.80691141.eng.abstr_task0
Sentence: The diagnosis of malalignments of the lower extremities includes analysis of the geometry of the whole leg . The first step in the diagnostic process is a standardized physical examination . It provides valuable background information for an effective radiological diagnosis . Even with a thorough standardized physical examination it is not possible to define exactly the deformity or decide on an operative procedure . The diagnosis of axis deviations in the frontal plane can be measured on a conventional plain X-ray of the whole leg . In this view it is very important that the knee joints are in a true a. p . view independent on torsional deformities of the lower legs . Today the gold standard to measure the torsion and length of the lower extremities is the CT scan . However , the multitude of analytical methods for CT measurements described in the literature do not lend themselves readily to comparison ; thus , it is difficult to identify a clear method of choice . Not every CT measurement is better than a physical examination . Evidence of reproducibility and accuracy is a prerequisite for useful interpretation of the results . Up to this point in the literature there are only reference values for the Ulm CT Method . One alternative is the MR scan , which avoids radiological risks , but the reproducibility and accuracy of the MRI method are not as good as for the CT method . Another alternative is ultrasound , where recent advances in the measurement of torsion and length of the lower extremities have proven competitive with or superior to the accuracy of MRI . The three-dimensional determination of the torsion and length of the lower extremities by ultrasound has now assumed a leading role in the non-radiological diagnosis of malalignments of the lower extremities in children and adolescents . This method furthermore is increasingly being used in preoperative planning of leg deformities in adults . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O" ]
The diagnosis of malalignments of the lower extremities includes analysis of the geometry of the whole leg . The first step in the diagnostic process is a standardized physical examination . It provides valuable background information for an effective radiological diagnosis . Even with a thorough standardized physical examination it is not possible to define exactly the deformity or decide on an operative procedure . The diagnosis of axis deviations in the frontal plane can be measured on a conventional plain X-ray of the whole leg . In this view it is very important that the knee joints are in a true a. p . view independent on torsional deformities of the lower legs . Today the gold standard to measure the torsion and length of the lower extremities is the CT scan . However , the multitude of analytical methods for CT measurements described in the literature do not lend themselves readily to comparison ; thus , it is difficult to identify a clear method of choice . Not every CT measurement is better than a physical examination . Evidence of reproducibility and accuracy is a prerequisite for useful interpretation of the results . Up to this point in the literature there are only reference values for the Ulm CT Method . One alternative is the MR scan , which avoids radiological risks , but the reproducibility and accuracy of the MRI method are not as good as for the CT method . Another alternative is ultrasound , where recent advances in the measurement of torsion and length of the lower extremities have proven competitive with or superior to the accuracy of MRI . The three-dimensional determination of the torsion and length of the lower extremities by ultrasound has now assumed a leading role in the non-radiological diagnosis of malalignments of the lower extremities in children and adolescents . This method furthermore is increasingly being used in preoperative planning of leg deformities in adults .
[ "The", "diagnosis", "of", "malalignments", "of", "the", "lower", "extremities", "includes", "analysis", "of", "the", "geometry", "of", "the", "whole", "leg", ".", "The", "first", "step", "in", "the", "diagnostic", "process", "is", "a", "standardized", "physical", "examination", ".", "It", "provides", "valuable", "background", "information", "for", "an", "effective", "radiological", "diagnosis", ".", "Even", "with", "a", "thorough", "standardized", "physical", "examination", "it", "is", "not", "possible", "to", "define", "exactly", "the", "deformity", "or", "decide", "on", "an", "operative", "procedure", ".", "The", "diagnosis", "of", "axis", "deviations", "in", "the", "frontal", "plane", "can", "be", "measured", "on", "a", "conventional", "plain", "X", "-", "ray", "of", "the", "whole", "leg", ".", "In", "this", "view", "it", "is", "very", "important", "that", "the", "knee", "joints", "are", "in", "a", "true", "a.", "p", ".", "view", "independent", "on", "torsional", "deformities", "of", "the", "lower", "legs", ".", "Today", "the", "gold", "standard", "to", "measure", "the", "torsion", "and", "length", "of", "the", "lower", "extremities", "is", "the", "CT", "scan", ".", "However", ",", "the", "multitude", "of", "analytical", "methods", "for", "CT", "measurements", "described", "in", "the", "literature", "do", "not", "lend", "themselves", "readily", "to", "comparison", ";", "thus", ",", "it", "is", "difficult", "to", "identify", "a", "clear", "method", "of", "choice", ".", "Not", "every", "CT", "measurement", "is", "better", "than", "a", "physical", "examination", ".", "Evidence", "of", "reproducibility", "and", "accuracy", "is", "a", "prerequisite", "for", "useful", "interpretation", "of", "the", "results", ".", "Up", "to", "this", "point", "in", "the", "literature", "there", "are", "only", "reference", "values", "for", "the", "Ulm", "CT", "Method", ".", "One", "alternative", "is", "the", "MR", "scan", ",", "which", "avoids", "radiological", "risks", ",", "but", "the", "reproducibility", "and", "accuracy", "of", "the", "MRI", "method", "are", "not", "as", "good", "as", "for", "the", "CT", "method", ".", "Another", "alternative", "is", "ultrasound", ",", "where", "recent", "advances", "in", "the", "measurement", "of", "torsion", "and", "length", "of", "the", "lower", "extremities", "have", "proven", "competitive", "with", "or", "superior", "to", "the", "accuracy", "of", "MRI", ".", "The", "three", "-", "dimensional", "determination", "of", "the", "torsion", "and", "length", "of", "the", "lower", "extremities", "by", "ultrasound", "has", "now", "assumed", "a", "leading", "role", "in", "the", "non", "-", "radiological", "diagnosis", "of", "malalignments", "of", "the", "lower", "extremities", "in", "children", "and", "adolescents", ".", "This", "method", "furthermore", "is", "increasingly", "being", "used", "in", "preoperative", "planning", "of", "leg", "deformities", "in", "adults", "." ]
[ "umlsterm" ]
diagnosis is an umlsterm, lower extremities is an umlsterm, analysis is an umlsterm, leg is an umlsterm, diagnostic is an umlsterm, physical examination is an umlsterm, diagnosis is an umlsterm, physical examination is an umlsterm, deformity is an umlsterm, operative procedure is an umlsterm, diagnosis is an umlsterm, axis is an umlsterm, X - ray is an umlsterm, leg is an umlsterm, knee joints is an umlsterm, deformities is an umlsterm, legs is an umlsterm, gold is an umlsterm, standard is an umlsterm, torsion is an umlsterm, lower extremities is an umlsterm, CT scan is an umlsterm, methods is an umlsterm, measurements is an umlsterm, literature is an umlsterm, method is an umlsterm, choice is an umlsterm, measurement is an umlsterm, physical examination is an umlsterm, literature is an umlsterm, reference values is an umlsterm, Method is an umlsterm, risks is an umlsterm, MRI is an umlsterm, method is an umlsterm, method is an umlsterm, ultrasound is an umlsterm, measurement is an umlsterm, torsion is an umlsterm, lower extremities is an umlsterm, proven is an umlsterm, MRI is an umlsterm, determination is an umlsterm, torsion is an umlsterm, lower extremities is an umlsterm, ultrasound is an umlsterm, role is an umlsterm, diagnosis is an umlsterm, lower extremities is an umlsterm, children is an umlsterm, adolescents is an umlsterm, method is an umlsterm, planning is an umlsterm, leg is an umlsterm, deformities is an umlsterm, adults is an umlsterm
DerChirurg.80691141.eng.abstr_task1
Sentence: The diagnosis of malalignments of the lower extremities includes analysis of the geometry of the whole leg . The first step in the diagnostic process is a standardized physical examination . It provides valuable background information for an effective radiological diagnosis . Even with a thorough standardized physical examination it is not possible to define exactly the deformity or decide on an operative procedure . The diagnosis of axis deviations in the frontal plane can be measured on a conventional plain X-ray of the whole leg . In this view it is very important that the knee joints are in a true a. p . view independent on torsional deformities of the lower legs . Today the gold standard to measure the torsion and length of the lower extremities is the CT scan . However , the multitude of analytical methods for CT measurements described in the literature do not lend themselves readily to comparison ; thus , it is difficult to identify a clear method of choice . Not every CT measurement is better than a physical examination . Evidence of reproducibility and accuracy is a prerequisite for useful interpretation of the results . Up to this point in the literature there are only reference values for the Ulm CT Method . One alternative is the MR scan , which avoids radiological risks , but the reproducibility and accuracy of the MRI method are not as good as for the CT method . Another alternative is ultrasound , where recent advances in the measurement of torsion and length of the lower extremities have proven competitive with or superior to the accuracy of MRI . The three-dimensional determination of the torsion and length of the lower extremities by ultrasound has now assumed a leading role in the non-radiological diagnosis of malalignments of the lower extremities in children and adolescents . This method furthermore is increasingly being used in preoperative planning of leg deformities in adults . Instructions: please typing these entity words according to sentence: diagnosis, lower extremities, analysis, leg, diagnostic, physical examination, diagnosis, physical examination, deformity, operative procedure, diagnosis, axis, X - ray, leg, knee joints, deformities, legs, gold, standard, torsion, lower extremities, CT scan, methods, measurements, literature, method, choice, measurement, physical examination, literature, reference values, Method, risks, MRI, method, method, ultrasound, measurement, torsion, lower extremities, proven, MRI, determination, torsion, lower extremities, ultrasound, role, diagnosis, lower extremities, children, adolescents, method, planning, leg, deformities, adults Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O" ]
The diagnosis of malalignments of the lower extremities includes analysis of the geometry of the whole leg . The first step in the diagnostic process is a standardized physical examination . It provides valuable background information for an effective radiological diagnosis . Even with a thorough standardized physical examination it is not possible to define exactly the deformity or decide on an operative procedure . The diagnosis of axis deviations in the frontal plane can be measured on a conventional plain X-ray of the whole leg . In this view it is very important that the knee joints are in a true a. p . view independent on torsional deformities of the lower legs . Today the gold standard to measure the torsion and length of the lower extremities is the CT scan . However , the multitude of analytical methods for CT measurements described in the literature do not lend themselves readily to comparison ; thus , it is difficult to identify a clear method of choice . Not every CT measurement is better than a physical examination . Evidence of reproducibility and accuracy is a prerequisite for useful interpretation of the results . Up to this point in the literature there are only reference values for the Ulm CT Method . One alternative is the MR scan , which avoids radiological risks , but the reproducibility and accuracy of the MRI method are not as good as for the CT method . Another alternative is ultrasound , where recent advances in the measurement of torsion and length of the lower extremities have proven competitive with or superior to the accuracy of MRI . The three-dimensional determination of the torsion and length of the lower extremities by ultrasound has now assumed a leading role in the non-radiological diagnosis of malalignments of the lower extremities in children and adolescents . This method furthermore is increasingly being used in preoperative planning of leg deformities in adults .
[ "The", "diagnosis", "of", "malalignments", "of", "the", "lower", "extremities", "includes", "analysis", "of", "the", "geometry", "of", "the", "whole", "leg", ".", "The", "first", "step", "in", "the", "diagnostic", "process", "is", "a", "standardized", "physical", "examination", ".", "It", "provides", "valuable", "background", "information", "for", "an", "effective", "radiological", "diagnosis", ".", "Even", "with", "a", "thorough", "standardized", "physical", "examination", "it", "is", "not", "possible", "to", "define", "exactly", "the", "deformity", "or", "decide", "on", "an", "operative", "procedure", ".", "The", "diagnosis", "of", "axis", "deviations", "in", "the", "frontal", "plane", "can", "be", "measured", "on", "a", "conventional", "plain", "X", "-", "ray", "of", "the", "whole", "leg", ".", "In", "this", "view", "it", "is", "very", "important", "that", "the", "knee", "joints", "are", "in", "a", "true", "a.", "p", ".", "view", "independent", "on", "torsional", "deformities", "of", "the", "lower", "legs", ".", "Today", "the", "gold", "standard", "to", "measure", "the", "torsion", "and", "length", "of", "the", "lower", "extremities", "is", "the", "CT", "scan", ".", "However", ",", "the", "multitude", "of", "analytical", "methods", "for", "CT", "measurements", "described", "in", "the", "literature", "do", "not", "lend", "themselves", "readily", "to", "comparison", ";", "thus", ",", "it", "is", "difficult", "to", "identify", "a", "clear", "method", "of", "choice", ".", "Not", "every", "CT", "measurement", "is", "better", "than", "a", "physical", "examination", ".", "Evidence", "of", "reproducibility", "and", "accuracy", "is", "a", "prerequisite", "for", "useful", "interpretation", "of", "the", "results", ".", "Up", "to", "this", "point", "in", "the", "literature", "there", "are", "only", "reference", "values", "for", "the", "Ulm", "CT", "Method", ".", "One", "alternative", "is", "the", "MR", "scan", ",", "which", "avoids", "radiological", "risks", ",", "but", "the", "reproducibility", "and", "accuracy", "of", "the", "MRI", "method", "are", "not", "as", "good", "as", "for", "the", "CT", "method", ".", "Another", "alternative", "is", "ultrasound", ",", "where", "recent", "advances", "in", "the", "measurement", "of", "torsion", "and", "length", "of", "the", "lower", "extremities", "have", "proven", "competitive", "with", "or", "superior", "to", "the", "accuracy", "of", "MRI", ".", "The", "three", "-", "dimensional", "determination", "of", "the", "torsion", "and", "length", "of", "the", "lower", "extremities", "by", "ultrasound", "has", "now", "assumed", "a", "leading", "role", "in", "the", "non", "-", "radiological", "diagnosis", "of", "malalignments", "of", "the", "lower", "extremities", "in", "children", "and", "adolescents", ".", "This", "method", "furthermore", "is", "increasingly", "being", "used", "in", "preoperative", "planning", "of", "leg", "deformities", "in", "adults", "." ]
[ "umlsterm" ]
diagnosis, lower extremities, analysis, leg, diagnostic, physical examination, diagnosis, physical examination, deformity, operative procedure, diagnosis, axis, X - ray, leg, knee joints, deformities, legs, gold, standard, torsion, lower extremities, CT scan, methods, measurements, literature, method, choice, measurement, physical examination, literature, reference values, Method, risks, MRI, method, method, ultrasound, measurement, torsion, lower extremities, proven, MRI, determination, torsion, lower extremities, ultrasound, role, diagnosis, lower extremities, children, adolescents, method, planning, leg, deformities, adults
DerChirurg.80691141.eng.abstr_task2
Sentence: The diagnosis of malalignments of the lower extremities includes analysis of the geometry of the whole leg . The first step in the diagnostic process is a standardized physical examination . It provides valuable background information for an effective radiological diagnosis . Even with a thorough standardized physical examination it is not possible to define exactly the deformity or decide on an operative procedure . The diagnosis of axis deviations in the frontal plane can be measured on a conventional plain X-ray of the whole leg . In this view it is very important that the knee joints are in a true a. p . view independent on torsional deformities of the lower legs . Today the gold standard to measure the torsion and length of the lower extremities is the CT scan . However , the multitude of analytical methods for CT measurements described in the literature do not lend themselves readily to comparison ; thus , it is difficult to identify a clear method of choice . Not every CT measurement is better than a physical examination . Evidence of reproducibility and accuracy is a prerequisite for useful interpretation of the results . Up to this point in the literature there are only reference values for the Ulm CT Method . One alternative is the MR scan , which avoids radiological risks , but the reproducibility and accuracy of the MRI method are not as good as for the CT method . Another alternative is ultrasound , where recent advances in the measurement of torsion and length of the lower extremities have proven competitive with or superior to the accuracy of MRI . The three-dimensional determination of the torsion and length of the lower extremities by ultrasound has now assumed a leading role in the non-radiological diagnosis of malalignments of the lower extremities in children and adolescents . This method furthermore is increasingly being used in preoperative planning of leg deformities in adults . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O" ]
The diagnosis of malalignments of the lower extremities includes analysis of the geometry of the whole leg . The first step in the diagnostic process is a standardized physical examination . It provides valuable background information for an effective radiological diagnosis . Even with a thorough standardized physical examination it is not possible to define exactly the deformity or decide on an operative procedure . The diagnosis of axis deviations in the frontal plane can be measured on a conventional plain X-ray of the whole leg . In this view it is very important that the knee joints are in a true a. p . view independent on torsional deformities of the lower legs . Today the gold standard to measure the torsion and length of the lower extremities is the CT scan . However , the multitude of analytical methods for CT measurements described in the literature do not lend themselves readily to comparison ; thus , it is difficult to identify a clear method of choice . Not every CT measurement is better than a physical examination . Evidence of reproducibility and accuracy is a prerequisite for useful interpretation of the results . Up to this point in the literature there are only reference values for the Ulm CT Method . One alternative is the MR scan , which avoids radiological risks , but the reproducibility and accuracy of the MRI method are not as good as for the CT method . Another alternative is ultrasound , where recent advances in the measurement of torsion and length of the lower extremities have proven competitive with or superior to the accuracy of MRI . The three-dimensional determination of the torsion and length of the lower extremities by ultrasound has now assumed a leading role in the non-radiological diagnosis of malalignments of the lower extremities in children and adolescents . This method furthermore is increasingly being used in preoperative planning of leg deformities in adults .
[ "The", "diagnosis", "of", "malalignments", "of", "the", "lower", "extremities", "includes", "analysis", "of", "the", "geometry", "of", "the", "whole", "leg", ".", "The", "first", "step", "in", "the", "diagnostic", "process", "is", "a", "standardized", "physical", "examination", ".", "It", "provides", "valuable", "background", "information", "for", "an", "effective", "radiological", "diagnosis", ".", "Even", "with", "a", "thorough", "standardized", "physical", "examination", "it", "is", "not", "possible", "to", "define", "exactly", "the", "deformity", "or", "decide", "on", "an", "operative", "procedure", ".", "The", "diagnosis", "of", "axis", "deviations", "in", "the", "frontal", "plane", "can", "be", "measured", "on", "a", "conventional", "plain", "X", "-", "ray", "of", "the", "whole", "leg", ".", "In", "this", "view", "it", "is", "very", "important", "that", "the", "knee", "joints", "are", "in", "a", "true", "a.", "p", ".", "view", "independent", "on", "torsional", "deformities", "of", "the", "lower", "legs", ".", "Today", "the", "gold", "standard", "to", "measure", "the", "torsion", "and", "length", "of", "the", "lower", "extremities", "is", "the", "CT", "scan", ".", "However", ",", "the", "multitude", "of", "analytical", "methods", "for", "CT", "measurements", "described", "in", "the", "literature", "do", "not", "lend", "themselves", "readily", "to", "comparison", ";", "thus", ",", "it", "is", "difficult", "to", "identify", "a", "clear", "method", "of", "choice", ".", "Not", "every", "CT", "measurement", "is", "better", "than", "a", "physical", "examination", ".", "Evidence", "of", "reproducibility", "and", "accuracy", "is", "a", "prerequisite", "for", "useful", "interpretation", "of", "the", "results", ".", "Up", "to", "this", "point", "in", "the", "literature", "there", "are", "only", "reference", "values", "for", "the", "Ulm", "CT", "Method", ".", "One", "alternative", "is", "the", "MR", "scan", ",", "which", "avoids", "radiological", "risks", ",", "but", "the", "reproducibility", "and", "accuracy", "of", "the", "MRI", "method", "are", "not", "as", "good", "as", "for", "the", "CT", "method", ".", "Another", "alternative", "is", "ultrasound", ",", "where", "recent", "advances", "in", "the", "measurement", "of", "torsion", "and", "length", "of", "the", "lower", "extremities", "have", "proven", "competitive", "with", "or", "superior", "to", "the", "accuracy", "of", "MRI", ".", "The", "three", "-", "dimensional", "determination", "of", "the", "torsion", "and", "length", "of", "the", "lower", "extremities", "by", "ultrasound", "has", "now", "assumed", "a", "leading", "role", "in", "the", "non", "-", "radiological", "diagnosis", "of", "malalignments", "of", "the", "lower", "extremities", "in", "children", "and", "adolescents", ".", "This", "method", "furthermore", "is", "increasingly", "being", "used", "in", "preoperative", "planning", "of", "leg", "deformities", "in", "adults", "." ]
[ "umlsterm" ]
HIF-2α is a GENE-Y, ATM is a GENE-Y, Chk-2 is a GENE-Y, arsenite is a CHEMICAL, benzo(a)pyrene is a CHEMICAL
23333640_task0
Sentence: The inhibition of HIF-2α on the ATM/Chk-2 pathway is involved in the promotion effect of arsenite on benzo(a)pyrene-induced cell transformation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL
[ "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]
The inhibition of HIF-2α on the ATM/Chk-2 pathway is involved in the promotion effect of arsenite on benzo(a)pyrene-induced cell transformation.
[ "The", "inhibition", "of", "HIF-2α", "on", "the", "ATM", "/", "Chk-2", "pathway", "is", "involved", "in", "the", "promotion", "effect", "of", "arsenite", "on", "benzo(a)pyrene", "-", "induced", "cell", "transformation", "." ]
[ "CHEMICAL", "GENE-Y" ]
HIF-2α is a GENE-Y, ATM is a GENE-Y, Chk-2 is a GENE-Y, arsenite is a CHEMICAL, benzo(a)pyrene is a CHEMICAL
23333640_task1
Sentence: The inhibition of HIF-2α on the ATM/Chk-2 pathway is involved in the promotion effect of arsenite on benzo(a)pyrene-induced cell transformation. Instructions: please typing these entity words according to sentence: HIF-2α, ATM, Chk-2, arsenite, benzo(a)pyrene Options: GENE-Y, CHEMICAL
[ "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]
The inhibition of HIF-2α on the ATM/Chk-2 pathway is involved in the promotion effect of arsenite on benzo(a)pyrene-induced cell transformation.
[ "The", "inhibition", "of", "HIF-2α", "on", "the", "ATM", "/", "Chk-2", "pathway", "is", "involved", "in", "the", "promotion", "effect", "of", "arsenite", "on", "benzo(a)pyrene", "-", "induced", "cell", "transformation", "." ]
[ "CHEMICAL", "GENE-Y" ]
HIF-2α, ATM, Chk-2, arsenite, benzo(a)pyrene
23333640_task2
Sentence: The inhibition of HIF-2α on the ATM/Chk-2 pathway is involved in the promotion effect of arsenite on benzo(a)pyrene-induced cell transformation. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]
The inhibition of HIF-2α on the ATM/Chk-2 pathway is involved in the promotion effect of arsenite on benzo(a)pyrene-induced cell transformation.
[ "The", "inhibition", "of", "HIF-2α", "on", "the", "ATM", "/", "Chk-2", "pathway", "is", "involved", "in", "the", "promotion", "effect", "of", "arsenite", "on", "benzo(a)pyrene", "-", "induced", "cell", "transformation", "." ]
[ "CHEMICAL", "GENE-Y" ]
XRCC3 is a Genes & Molecular Sequences, XPD is a Genes & Molecular Sequences
14842_task0
Sentence: Susceptibility of XRCC3, XPD, and X Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Genes & Molecular Sequences
[ "O", "O", "B-Genes & Molecular Sequences", "O", "B-Genes & Molecular Sequences", "O", "O", "O" ]
Susceptibility of XRCC3, XPD, and X
[ "Susceptibility", "of", "XRCC3", ",", "XPD", ",", "and", "X" ]
[ "Diseases & Disorders", "", "Genes & Molecular Sequences", "SNP & Sequence variations" ]
XRCC3 is a Genes & Molecular Sequences, XPD is a Genes & Molecular Sequences
14842_task1
Sentence: Susceptibility of XRCC3, XPD, and X Instructions: please typing these entity words according to sentence: XRCC3, XPD Options: Genes & Molecular Sequences
[ "O", "O", "B-Genes & Molecular Sequences", "O", "B-Genes & Molecular Sequences", "O", "O", "O" ]
Susceptibility of XRCC3, XPD, and X
[ "Susceptibility", "of", "XRCC3", ",", "XPD", ",", "and", "X" ]
[ "Diseases & Disorders", "", "Genes & Molecular Sequences", "SNP & Sequence variations" ]
XRCC3, XPD
14842_task2
Sentence: Susceptibility of XRCC3, XPD, and X Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Genes & Molecular Sequences", "O", "B-Genes & Molecular Sequences", "O", "O", "O" ]
Susceptibility of XRCC3, XPD, and X
[ "Susceptibility", "of", "XRCC3", ",", "XPD", ",", "and", "X" ]
[ "Diseases & Disorders", "", "Genes & Molecular Sequences", "SNP & Sequence variations" ]
superoxide dismutase is a protein, catalase is a protein, glutathione peroxidase is a protein, glutathione reductase is a protein, glutathione S - transferase is a protein, ascorbic acid is a compound, reduced glutathione is a compound
DS.d1634_task0
Sentence: In addition to lipid peroxidation, the activities of antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glutathione S-transferase and two non-enzymatic antioxidants (ascorbic acid and reduced glutathione) were investigated in order to understand their variation with respect to pollution status of the sampling locations. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "B-protein", "I-protein", "O", "B-protein", "I-protein", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "B-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In addition to lipid peroxidation, the activities of antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glutathione S-transferase and two non-enzymatic antioxidants (ascorbic acid and reduced glutathione) were investigated in order to understand their variation with respect to pollution status of the sampling locations.
[ "In", "addition", "to", "lipid", "peroxidation", ",", "the", "activities", "of", "antioxidant", "enzymes", "such", "as", "superoxide", "dismutase", ",", "catalase", ",", "glutathione", "peroxidase", ",", "glutathione", "reductase", "and", "glutathione", "S", "-", "transferase", "and", "two", "non", "-", "enzymatic", "antioxidants", "(", "ascorbic", "acid", "and", "reduced", "glutathione", ")", "were", "investigated", "in", "order", "to", "understand", "their", "variation", "with", "respect", "to", "pollution", "status", "of", "the", "sampling", "locations", "." ]
[ "protein", "compound" ]
superoxide dismutase is a protein, catalase is a protein, glutathione peroxidase is a protein, glutathione reductase is a protein, glutathione S - transferase is a protein, ascorbic acid is a compound, reduced glutathione is a compound
DS.d1634_task1
Sentence: In addition to lipid peroxidation, the activities of antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glutathione S-transferase and two non-enzymatic antioxidants (ascorbic acid and reduced glutathione) were investigated in order to understand their variation with respect to pollution status of the sampling locations. Instructions: please typing these entity words according to sentence: superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glutathione S - transferase, ascorbic acid, reduced glutathione Options: compound, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "B-protein", "I-protein", "O", "B-protein", "I-protein", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "B-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In addition to lipid peroxidation, the activities of antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glutathione S-transferase and two non-enzymatic antioxidants (ascorbic acid and reduced glutathione) were investigated in order to understand their variation with respect to pollution status of the sampling locations.
[ "In", "addition", "to", "lipid", "peroxidation", ",", "the", "activities", "of", "antioxidant", "enzymes", "such", "as", "superoxide", "dismutase", ",", "catalase", ",", "glutathione", "peroxidase", ",", "glutathione", "reductase", "and", "glutathione", "S", "-", "transferase", "and", "two", "non", "-", "enzymatic", "antioxidants", "(", "ascorbic", "acid", "and", "reduced", "glutathione", ")", "were", "investigated", "in", "order", "to", "understand", "their", "variation", "with", "respect", "to", "pollution", "status", "of", "the", "sampling", "locations", "." ]
[ "protein", "compound" ]
superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glutathione S - transferase, ascorbic acid, reduced glutathione
DS.d1634_task2
Sentence: In addition to lipid peroxidation, the activities of antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glutathione S-transferase and two non-enzymatic antioxidants (ascorbic acid and reduced glutathione) were investigated in order to understand their variation with respect to pollution status of the sampling locations. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "B-protein", "I-protein", "O", "B-protein", "I-protein", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "B-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In addition to lipid peroxidation, the activities of antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glutathione S-transferase and two non-enzymatic antioxidants (ascorbic acid and reduced glutathione) were investigated in order to understand their variation with respect to pollution status of the sampling locations.
[ "In", "addition", "to", "lipid", "peroxidation", ",", "the", "activities", "of", "antioxidant", "enzymes", "such", "as", "superoxide", "dismutase", ",", "catalase", ",", "glutathione", "peroxidase", ",", "glutathione", "reductase", "and", "glutathione", "S", "-", "transferase", "and", "two", "non", "-", "enzymatic", "antioxidants", "(", "ascorbic", "acid", "and", "reduced", "glutathione", ")", "were", "investigated", "in", "order", "to", "understand", "their", "variation", "with", "respect", "to", "pollution", "status", "of", "the", "sampling", "locations", "." ]
[ "protein", "compound" ]
FOS is a gene, patient is a cohort-patient, patients is a cohort-patient, FOS is a gene, patient is a cohort-patient, patients is a cohort-patient, patients is a cohort-patient, colon cancer is a disease, FOS is a gene, MLH3 is a gene, KIAA0317 is a gene, SIPA1L1 is a gene, NUMB is a gene, SYNJ2BP is a gene, PSEN1 is a gene
68_task0
Sentence: ** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Down-regulation of mRNA expression in human chromosomal region 14q24.1-14q24.3 – the FOS region (patient counts with coordinate up-regulation). Grayscale cross-comparison plot of up-regulation patterns across patients (analogous to Figures 7, 10, 13). View this plot in conjunction with Figures 30 and 32. Down-regulation of mRNA expression in human chromosomal region 14q24.1-14q24.3 – the FOS region (patient counts with coordinate down-regulation). Grayscale cross-comparison plot of down-regulation patterns across patients (analogous to Figures 8, 11, 14). View this plot in conjunction with Figures 30 and 31. Note, that many more patients show down-regulation as indicated by dark spots in this plot than up-regulation as indicated by dark spots in Figure 31. This region has been reported in other studies to be frequently deleted in colon cancer metastases (see Table 1). The FOS oncogene is the 5th gene from the right and is one of the most strongly down-regulated genes in this region. Note the expression of MLH3, KIAA0317, KIAA0440/SIPA1L1, NUMB, SYNJ2BP and PSEN1. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: disease, gene, cohort-patient
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "I-disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "B-gene", "O", "O", "O", "B-gene", "O", "B-gene", "O", "B-gene", "O", "B-gene", "O", "O" ]
** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Down-regulation of mRNA expression in human chromosomal region 14q24.1-14q24.3 – the FOS region (patient counts with coordinate up-regulation). Grayscale cross-comparison plot of up-regulation patterns across patients (analogous to Figures 7, 10, 13). View this plot in conjunction with Figures 30 and 32. Down-regulation of mRNA expression in human chromosomal region 14q24.1-14q24.3 – the FOS region (patient counts with coordinate down-regulation). Grayscale cross-comparison plot of down-regulation patterns across patients (analogous to Figures 8, 11, 14). View this plot in conjunction with Figures 30 and 31. Note, that many more patients show down-regulation as indicated by dark spots in this plot than up-regulation as indicated by dark spots in Figure 31. This region has been reported in other studies to be frequently deleted in colon cancer metastases (see Table 1). The FOS oncogene is the 5th gene from the right and is one of the most strongly down-regulated genes in this region. Note the expression of MLH3, KIAA0317, KIAA0440/SIPA1L1, NUMB, SYNJ2BP and PSEN1.
[ "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "Down", "-", "regulation", "of", "mRNA", "expression", "in", "human", "chromosomal", "region", "14q24.1", "-", "14q24.3", "–", "the", "FOS", "region", "(", "patient", "counts", "with", "coordinate", "up", "-", "regulation", ")", ".", "Grayscale", "cross", "-", "comparison", "plot", "of", "up", "-", "regulation", "patterns", "across", "patients", "(", "analogous", "to", "Figures", "7", ",", "10", ",", "13", ")", ".", "View", "this", "plot", "in", "conjunction", "with", "Figures", "30", "and", "32", ".", "\n\n", "Down", "-", "regulation", "of", "mRNA", "expression", "in", "human", "chromosomal", "region", "14q24.1", "-", "14q24.3", "–", "the", "FOS", "region", "(", "patient", "counts", "with", "coordinate", "down", "-", "regulation", ")", ".", "Grayscale", "cross", "-", "comparison", "plot", "of", "down", "-", "regulation", "patterns", "across", "patients", "(", "analogous", "to", "Figures", "8", ",", "11", ",", "14", ")", ".", "View", "this", "plot", "in", "conjunction", "with", "Figures", "30", "and", "31", ".", "Note", ",", "that", "many", "more", "patients", "show", "down", "-", "regulation", "as", "indicated", "by", "dark", "spots", "in", "this", "plot", "than", "up", "-", "regulation", "as", "indicated", "by", "dark", "spots", "in", "Figure", "31", ".", "This", "region", "has", "been", "reported", "in", "other", "studies", "to", "be", "frequently", "deleted", "in", "colon", "cancer", "metastases", "(", "see", "Table", "1", ")", ".", "The", "FOS", "oncogene", "is", "the", "5th", "gene", "from", "the", "right", "and", "is", "one", "of", "the", "most", "strongly", "down", "-", "regulated", "genes", "in", "this", "region", ".", "Note", "the", "expression", "of", "MLH3", ",", "KIAA0317", ",", "KIAA0440", "/", "SIPA1L1", ",", "NUMB", ",", "SYNJ2BP", "and", "PSEN1", ".", "\n\n" ]
[ "disease", "gene", "cohort-patient", "body-part" ]
FOS is a gene, patient is a cohort-patient, patients is a cohort-patient, FOS is a gene, patient is a cohort-patient, patients is a cohort-patient, patients is a cohort-patient, colon cancer is a disease, FOS is a gene, MLH3 is a gene, KIAA0317 is a gene, SIPA1L1 is a gene, NUMB is a gene, SYNJ2BP is a gene, PSEN1 is a gene
68_task1
Sentence: ** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Down-regulation of mRNA expression in human chromosomal region 14q24.1-14q24.3 – the FOS region (patient counts with coordinate up-regulation). Grayscale cross-comparison plot of up-regulation patterns across patients (analogous to Figures 7, 10, 13). View this plot in conjunction with Figures 30 and 32. Down-regulation of mRNA expression in human chromosomal region 14q24.1-14q24.3 – the FOS region (patient counts with coordinate down-regulation). Grayscale cross-comparison plot of down-regulation patterns across patients (analogous to Figures 8, 11, 14). View this plot in conjunction with Figures 30 and 31. Note, that many more patients show down-regulation as indicated by dark spots in this plot than up-regulation as indicated by dark spots in Figure 31. This region has been reported in other studies to be frequently deleted in colon cancer metastases (see Table 1). The FOS oncogene is the 5th gene from the right and is one of the most strongly down-regulated genes in this region. Note the expression of MLH3, KIAA0317, KIAA0440/SIPA1L1, NUMB, SYNJ2BP and PSEN1. Instructions: please typing these entity words according to sentence: FOS, patient, patients, FOS, patient, patients, patients, colon cancer, FOS, MLH3, KIAA0317, SIPA1L1, NUMB, SYNJ2BP, PSEN1 Options: disease, gene, cohort-patient
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "I-disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "B-gene", "O", "O", "O", "B-gene", "O", "B-gene", "O", "B-gene", "O", "B-gene", "O", "O" ]
** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Down-regulation of mRNA expression in human chromosomal region 14q24.1-14q24.3 – the FOS region (patient counts with coordinate up-regulation). Grayscale cross-comparison plot of up-regulation patterns across patients (analogous to Figures 7, 10, 13). View this plot in conjunction with Figures 30 and 32. Down-regulation of mRNA expression in human chromosomal region 14q24.1-14q24.3 – the FOS region (patient counts with coordinate down-regulation). Grayscale cross-comparison plot of down-regulation patterns across patients (analogous to Figures 8, 11, 14). View this plot in conjunction with Figures 30 and 31. Note, that many more patients show down-regulation as indicated by dark spots in this plot than up-regulation as indicated by dark spots in Figure 31. This region has been reported in other studies to be frequently deleted in colon cancer metastases (see Table 1). The FOS oncogene is the 5th gene from the right and is one of the most strongly down-regulated genes in this region. Note the expression of MLH3, KIAA0317, KIAA0440/SIPA1L1, NUMB, SYNJ2BP and PSEN1.
[ "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "Down", "-", "regulation", "of", "mRNA", "expression", "in", "human", "chromosomal", "region", "14q24.1", "-", "14q24.3", "–", "the", "FOS", "region", "(", "patient", "counts", "with", "coordinate", "up", "-", "regulation", ")", ".", "Grayscale", "cross", "-", "comparison", "plot", "of", "up", "-", "regulation", "patterns", "across", "patients", "(", "analogous", "to", "Figures", "7", ",", "10", ",", "13", ")", ".", "View", "this", "plot", "in", "conjunction", "with", "Figures", "30", "and", "32", ".", "\n\n", "Down", "-", "regulation", "of", "mRNA", "expression", "in", "human", "chromosomal", "region", "14q24.1", "-", "14q24.3", "–", "the", "FOS", "region", "(", "patient", "counts", "with", "coordinate", "down", "-", "regulation", ")", ".", "Grayscale", "cross", "-", "comparison", "plot", "of", "down", "-", "regulation", "patterns", "across", "patients", "(", "analogous", "to", "Figures", "8", ",", "11", ",", "14", ")", ".", "View", "this", "plot", "in", "conjunction", "with", "Figures", "30", "and", "31", ".", "Note", ",", "that", "many", "more", "patients", "show", "down", "-", "regulation", "as", "indicated", "by", "dark", "spots", "in", "this", "plot", "than", "up", "-", "regulation", "as", "indicated", "by", "dark", "spots", "in", "Figure", "31", ".", "This", "region", "has", "been", "reported", "in", "other", "studies", "to", "be", "frequently", "deleted", "in", "colon", "cancer", "metastases", "(", "see", "Table", "1", ")", ".", "The", "FOS", "oncogene", "is", "the", "5th", "gene", "from", "the", "right", "and", "is", "one", "of", "the", "most", "strongly", "down", "-", "regulated", "genes", "in", "this", "region", ".", "Note", "the", "expression", "of", "MLH3", ",", "KIAA0317", ",", "KIAA0440", "/", "SIPA1L1", ",", "NUMB", ",", "SYNJ2BP", "and", "PSEN1", ".", "\n\n" ]
[ "disease", "gene", "cohort-patient", "body-part" ]
FOS, patient, patients, FOS, patient, patients, patients, colon cancer, FOS, MLH3, KIAA0317, SIPA1L1, NUMB, SYNJ2BP, PSEN1
68_task2
Sentence: ** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Down-regulation of mRNA expression in human chromosomal region 14q24.1-14q24.3 – the FOS region (patient counts with coordinate up-regulation). Grayscale cross-comparison plot of up-regulation patterns across patients (analogous to Figures 7, 10, 13). View this plot in conjunction with Figures 30 and 32. Down-regulation of mRNA expression in human chromosomal region 14q24.1-14q24.3 – the FOS region (patient counts with coordinate down-regulation). Grayscale cross-comparison plot of down-regulation patterns across patients (analogous to Figures 8, 11, 14). View this plot in conjunction with Figures 30 and 31. Note, that many more patients show down-regulation as indicated by dark spots in this plot than up-regulation as indicated by dark spots in Figure 31. This region has been reported in other studies to be frequently deleted in colon cancer metastases (see Table 1). The FOS oncogene is the 5th gene from the right and is one of the most strongly down-regulated genes in this region. Note the expression of MLH3, KIAA0317, KIAA0440/SIPA1L1, NUMB, SYNJ2BP and PSEN1. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "I-disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "B-gene", "O", "O", "O", "B-gene", "O", "B-gene", "O", "B-gene", "O", "B-gene", "O", "O" ]
** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Down-regulation of mRNA expression in human chromosomal region 14q24.1-14q24.3 – the FOS region (patient counts with coordinate up-regulation). Grayscale cross-comparison plot of up-regulation patterns across patients (analogous to Figures 7, 10, 13). View this plot in conjunction with Figures 30 and 32. Down-regulation of mRNA expression in human chromosomal region 14q24.1-14q24.3 – the FOS region (patient counts with coordinate down-regulation). Grayscale cross-comparison plot of down-regulation patterns across patients (analogous to Figures 8, 11, 14). View this plot in conjunction with Figures 30 and 31. Note, that many more patients show down-regulation as indicated by dark spots in this plot than up-regulation as indicated by dark spots in Figure 31. This region has been reported in other studies to be frequently deleted in colon cancer metastases (see Table 1). The FOS oncogene is the 5th gene from the right and is one of the most strongly down-regulated genes in this region. Note the expression of MLH3, KIAA0317, KIAA0440/SIPA1L1, NUMB, SYNJ2BP and PSEN1.
[ "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "Down", "-", "regulation", "of", "mRNA", "expression", "in", "human", "chromosomal", "region", "14q24.1", "-", "14q24.3", "–", "the", "FOS", "region", "(", "patient", "counts", "with", "coordinate", "up", "-", "regulation", ")", ".", "Grayscale", "cross", "-", "comparison", "plot", "of", "up", "-", "regulation", "patterns", "across", "patients", "(", "analogous", "to", "Figures", "7", ",", "10", ",", "13", ")", ".", "View", "this", "plot", "in", "conjunction", "with", "Figures", "30", "and", "32", ".", "\n\n", "Down", "-", "regulation", "of", "mRNA", "expression", "in", "human", "chromosomal", "region", "14q24.1", "-", "14q24.3", "–", "the", "FOS", "region", "(", "patient", "counts", "with", "coordinate", "down", "-", "regulation", ")", ".", "Grayscale", "cross", "-", "comparison", "plot", "of", "down", "-", "regulation", "patterns", "across", "patients", "(", "analogous", "to", "Figures", "8", ",", "11", ",", "14", ")", ".", "View", "this", "plot", "in", "conjunction", "with", "Figures", "30", "and", "31", ".", "Note", ",", "that", "many", "more", "patients", "show", "down", "-", "regulation", "as", "indicated", "by", "dark", "spots", "in", "this", "plot", "than", "up", "-", "regulation", "as", "indicated", "by", "dark", "spots", "in", "Figure", "31", ".", "This", "region", "has", "been", "reported", "in", "other", "studies", "to", "be", "frequently", "deleted", "in", "colon", "cancer", "metastases", "(", "see", "Table", "1", ")", ".", "The", "FOS", "oncogene", "is", "the", "5th", "gene", "from", "the", "right", "and", "is", "one", "of", "the", "most", "strongly", "down", "-", "regulated", "genes", "in", "this", "region", ".", "Note", "the", "expression", "of", "MLH3", ",", "KIAA0317", ",", "KIAA0440", "/", "SIPA1L1", ",", "NUMB", ",", "SYNJ2BP", "and", "PSEN1", ".", "\n\n" ]
[ "disease", "gene", "cohort-patient", "body-part" ]
diacylglycerol acyltransferase is a GENE-Y, prenylflavonoids is a CHEMICAL
15114505_task0
Sentence: In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids from Sophora flavescens. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL
[ "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O" ]
In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids from Sophora flavescens.
[ "In", "vitro", "inhibition", "of", "diacylglycerol", "acyltransferase", "by", "prenylflavonoids", "from", "Sophora", "flavescens", "." ]
[ "GENE-Y", "CHEMICAL" ]
diacylglycerol acyltransferase is a GENE-Y, prenylflavonoids is a CHEMICAL
15114505_task1
Sentence: In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids from Sophora flavescens. Instructions: please typing these entity words according to sentence: diacylglycerol acyltransferase, prenylflavonoids Options: GENE-Y, CHEMICAL
[ "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O" ]
In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids from Sophora flavescens.
[ "In", "vitro", "inhibition", "of", "diacylglycerol", "acyltransferase", "by", "prenylflavonoids", "from", "Sophora", "flavescens", "." ]
[ "GENE-Y", "CHEMICAL" ]
diacylglycerol acyltransferase, prenylflavonoids
15114505_task2
Sentence: In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids from Sophora flavescens. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O" ]
In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids from Sophora flavescens.
[ "In", "vitro", "inhibition", "of", "diacylglycerol", "acyltransferase", "by", "prenylflavonoids", "from", "Sophora", "flavescens", "." ]
[ "GENE-Y", "CHEMICAL" ]
Emotionen is an umlsterm, Itemanalyse is an umlsterm, Patienten is an umlsterm, Instrumente is an umlsterm, Therapieresponse is an umlsterm
DerNervenarzt.80690586.ger.abstr_task0
Sentence: Wir untersuchten 3 kurze bzw. vielversprechende Selbstratingskalen zur Abbildung emotionaler insbesondere depressiver Befindlichkeit : , eine sehr einfache visuelle Analogskala mit nur 5 Items , eine Kurzform der Eigenschaftswoerterliste " " und eine sehr differenzierte Skala zur Erfassung von gegenwaertiger Auspraegung , moeglicher Ansprechbarkeit und Ausdrucksfaehigkeit verschiedener Emotionen . Hierzu ueberprueften wir statistische Kennwerte der Itemanalyse , Reliabilitaet , Validitaet und Verlaufsmessung anhand einer Stichprobe stationaerer depressiver Patienten ( n=35) bei Aufnahme und nach 4 Wochen in weitgehender Remission . Die Verfahren erwiesen sich als reliable ( Cronbach- zwischen 0.48 und 0.97 ) und z.T. sehr valide Instrumente ( konkurrente Validitaet zwischen 0.04 und 0.87 ) , die jedoch zur zuverlaessigen Verlaufsmessung noch weiter validiert werden muessten . Vielversprechend erscheinen Ansaetze , depressive Subsyndrome wie etwa Antrieb " oder " positive Emotionalitaet " " getrennt zu erfassen , um so z.B. beginnende Therapieresponse besser dokumentieren zu koennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Wir untersuchten 3 kurze bzw. vielversprechende Selbstratingskalen zur Abbildung emotionaler insbesondere depressiver Befindlichkeit : , eine sehr einfache visuelle Analogskala mit nur 5 Items , eine Kurzform der Eigenschaftswoerterliste " " und eine sehr differenzierte Skala zur Erfassung von gegenwaertiger Auspraegung , moeglicher Ansprechbarkeit und Ausdrucksfaehigkeit verschiedener Emotionen . Hierzu ueberprueften wir statistische Kennwerte der Itemanalyse , Reliabilitaet , Validitaet und Verlaufsmessung anhand einer Stichprobe stationaerer depressiver Patienten ( n=35) bei Aufnahme und nach 4 Wochen in weitgehender Remission . Die Verfahren erwiesen sich als reliable ( Cronbach- zwischen 0.48 und 0.97 ) und z.T. sehr valide Instrumente ( konkurrente Validitaet zwischen 0.04 und 0.87 ) , die jedoch zur zuverlaessigen Verlaufsmessung noch weiter validiert werden muessten . Vielversprechend erscheinen Ansaetze , depressive Subsyndrome wie etwa Antrieb " oder " positive Emotionalitaet " " getrennt zu erfassen , um so z.B. beginnende Therapieresponse besser dokumentieren zu koennen .
[ "Wir", "untersuchten", "3", "kurze", "bzw", ".", "vielversprechende", "Selbstratingskalen", "zur", "Abbildung", "emotionaler", "insbesondere", "depressiver", "Befindlichkeit", ":", ",", "eine", "sehr", "einfache", "visuelle", "Analogskala", "mit", "nur", "5", "Items", ",", "eine", "Kurzform", "der", "Eigenschaftswoerterliste", "\"", "\"", "und", "eine", "sehr", "differenzierte", "Skala", "zur", "Erfassung", "von", "gegenwaertiger", "Auspraegung", ",", "moeglicher", "Ansprechbarkeit", "und", "Ausdrucksfaehigkeit", "verschiedener", "Emotionen", ".", "Hierzu", "ueberprueften", "wir", "statistische", "Kennwerte", "der", "Itemanalyse", ",", "Reliabilitaet", ",", "Validitaet", "und", "Verlaufsmessung", "anhand", "einer", "Stichprobe", "stationaerer", "depressiver", "Patienten", "(", "n=35", ")", "bei", "Aufnahme", "und", "nach", "4", "Wochen", "in", "weitgehender", "Remission", ".", "Die", "Verfahren", "erwiesen", "sich", "als", "reliable", "(", "Cronbach-", "zwischen", "0.48", "und", "0.97", ")", "und", "z.", "T.", "sehr", "valide", "Instrumente", "(", "konkurrente", "Validitaet", "zwischen", "0.04", "und", "0.87", ")", ",", "die", "jedoch", "zur", "zuverlaessigen", "Verlaufsmessung", "noch", "weiter", "validiert", "werden", "muessten", ".", "Vielversprechend", "erscheinen", "Ansaetze", ",", "depressive", "Subsyndrome", "wie", "etwa", "Antrieb", "\"", "oder", "\"", "positive", "Emotionalitaet", "\"", "\"", "getrennt", "zu", "erfassen", ",", "um", "so", "z.", "B.", "beginnende", "Therapieresponse", "besser", "dokumentieren", "zu", "koennen", "." ]
[ "umlsterm" ]
Emotionen is an umlsterm, Itemanalyse is an umlsterm, Patienten is an umlsterm, Instrumente is an umlsterm, Therapieresponse is an umlsterm
DerNervenarzt.80690586.ger.abstr_task1
Sentence: Wir untersuchten 3 kurze bzw. vielversprechende Selbstratingskalen zur Abbildung emotionaler insbesondere depressiver Befindlichkeit : , eine sehr einfache visuelle Analogskala mit nur 5 Items , eine Kurzform der Eigenschaftswoerterliste " " und eine sehr differenzierte Skala zur Erfassung von gegenwaertiger Auspraegung , moeglicher Ansprechbarkeit und Ausdrucksfaehigkeit verschiedener Emotionen . Hierzu ueberprueften wir statistische Kennwerte der Itemanalyse , Reliabilitaet , Validitaet und Verlaufsmessung anhand einer Stichprobe stationaerer depressiver Patienten ( n=35) bei Aufnahme und nach 4 Wochen in weitgehender Remission . Die Verfahren erwiesen sich als reliable ( Cronbach- zwischen 0.48 und 0.97 ) und z.T. sehr valide Instrumente ( konkurrente Validitaet zwischen 0.04 und 0.87 ) , die jedoch zur zuverlaessigen Verlaufsmessung noch weiter validiert werden muessten . Vielversprechend erscheinen Ansaetze , depressive Subsyndrome wie etwa Antrieb " oder " positive Emotionalitaet " " getrennt zu erfassen , um so z.B. beginnende Therapieresponse besser dokumentieren zu koennen . Instructions: please typing these entity words according to sentence: Emotionen, Itemanalyse, Patienten, Instrumente, Therapieresponse Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Wir untersuchten 3 kurze bzw. vielversprechende Selbstratingskalen zur Abbildung emotionaler insbesondere depressiver Befindlichkeit : , eine sehr einfache visuelle Analogskala mit nur 5 Items , eine Kurzform der Eigenschaftswoerterliste " " und eine sehr differenzierte Skala zur Erfassung von gegenwaertiger Auspraegung , moeglicher Ansprechbarkeit und Ausdrucksfaehigkeit verschiedener Emotionen . Hierzu ueberprueften wir statistische Kennwerte der Itemanalyse , Reliabilitaet , Validitaet und Verlaufsmessung anhand einer Stichprobe stationaerer depressiver Patienten ( n=35) bei Aufnahme und nach 4 Wochen in weitgehender Remission . Die Verfahren erwiesen sich als reliable ( Cronbach- zwischen 0.48 und 0.97 ) und z.T. sehr valide Instrumente ( konkurrente Validitaet zwischen 0.04 und 0.87 ) , die jedoch zur zuverlaessigen Verlaufsmessung noch weiter validiert werden muessten . Vielversprechend erscheinen Ansaetze , depressive Subsyndrome wie etwa Antrieb " oder " positive Emotionalitaet " " getrennt zu erfassen , um so z.B. beginnende Therapieresponse besser dokumentieren zu koennen .
[ "Wir", "untersuchten", "3", "kurze", "bzw", ".", "vielversprechende", "Selbstratingskalen", "zur", "Abbildung", "emotionaler", "insbesondere", "depressiver", "Befindlichkeit", ":", ",", "eine", "sehr", "einfache", "visuelle", "Analogskala", "mit", "nur", "5", "Items", ",", "eine", "Kurzform", "der", "Eigenschaftswoerterliste", "\"", "\"", "und", "eine", "sehr", "differenzierte", "Skala", "zur", "Erfassung", "von", "gegenwaertiger", "Auspraegung", ",", "moeglicher", "Ansprechbarkeit", "und", "Ausdrucksfaehigkeit", "verschiedener", "Emotionen", ".", "Hierzu", "ueberprueften", "wir", "statistische", "Kennwerte", "der", "Itemanalyse", ",", "Reliabilitaet", ",", "Validitaet", "und", "Verlaufsmessung", "anhand", "einer", "Stichprobe", "stationaerer", "depressiver", "Patienten", "(", "n=35", ")", "bei", "Aufnahme", "und", "nach", "4", "Wochen", "in", "weitgehender", "Remission", ".", "Die", "Verfahren", "erwiesen", "sich", "als", "reliable", "(", "Cronbach-", "zwischen", "0.48", "und", "0.97", ")", "und", "z.", "T.", "sehr", "valide", "Instrumente", "(", "konkurrente", "Validitaet", "zwischen", "0.04", "und", "0.87", ")", ",", "die", "jedoch", "zur", "zuverlaessigen", "Verlaufsmessung", "noch", "weiter", "validiert", "werden", "muessten", ".", "Vielversprechend", "erscheinen", "Ansaetze", ",", "depressive", "Subsyndrome", "wie", "etwa", "Antrieb", "\"", "oder", "\"", "positive", "Emotionalitaet", "\"", "\"", "getrennt", "zu", "erfassen", ",", "um", "so", "z.", "B.", "beginnende", "Therapieresponse", "besser", "dokumentieren", "zu", "koennen", "." ]
[ "umlsterm" ]
Emotionen, Itemanalyse, Patienten, Instrumente, Therapieresponse
DerNervenarzt.80690586.ger.abstr_task2
Sentence: Wir untersuchten 3 kurze bzw. vielversprechende Selbstratingskalen zur Abbildung emotionaler insbesondere depressiver Befindlichkeit : , eine sehr einfache visuelle Analogskala mit nur 5 Items , eine Kurzform der Eigenschaftswoerterliste " " und eine sehr differenzierte Skala zur Erfassung von gegenwaertiger Auspraegung , moeglicher Ansprechbarkeit und Ausdrucksfaehigkeit verschiedener Emotionen . Hierzu ueberprueften wir statistische Kennwerte der Itemanalyse , Reliabilitaet , Validitaet und Verlaufsmessung anhand einer Stichprobe stationaerer depressiver Patienten ( n=35) bei Aufnahme und nach 4 Wochen in weitgehender Remission . Die Verfahren erwiesen sich als reliable ( Cronbach- zwischen 0.48 und 0.97 ) und z.T. sehr valide Instrumente ( konkurrente Validitaet zwischen 0.04 und 0.87 ) , die jedoch zur zuverlaessigen Verlaufsmessung noch weiter validiert werden muessten . Vielversprechend erscheinen Ansaetze , depressive Subsyndrome wie etwa Antrieb " oder " positive Emotionalitaet " " getrennt zu erfassen , um so z.B. beginnende Therapieresponse besser dokumentieren zu koennen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Wir untersuchten 3 kurze bzw. vielversprechende Selbstratingskalen zur Abbildung emotionaler insbesondere depressiver Befindlichkeit : , eine sehr einfache visuelle Analogskala mit nur 5 Items , eine Kurzform der Eigenschaftswoerterliste " " und eine sehr differenzierte Skala zur Erfassung von gegenwaertiger Auspraegung , moeglicher Ansprechbarkeit und Ausdrucksfaehigkeit verschiedener Emotionen . Hierzu ueberprueften wir statistische Kennwerte der Itemanalyse , Reliabilitaet , Validitaet und Verlaufsmessung anhand einer Stichprobe stationaerer depressiver Patienten ( n=35) bei Aufnahme und nach 4 Wochen in weitgehender Remission . Die Verfahren erwiesen sich als reliable ( Cronbach- zwischen 0.48 und 0.97 ) und z.T. sehr valide Instrumente ( konkurrente Validitaet zwischen 0.04 und 0.87 ) , die jedoch zur zuverlaessigen Verlaufsmessung noch weiter validiert werden muessten . Vielversprechend erscheinen Ansaetze , depressive Subsyndrome wie etwa Antrieb " oder " positive Emotionalitaet " " getrennt zu erfassen , um so z.B. beginnende Therapieresponse besser dokumentieren zu koennen .
[ "Wir", "untersuchten", "3", "kurze", "bzw", ".", "vielversprechende", "Selbstratingskalen", "zur", "Abbildung", "emotionaler", "insbesondere", "depressiver", "Befindlichkeit", ":", ",", "eine", "sehr", "einfache", "visuelle", "Analogskala", "mit", "nur", "5", "Items", ",", "eine", "Kurzform", "der", "Eigenschaftswoerterliste", "\"", "\"", "und", "eine", "sehr", "differenzierte", "Skala", "zur", "Erfassung", "von", "gegenwaertiger", "Auspraegung", ",", "moeglicher", "Ansprechbarkeit", "und", "Ausdrucksfaehigkeit", "verschiedener", "Emotionen", ".", "Hierzu", "ueberprueften", "wir", "statistische", "Kennwerte", "der", "Itemanalyse", ",", "Reliabilitaet", ",", "Validitaet", "und", "Verlaufsmessung", "anhand", "einer", "Stichprobe", "stationaerer", "depressiver", "Patienten", "(", "n=35", ")", "bei", "Aufnahme", "und", "nach", "4", "Wochen", "in", "weitgehender", "Remission", ".", "Die", "Verfahren", "erwiesen", "sich", "als", "reliable", "(", "Cronbach-", "zwischen", "0.48", "und", "0.97", ")", "und", "z.", "T.", "sehr", "valide", "Instrumente", "(", "konkurrente", "Validitaet", "zwischen", "0.04", "und", "0.87", ")", ",", "die", "jedoch", "zur", "zuverlaessigen", "Verlaufsmessung", "noch", "weiter", "validiert", "werden", "muessten", ".", "Vielversprechend", "erscheinen", "Ansaetze", ",", "depressive", "Subsyndrome", "wie", "etwa", "Antrieb", "\"", "oder", "\"", "positive", "Emotionalitaet", "\"", "\"", "getrennt", "zu", "erfassen", ",", "um", "so", "z.", "B.", "beginnende", "Therapieresponse", "besser", "dokumentieren", "zu", "koennen", "." ]
[ "umlsterm" ]
RAD52 is a Gene/protein/RNA, RAD51 is a Gene/protein/RNA, RAD51 is a Gene, RAD52 is a Gene, RAD52 is a Gene/protein/RNA, Rad51 is a Individual_protein, Rad52 is a Individual_protein
289_task0
Sentence: From these observations it is concluded that (i) RAD52 is required for high levels of both gene conversions and reciprocal crossovers, (ii) that RAD51 is not required for intrachromosomal crossovers, and (iii) that RAD51 and RAD52 have different functions, or that RAD52 has functions in addition to those of the Rad51/Rad52 protein complex. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA, Gene, Individual_protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O" ]
From these observations it is concluded that (i) RAD52 is required for high levels of both gene conversions and reciprocal crossovers, (ii) that RAD51 is not required for intrachromosomal crossovers, and (iii) that RAD51 and RAD52 have different functions, or that RAD52 has functions in addition to those of the Rad51/Rad52 protein complex.
[ "From", "these", "observations", "it", "is", "concluded", "that", "(", "i", ")", "RAD52", "is", "required", "for", "high", "levels", "of", "both", "gene", "conversions", "and", "reciprocal", "crossovers", ",", "(", "ii", ")", "that", "RAD51", "is", "not", "required", "for", "intrachromosomal", "crossovers", ",", "and", "(", "iii", ")", "that", "RAD51", "and", "RAD52", "have", "different", "functions", ",", "or", "that", "RAD52", "has", "functions", "in", "addition", "to", "those", "of", "the", "Rad51", "/", "Rad52", "protein", "complex", "." ]
[ "Gene/protein/RNA", "Gene", "Individual_protein" ]
RAD52 is a Gene/protein/RNA, RAD51 is a Gene/protein/RNA, RAD51 is a Gene, RAD52 is a Gene, RAD52 is a Gene/protein/RNA, Rad51 is a Individual_protein, Rad52 is a Individual_protein
289_task1
Sentence: From these observations it is concluded that (i) RAD52 is required for high levels of both gene conversions and reciprocal crossovers, (ii) that RAD51 is not required for intrachromosomal crossovers, and (iii) that RAD51 and RAD52 have different functions, or that RAD52 has functions in addition to those of the Rad51/Rad52 protein complex. Instructions: please typing these entity words according to sentence: RAD52, RAD51, RAD51, RAD52, RAD52, Rad51, Rad52 Options: Gene/protein/RNA, Gene, Individual_protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O" ]
From these observations it is concluded that (i) RAD52 is required for high levels of both gene conversions and reciprocal crossovers, (ii) that RAD51 is not required for intrachromosomal crossovers, and (iii) that RAD51 and RAD52 have different functions, or that RAD52 has functions in addition to those of the Rad51/Rad52 protein complex.
[ "From", "these", "observations", "it", "is", "concluded", "that", "(", "i", ")", "RAD52", "is", "required", "for", "high", "levels", "of", "both", "gene", "conversions", "and", "reciprocal", "crossovers", ",", "(", "ii", ")", "that", "RAD51", "is", "not", "required", "for", "intrachromosomal", "crossovers", ",", "and", "(", "iii", ")", "that", "RAD51", "and", "RAD52", "have", "different", "functions", ",", "or", "that", "RAD52", "has", "functions", "in", "addition", "to", "those", "of", "the", "Rad51", "/", "Rad52", "protein", "complex", "." ]
[ "Gene/protein/RNA", "Gene", "Individual_protein" ]
RAD52, RAD51, RAD51, RAD52, RAD52, Rad51, Rad52
289_task2
Sentence: From these observations it is concluded that (i) RAD52 is required for high levels of both gene conversions and reciprocal crossovers, (ii) that RAD51 is not required for intrachromosomal crossovers, and (iii) that RAD51 and RAD52 have different functions, or that RAD52 has functions in addition to those of the Rad51/Rad52 protein complex. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O" ]
From these observations it is concluded that (i) RAD52 is required for high levels of both gene conversions and reciprocal crossovers, (ii) that RAD51 is not required for intrachromosomal crossovers, and (iii) that RAD51 and RAD52 have different functions, or that RAD52 has functions in addition to those of the Rad51/Rad52 protein complex.
[ "From", "these", "observations", "it", "is", "concluded", "that", "(", "i", ")", "RAD52", "is", "required", "for", "high", "levels", "of", "both", "gene", "conversions", "and", "reciprocal", "crossovers", ",", "(", "ii", ")", "that", "RAD51", "is", "not", "required", "for", "intrachromosomal", "crossovers", ",", "and", "(", "iii", ")", "that", "RAD51", "and", "RAD52", "have", "different", "functions", ",", "or", "that", "RAD52", "has", "functions", "in", "addition", "to", "those", "of", "the", "Rad51", "/", "Rad52", "protein", "complex", "." ]
[ "Gene/protein/RNA", "Gene", "Individual_protein" ]
Abstract is an umlsterm, Prostate - specific antigen is an umlsterm, PSA is an umlsterm, marker is an umlsterm, prostate cancer is an umlsterm, monitoring of patients is an umlsterm, diagnosis is an umlsterm, forms is an umlsterm, PSA is an umlsterm, human is an umlsterm, kallikrein is an umlsterm, benign prostatic hyperplasia is an umlsterm, prostate cancer is an umlsterm, prostate cancer is an umlsterm, PSA is an umlsterm
DerUrologeA.00390313.eng.abstr_task0
Sentence: Abstract Prostate-specific antigen ( PSA ) is the most useful marker in the early detection of prostate cancer and in the monitoring of patients with this diagnosis . Molecular forms of PSA and human kallikrein 2 ( hK2) have been used to discriminate between benign prostatic hyperplasia and prostate cancer , as well as for the detection of prostate cancer within the gray zone of PSA . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Abstract Prostate-specific antigen ( PSA ) is the most useful marker in the early detection of prostate cancer and in the monitoring of patients with this diagnosis . Molecular forms of PSA and human kallikrein 2 ( hK2) have been used to discriminate between benign prostatic hyperplasia and prostate cancer , as well as for the detection of prostate cancer within the gray zone of PSA .
[ "Abstract", "Prostate", "-", "specific", "antigen", "(", "PSA", ")", "is", "the", "most", "useful", "marker", "in", "the", "early", "detection", "of", "prostate", "cancer", "and", "in", "the", "monitoring", "of", "patients", "with", "this", "diagnosis", ".", "Molecular", "forms", "of", "PSA", "and", "human", "kallikrein", "2", "(", "hK2", ")", "have", "been", "used", "to", "discriminate", "between", "benign", "prostatic", "hyperplasia", "and", "prostate", "cancer", ",", "as", "well", "as", "for", "the", "detection", "of", "prostate", "cancer", "within", "the", "gray", "zone", "of", "PSA", "." ]
[ "umlsterm" ]
Abstract is an umlsterm, Prostate - specific antigen is an umlsterm, PSA is an umlsterm, marker is an umlsterm, prostate cancer is an umlsterm, monitoring of patients is an umlsterm, diagnosis is an umlsterm, forms is an umlsterm, PSA is an umlsterm, human is an umlsterm, kallikrein is an umlsterm, benign prostatic hyperplasia is an umlsterm, prostate cancer is an umlsterm, prostate cancer is an umlsterm, PSA is an umlsterm
DerUrologeA.00390313.eng.abstr_task1
Sentence: Abstract Prostate-specific antigen ( PSA ) is the most useful marker in the early detection of prostate cancer and in the monitoring of patients with this diagnosis . Molecular forms of PSA and human kallikrein 2 ( hK2) have been used to discriminate between benign prostatic hyperplasia and prostate cancer , as well as for the detection of prostate cancer within the gray zone of PSA . Instructions: please typing these entity words according to sentence: Abstract, Prostate - specific antigen, PSA, marker, prostate cancer, monitoring of patients, diagnosis, forms, PSA, human, kallikrein, benign prostatic hyperplasia, prostate cancer, prostate cancer, PSA Options: umlsterm
[ "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Abstract Prostate-specific antigen ( PSA ) is the most useful marker in the early detection of prostate cancer and in the monitoring of patients with this diagnosis . Molecular forms of PSA and human kallikrein 2 ( hK2) have been used to discriminate between benign prostatic hyperplasia and prostate cancer , as well as for the detection of prostate cancer within the gray zone of PSA .
[ "Abstract", "Prostate", "-", "specific", "antigen", "(", "PSA", ")", "is", "the", "most", "useful", "marker", "in", "the", "early", "detection", "of", "prostate", "cancer", "and", "in", "the", "monitoring", "of", "patients", "with", "this", "diagnosis", ".", "Molecular", "forms", "of", "PSA", "and", "human", "kallikrein", "2", "(", "hK2", ")", "have", "been", "used", "to", "discriminate", "between", "benign", "prostatic", "hyperplasia", "and", "prostate", "cancer", ",", "as", "well", "as", "for", "the", "detection", "of", "prostate", "cancer", "within", "the", "gray", "zone", "of", "PSA", "." ]
[ "umlsterm" ]
Abstract, Prostate - specific antigen, PSA, marker, prostate cancer, monitoring of patients, diagnosis, forms, PSA, human, kallikrein, benign prostatic hyperplasia, prostate cancer, prostate cancer, PSA
DerUrologeA.00390313.eng.abstr_task2
Sentence: Abstract Prostate-specific antigen ( PSA ) is the most useful marker in the early detection of prostate cancer and in the monitoring of patients with this diagnosis . Molecular forms of PSA and human kallikrein 2 ( hK2) have been used to discriminate between benign prostatic hyperplasia and prostate cancer , as well as for the detection of prostate cancer within the gray zone of PSA . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Abstract Prostate-specific antigen ( PSA ) is the most useful marker in the early detection of prostate cancer and in the monitoring of patients with this diagnosis . Molecular forms of PSA and human kallikrein 2 ( hK2) have been used to discriminate between benign prostatic hyperplasia and prostate cancer , as well as for the detection of prostate cancer within the gray zone of PSA .
[ "Abstract", "Prostate", "-", "specific", "antigen", "(", "PSA", ")", "is", "the", "most", "useful", "marker", "in", "the", "early", "detection", "of", "prostate", "cancer", "and", "in", "the", "monitoring", "of", "patients", "with", "this", "diagnosis", ".", "Molecular", "forms", "of", "PSA", "and", "human", "kallikrein", "2", "(", "hK2", ")", "have", "been", "used", "to", "discriminate", "between", "benign", "prostatic", "hyperplasia", "and", "prostate", "cancer", ",", "as", "well", "as", "for", "the", "detection", "of", "prostate", "cancer", "within", "the", "gray", "zone", "of", "PSA", "." ]
[ "umlsterm" ]
Tachykardien is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Notfalloperationen is an umlsterm, Intubation is an umlsterm, Ventilation is an umlsterm, Anaesthesie is an umlsterm, Fentanyl is an umlsterm, Etomidat is an umlsterm, Tachykardien is an umlsterm, Hypokaliaemie is an umlsterm, Hypoxie is an umlsterm, Hyperkapnie is an umlsterm, Thoraximpedanz - messende is an umlsterm, Komplikationen is an umlsterm, gezielt is an umlsterm
DerAnaesthesist.60450856.ger.abstr_task0
Sentence: Wir berichten ueber das Auftreten von unerwarteten Tachykardien waehrend der Narkoseeinleitung , die bei 2 Patienten durch frequenzadaptive Herzschrittmacher ( SM ) ausgeloest wurden . In beiden Faellen unterzogen sich Patienten mit frequenzadaptiven SM Notfalloperationen . Waehrend der Narkoseeinleitung stieg die stimulierte Herzfrequenz nach der Intubation und dem Beginn der kontrollierten Ventilation auf 140 bzw. 130 min-1 an . Zunaechst wurden die Anstiege der Herzfrequenz als inadaequate Anaesthesie gedeutet und die Narkosen mittels Fentanyl und Etomidat vertieft . Bei Fortdauer der Tachykardien wurden andere Ursachen wie Hypokaliaemie , Hypoxie , Hyperkapnie und allergische Reaktion ausgeschlossen , bevor an die Interaktion der frequenzadaptiven SM gedacht wurde . In beiden Faellen handelte es sich um Thoraximpedanz-messende Systeme . Mit Verminderung des Atemminutenvolumens sank die Herzfrequenz innerhalb von 3-5 min ab . Diese Fallbeispiele zeigen , dass das anaesthesiologische Management mit frequenzadaptiven SM interagieren kann . Zur Vermeidung derartiger Komplikationen muss der Anaesthesist an die Besonderheiten dieser Systeme denken , um das perioperative Management entsprechend auszurichten und intraoperativen Interaktionen durch Kenntnis der SM-Funktionsweise gezielt entgegenzuwirken . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Wir berichten ueber das Auftreten von unerwarteten Tachykardien waehrend der Narkoseeinleitung , die bei 2 Patienten durch frequenzadaptive Herzschrittmacher ( SM ) ausgeloest wurden . In beiden Faellen unterzogen sich Patienten mit frequenzadaptiven SM Notfalloperationen . Waehrend der Narkoseeinleitung stieg die stimulierte Herzfrequenz nach der Intubation und dem Beginn der kontrollierten Ventilation auf 140 bzw. 130 min-1 an . Zunaechst wurden die Anstiege der Herzfrequenz als inadaequate Anaesthesie gedeutet und die Narkosen mittels Fentanyl und Etomidat vertieft . Bei Fortdauer der Tachykardien wurden andere Ursachen wie Hypokaliaemie , Hypoxie , Hyperkapnie und allergische Reaktion ausgeschlossen , bevor an die Interaktion der frequenzadaptiven SM gedacht wurde . In beiden Faellen handelte es sich um Thoraximpedanz-messende Systeme . Mit Verminderung des Atemminutenvolumens sank die Herzfrequenz innerhalb von 3-5 min ab . Diese Fallbeispiele zeigen , dass das anaesthesiologische Management mit frequenzadaptiven SM interagieren kann . Zur Vermeidung derartiger Komplikationen muss der Anaesthesist an die Besonderheiten dieser Systeme denken , um das perioperative Management entsprechend auszurichten und intraoperativen Interaktionen durch Kenntnis der SM-Funktionsweise gezielt entgegenzuwirken .
[ "Wir", "berichten", "ueber", "das", "Auftreten", "von", "unerwarteten", "Tachykardien", "waehrend", "der", "Narkoseeinleitung", ",", "die", "bei", "2", "Patienten", "durch", "frequenzadaptive", "Herzschrittmacher", "(", "SM", ")", "ausgeloest", "wurden", ".", "In", "beiden", "Faellen", "unterzogen", "sich", "Patienten", "mit", "frequenzadaptiven", "SM", "Notfalloperationen", ".", "Waehrend", "der", "Narkoseeinleitung", "stieg", "die", "stimulierte", "Herzfrequenz", "nach", "der", "Intubation", "und", "dem", "Beginn", "der", "kontrollierten", "Ventilation", "auf", "140", "bzw", ".", "130", "min-1", "an", ".", "Zunaechst", "wurden", "die", "Anstiege", "der", "Herzfrequenz", "als", "inadaequate", "Anaesthesie", "gedeutet", "und", "die", "Narkosen", "mittels", "Fentanyl", "und", "Etomidat", "vertieft", ".", "Bei", "Fortdauer", "der", "Tachykardien", "wurden", "andere", "Ursachen", "wie", "Hypokaliaemie", ",", "Hypoxie", ",", "Hyperkapnie", "und", "allergische", "Reaktion", "ausgeschlossen", ",", "bevor", "an", "die", "Interaktion", "der", "frequenzadaptiven", "SM", "gedacht", "wurde", ".", "In", "beiden", "Faellen", "handelte", "es", "sich", "um", "Thoraximpedanz", "-", "messende", "Systeme", ".", "Mit", "Verminderung", "des", "Atemminutenvolumens", "sank", "die", "Herzfrequenz", "innerhalb", "von", "3", "-", "5", "min", "ab", ".", "Diese", "Fallbeispiele", "zeigen", ",", "dass", "das", "anaesthesiologische", "Management", "mit", "frequenzadaptiven", "SM", "interagieren", "kann", ".", "Zur", "Vermeidung", "derartiger", "Komplikationen", "muss", "der", "Anaesthesist", "an", "die", "Besonderheiten", "dieser", "Systeme", "denken", ",", "um", "das", "perioperative", "Management", "entsprechend", "auszurichten", "und", "intraoperativen", "Interaktionen", "durch", "Kenntnis", "der", "SM", "-", "Funktionsweise", "gezielt", "entgegenzuwirken", "." ]
[ "umlsterm" ]
Tachykardien is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Notfalloperationen is an umlsterm, Intubation is an umlsterm, Ventilation is an umlsterm, Anaesthesie is an umlsterm, Fentanyl is an umlsterm, Etomidat is an umlsterm, Tachykardien is an umlsterm, Hypokaliaemie is an umlsterm, Hypoxie is an umlsterm, Hyperkapnie is an umlsterm, Thoraximpedanz - messende is an umlsterm, Komplikationen is an umlsterm, gezielt is an umlsterm
DerAnaesthesist.60450856.ger.abstr_task1
Sentence: Wir berichten ueber das Auftreten von unerwarteten Tachykardien waehrend der Narkoseeinleitung , die bei 2 Patienten durch frequenzadaptive Herzschrittmacher ( SM ) ausgeloest wurden . In beiden Faellen unterzogen sich Patienten mit frequenzadaptiven SM Notfalloperationen . Waehrend der Narkoseeinleitung stieg die stimulierte Herzfrequenz nach der Intubation und dem Beginn der kontrollierten Ventilation auf 140 bzw. 130 min-1 an . Zunaechst wurden die Anstiege der Herzfrequenz als inadaequate Anaesthesie gedeutet und die Narkosen mittels Fentanyl und Etomidat vertieft . Bei Fortdauer der Tachykardien wurden andere Ursachen wie Hypokaliaemie , Hypoxie , Hyperkapnie und allergische Reaktion ausgeschlossen , bevor an die Interaktion der frequenzadaptiven SM gedacht wurde . In beiden Faellen handelte es sich um Thoraximpedanz-messende Systeme . Mit Verminderung des Atemminutenvolumens sank die Herzfrequenz innerhalb von 3-5 min ab . Diese Fallbeispiele zeigen , dass das anaesthesiologische Management mit frequenzadaptiven SM interagieren kann . Zur Vermeidung derartiger Komplikationen muss der Anaesthesist an die Besonderheiten dieser Systeme denken , um das perioperative Management entsprechend auszurichten und intraoperativen Interaktionen durch Kenntnis der SM-Funktionsweise gezielt entgegenzuwirken . Instructions: please typing these entity words according to sentence: Tachykardien, Patienten, Patienten, Notfalloperationen, Intubation, Ventilation, Anaesthesie, Fentanyl, Etomidat, Tachykardien, Hypokaliaemie, Hypoxie, Hyperkapnie, Thoraximpedanz - messende, Komplikationen, gezielt Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Wir berichten ueber das Auftreten von unerwarteten Tachykardien waehrend der Narkoseeinleitung , die bei 2 Patienten durch frequenzadaptive Herzschrittmacher ( SM ) ausgeloest wurden . In beiden Faellen unterzogen sich Patienten mit frequenzadaptiven SM Notfalloperationen . Waehrend der Narkoseeinleitung stieg die stimulierte Herzfrequenz nach der Intubation und dem Beginn der kontrollierten Ventilation auf 140 bzw. 130 min-1 an . Zunaechst wurden die Anstiege der Herzfrequenz als inadaequate Anaesthesie gedeutet und die Narkosen mittels Fentanyl und Etomidat vertieft . Bei Fortdauer der Tachykardien wurden andere Ursachen wie Hypokaliaemie , Hypoxie , Hyperkapnie und allergische Reaktion ausgeschlossen , bevor an die Interaktion der frequenzadaptiven SM gedacht wurde . In beiden Faellen handelte es sich um Thoraximpedanz-messende Systeme . Mit Verminderung des Atemminutenvolumens sank die Herzfrequenz innerhalb von 3-5 min ab . Diese Fallbeispiele zeigen , dass das anaesthesiologische Management mit frequenzadaptiven SM interagieren kann . Zur Vermeidung derartiger Komplikationen muss der Anaesthesist an die Besonderheiten dieser Systeme denken , um das perioperative Management entsprechend auszurichten und intraoperativen Interaktionen durch Kenntnis der SM-Funktionsweise gezielt entgegenzuwirken .
[ "Wir", "berichten", "ueber", "das", "Auftreten", "von", "unerwarteten", "Tachykardien", "waehrend", "der", "Narkoseeinleitung", ",", "die", "bei", "2", "Patienten", "durch", "frequenzadaptive", "Herzschrittmacher", "(", "SM", ")", "ausgeloest", "wurden", ".", "In", "beiden", "Faellen", "unterzogen", "sich", "Patienten", "mit", "frequenzadaptiven", "SM", "Notfalloperationen", ".", "Waehrend", "der", "Narkoseeinleitung", "stieg", "die", "stimulierte", "Herzfrequenz", "nach", "der", "Intubation", "und", "dem", "Beginn", "der", "kontrollierten", "Ventilation", "auf", "140", "bzw", ".", "130", "min-1", "an", ".", "Zunaechst", "wurden", "die", "Anstiege", "der", "Herzfrequenz", "als", "inadaequate", "Anaesthesie", "gedeutet", "und", "die", "Narkosen", "mittels", "Fentanyl", "und", "Etomidat", "vertieft", ".", "Bei", "Fortdauer", "der", "Tachykardien", "wurden", "andere", "Ursachen", "wie", "Hypokaliaemie", ",", "Hypoxie", ",", "Hyperkapnie", "und", "allergische", "Reaktion", "ausgeschlossen", ",", "bevor", "an", "die", "Interaktion", "der", "frequenzadaptiven", "SM", "gedacht", "wurde", ".", "In", "beiden", "Faellen", "handelte", "es", "sich", "um", "Thoraximpedanz", "-", "messende", "Systeme", ".", "Mit", "Verminderung", "des", "Atemminutenvolumens", "sank", "die", "Herzfrequenz", "innerhalb", "von", "3", "-", "5", "min", "ab", ".", "Diese", "Fallbeispiele", "zeigen", ",", "dass", "das", "anaesthesiologische", "Management", "mit", "frequenzadaptiven", "SM", "interagieren", "kann", ".", "Zur", "Vermeidung", "derartiger", "Komplikationen", "muss", "der", "Anaesthesist", "an", "die", "Besonderheiten", "dieser", "Systeme", "denken", ",", "um", "das", "perioperative", "Management", "entsprechend", "auszurichten", "und", "intraoperativen", "Interaktionen", "durch", "Kenntnis", "der", "SM", "-", "Funktionsweise", "gezielt", "entgegenzuwirken", "." ]
[ "umlsterm" ]
Tachykardien, Patienten, Patienten, Notfalloperationen, Intubation, Ventilation, Anaesthesie, Fentanyl, Etomidat, Tachykardien, Hypokaliaemie, Hypoxie, Hyperkapnie, Thoraximpedanz - messende, Komplikationen, gezielt
DerAnaesthesist.60450856.ger.abstr_task2
Sentence: Wir berichten ueber das Auftreten von unerwarteten Tachykardien waehrend der Narkoseeinleitung , die bei 2 Patienten durch frequenzadaptive Herzschrittmacher ( SM ) ausgeloest wurden . In beiden Faellen unterzogen sich Patienten mit frequenzadaptiven SM Notfalloperationen . Waehrend der Narkoseeinleitung stieg die stimulierte Herzfrequenz nach der Intubation und dem Beginn der kontrollierten Ventilation auf 140 bzw. 130 min-1 an . Zunaechst wurden die Anstiege der Herzfrequenz als inadaequate Anaesthesie gedeutet und die Narkosen mittels Fentanyl und Etomidat vertieft . Bei Fortdauer der Tachykardien wurden andere Ursachen wie Hypokaliaemie , Hypoxie , Hyperkapnie und allergische Reaktion ausgeschlossen , bevor an die Interaktion der frequenzadaptiven SM gedacht wurde . In beiden Faellen handelte es sich um Thoraximpedanz-messende Systeme . Mit Verminderung des Atemminutenvolumens sank die Herzfrequenz innerhalb von 3-5 min ab . Diese Fallbeispiele zeigen , dass das anaesthesiologische Management mit frequenzadaptiven SM interagieren kann . Zur Vermeidung derartiger Komplikationen muss der Anaesthesist an die Besonderheiten dieser Systeme denken , um das perioperative Management entsprechend auszurichten und intraoperativen Interaktionen durch Kenntnis der SM-Funktionsweise gezielt entgegenzuwirken . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Wir berichten ueber das Auftreten von unerwarteten Tachykardien waehrend der Narkoseeinleitung , die bei 2 Patienten durch frequenzadaptive Herzschrittmacher ( SM ) ausgeloest wurden . In beiden Faellen unterzogen sich Patienten mit frequenzadaptiven SM Notfalloperationen . Waehrend der Narkoseeinleitung stieg die stimulierte Herzfrequenz nach der Intubation und dem Beginn der kontrollierten Ventilation auf 140 bzw. 130 min-1 an . Zunaechst wurden die Anstiege der Herzfrequenz als inadaequate Anaesthesie gedeutet und die Narkosen mittels Fentanyl und Etomidat vertieft . Bei Fortdauer der Tachykardien wurden andere Ursachen wie Hypokaliaemie , Hypoxie , Hyperkapnie und allergische Reaktion ausgeschlossen , bevor an die Interaktion der frequenzadaptiven SM gedacht wurde . In beiden Faellen handelte es sich um Thoraximpedanz-messende Systeme . Mit Verminderung des Atemminutenvolumens sank die Herzfrequenz innerhalb von 3-5 min ab . Diese Fallbeispiele zeigen , dass das anaesthesiologische Management mit frequenzadaptiven SM interagieren kann . Zur Vermeidung derartiger Komplikationen muss der Anaesthesist an die Besonderheiten dieser Systeme denken , um das perioperative Management entsprechend auszurichten und intraoperativen Interaktionen durch Kenntnis der SM-Funktionsweise gezielt entgegenzuwirken .
[ "Wir", "berichten", "ueber", "das", "Auftreten", "von", "unerwarteten", "Tachykardien", "waehrend", "der", "Narkoseeinleitung", ",", "die", "bei", "2", "Patienten", "durch", "frequenzadaptive", "Herzschrittmacher", "(", "SM", ")", "ausgeloest", "wurden", ".", "In", "beiden", "Faellen", "unterzogen", "sich", "Patienten", "mit", "frequenzadaptiven", "SM", "Notfalloperationen", ".", "Waehrend", "der", "Narkoseeinleitung", "stieg", "die", "stimulierte", "Herzfrequenz", "nach", "der", "Intubation", "und", "dem", "Beginn", "der", "kontrollierten", "Ventilation", "auf", "140", "bzw", ".", "130", "min-1", "an", ".", "Zunaechst", "wurden", "die", "Anstiege", "der", "Herzfrequenz", "als", "inadaequate", "Anaesthesie", "gedeutet", "und", "die", "Narkosen", "mittels", "Fentanyl", "und", "Etomidat", "vertieft", ".", "Bei", "Fortdauer", "der", "Tachykardien", "wurden", "andere", "Ursachen", "wie", "Hypokaliaemie", ",", "Hypoxie", ",", "Hyperkapnie", "und", "allergische", "Reaktion", "ausgeschlossen", ",", "bevor", "an", "die", "Interaktion", "der", "frequenzadaptiven", "SM", "gedacht", "wurde", ".", "In", "beiden", "Faellen", "handelte", "es", "sich", "um", "Thoraximpedanz", "-", "messende", "Systeme", ".", "Mit", "Verminderung", "des", "Atemminutenvolumens", "sank", "die", "Herzfrequenz", "innerhalb", "von", "3", "-", "5", "min", "ab", ".", "Diese", "Fallbeispiele", "zeigen", ",", "dass", "das", "anaesthesiologische", "Management", "mit", "frequenzadaptiven", "SM", "interagieren", "kann", ".", "Zur", "Vermeidung", "derartiger", "Komplikationen", "muss", "der", "Anaesthesist", "an", "die", "Besonderheiten", "dieser", "Systeme", "denken", ",", "um", "das", "perioperative", "Management", "entsprechend", "auszurichten", "und", "intraoperativen", "Interaktionen", "durch", "Kenntnis", "der", "SM", "-", "Funktionsweise", "gezielt", "entgegenzuwirken", "." ]
[ "umlsterm" ]
Efficacy and safety is a Outcome_Other, mizolastine is a Intervention_Pharmacological, placebo - controlled is a Intervention_Control, loratadine is a Intervention_Pharmacological, chronic idiopathic urticaria is a Participant_Condition, Mizolastine is a Intervention_Pharmacological, mizolastine with loratadine is a Intervention_Pharmacological, chronic idiopathic urticaria ( CIU ) is a Participant_Condition, 247 is a Participant_Sample-size, relieved symptoms of CIU is a Outcome_Physical, severity of pruritus ( visual analogue score ( VAS ) assessed by patients ) is a Outcome_Physical, mizolastine and loratadine is a Intervention_Pharmacological, episodes of urticaria is a Outcome_Physical, Angioedema is a Outcome_Physical, Overall tolerability is a Outcome_Other, effects on cardiac repolarisation is a Outcome_Physical, mizolastine or loratadine is a Intervention_Pharmacological, effective and well tolerated is a Outcome_Other, urticarial symptoms is a Outcome_Physical
466_task0
Sentence: Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria : results of the MILOR Study . BACKGROUND Mizolastine is a novel histamine H1-antagonist registered in Europe for the management of allergic rhinitis and urticaria . OBJECTIVES To compare the clinical efficacy and safety of mizolastine with loratadine and placebo in patients with chronic idiopathic urticaria ( CIU ) . METHODS A multicentre , double-blind , parallel group study was designed in which 247 patients with CIU were randomised after a 1-week placebo run-in period to 10 mg daily mizolastine ( n = 88 ) , 10 mg daily loratadine ( n = 79 ) , or placebo ( n = 80 ) for a 4-week treatment period . RESULTS Mizolastine and loratadine both relieved symptoms of CIU . After 2 weeks ' treatment , the severity of pruritus ( visual analogue score ( VAS ) assessed by patients ) decreased significantly in both the mizolastine and loratadine groups compared with placebo ( mizolastine : -36.7 mm , P = 0.0001 ; loratadine : -29.8 , P = 0.0071 ; placebo : -16.3 ) ; this improvement with both active treatments was maintained throughout the treatment period , the difference being significant only for the mizolastine group ( P = 0.0090 ) . Both active treatments were also associated with reduced weekly episodes of urticaria compared with placebo , which was significant after 2 weeks ' treatment ( mizolastine : 7.9 episodes , P = 0.0061 ; loratadine : 8.3 , P = 0.0221 ; placebo : 13.3 ) . Angioedema was improved to a clinically significant extent with mizolastine , and loratadine compared with placebo in those patients who had this symptom before treatment . Overall tolerability of both treatments was similar to placebo , and there were no clinically relevant effects on cardiac repolarisation with either mizolastine or loratadine . CONCLUSION Mizolastine ( 10 mg daily ) is confirmed as an effective and well tolerated agent , comparable to loratadine and superior to placebo , for the management of CIU . Mizolastine acted as rapidly as loratadine in improving urticarial symptoms from the first day of treatment . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O" ]
Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria : results of the MILOR Study . BACKGROUND Mizolastine is a novel histamine H1-antagonist registered in Europe for the management of allergic rhinitis and urticaria . OBJECTIVES To compare the clinical efficacy and safety of mizolastine with loratadine and placebo in patients with chronic idiopathic urticaria ( CIU ) . METHODS A multicentre , double-blind , parallel group study was designed in which 247 patients with CIU were randomised after a 1-week placebo run-in period to 10 mg daily mizolastine ( n = 88 ) , 10 mg daily loratadine ( n = 79 ) , or placebo ( n = 80 ) for a 4-week treatment period . RESULTS Mizolastine and loratadine both relieved symptoms of CIU . After 2 weeks ' treatment , the severity of pruritus ( visual analogue score ( VAS ) assessed by patients ) decreased significantly in both the mizolastine and loratadine groups compared with placebo ( mizolastine : -36.7 mm , P = 0.0001 ; loratadine : -29.8 , P = 0.0071 ; placebo : -16.3 ) ; this improvement with both active treatments was maintained throughout the treatment period , the difference being significant only for the mizolastine group ( P = 0.0090 ) . Both active treatments were also associated with reduced weekly episodes of urticaria compared with placebo , which was significant after 2 weeks ' treatment ( mizolastine : 7.9 episodes , P = 0.0061 ; loratadine : 8.3 , P = 0.0221 ; placebo : 13.3 ) . Angioedema was improved to a clinically significant extent with mizolastine , and loratadine compared with placebo in those patients who had this symptom before treatment . Overall tolerability of both treatments was similar to placebo , and there were no clinically relevant effects on cardiac repolarisation with either mizolastine or loratadine . CONCLUSION Mizolastine ( 10 mg daily ) is confirmed as an effective and well tolerated agent , comparable to loratadine and superior to placebo , for the management of CIU . Mizolastine acted as rapidly as loratadine in improving urticarial symptoms from the first day of treatment .
[ "Efficacy", "and", "safety", "of", "mizolastine", "10", "mg", "in", "a", "placebo", "-", "controlled", "comparison", "with", "loratadine", "in", "chronic", "idiopathic", "urticaria", ":", "results", "of", "the", "MILOR", "Study", ".", "BACKGROUND", "Mizolastine", "is", "a", "novel", "histamine", "H1-antagonist", "registered", "in", "Europe", "for", "the", "management", "of", "allergic", "rhinitis", "and", "urticaria", ".", "OBJECTIVES", "To", "compare", "the", "clinical", "efficacy", "and", "safety", "of", "mizolastine", "with", "loratadine", "and", "placebo", "in", "patients", "with", "chronic", "idiopathic", "urticaria", "(", "CIU", ")", ".", "METHODS", "A", "multicentre", ",", "double", "-", "blind", ",", "parallel", "group", "study", "was", "designed", "in", "which", "247", "patients", "with", "CIU", "were", "randomised", "after", "a", "1-week", "placebo", "run", "-", "in", "period", "to", "10", "mg", "daily", "mizolastine", "(", "n", "=", "88", ")", ",", "10", "mg", "daily", "loratadine", "(", "n", "=", "79", ")", ",", "or", "placebo", "(", "n", "=", "80", ")", "for", "a", "4-week", "treatment", "period", ".", "RESULTS", "Mizolastine", "and", "loratadine", "both", "relieved", "symptoms", "of", "CIU", ".", "After", "2", "weeks", "'", "treatment", ",", "the", "severity", "of", "pruritus", "(", "visual", "analogue", "score", "(", "VAS", ")", "assessed", "by", "patients", ")", "decreased", "significantly", "in", "both", "the", "mizolastine", "and", "loratadine", "groups", "compared", "with", "placebo", "(", "mizolastine", ":", "-36.7", "mm", ",", "P", "=", "0.0001", ";", "loratadine", ":", "-29.8", ",", "P", "=", "0.0071", ";", "placebo", ":", "-16.3", ")", ";", "this", "improvement", "with", "both", "active", "treatments", "was", "maintained", "throughout", "the", "treatment", "period", ",", "the", "difference", "being", "significant", "only", "for", "the", "mizolastine", "group", "(", "P", "=", "0.0090", ")", ".", "Both", "active", "treatments", "were", "also", "associated", "with", "reduced", "weekly", "episodes", "of", "urticaria", "compared", "with", "placebo", ",", "which", "was", "significant", "after", "2", "weeks", "'", "treatment", "(", "mizolastine", ":", "7.9", "episodes", ",", "P", "=", "0.0061", ";", "loratadine", ":", "8.3", ",", "P", "=", "0.0221", ";", "placebo", ":", "13.3", ")", ".", "Angioedema", "was", "improved", "to", "a", "clinically", "significant", "extent", "with", "mizolastine", ",", "and", "loratadine", "compared", "with", "placebo", "in", "those", "patients", "who", "had", "this", "symptom", "before", "treatment", ".", "Overall", "tolerability", "of", "both", "treatments", "was", "similar", "to", "placebo", ",", "and", "there", "were", "no", "clinically", "relevant", "effects", "on", "cardiac", "repolarisation", "with", "either", "mizolastine", "or", "loratadine", ".", "CONCLUSION", "Mizolastine", "(", "10", "mg", "daily", ")", "is", "confirmed", "as", "an", "effective", "and", "well", "tolerated", "agent", ",", "comparable", "to", "loratadine", "and", "superior", "to", "placebo", ",", "for", "the", "management", "of", "CIU", ".", "Mizolastine", "acted", "as", "rapidly", "as", "loratadine", "in", "improving", "urticarial", "symptoms", "from", "the", "first", "day", "of", "treatment", "." ]
[ "Outcome_Physical", "Participant_Condition", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]
Efficacy and safety is a Outcome_Other, mizolastine is a Intervention_Pharmacological, placebo - controlled is a Intervention_Control, loratadine is a Intervention_Pharmacological, chronic idiopathic urticaria is a Participant_Condition, Mizolastine is a Intervention_Pharmacological, mizolastine with loratadine is a Intervention_Pharmacological, chronic idiopathic urticaria ( CIU ) is a Participant_Condition, 247 is a Participant_Sample-size, relieved symptoms of CIU is a Outcome_Physical, severity of pruritus ( visual analogue score ( VAS ) assessed by patients ) is a Outcome_Physical, mizolastine and loratadine is a Intervention_Pharmacological, episodes of urticaria is a Outcome_Physical, Angioedema is a Outcome_Physical, Overall tolerability is a Outcome_Other, effects on cardiac repolarisation is a Outcome_Physical, mizolastine or loratadine is a Intervention_Pharmacological, effective and well tolerated is a Outcome_Other, urticarial symptoms is a Outcome_Physical
466_task1
Sentence: Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria : results of the MILOR Study . BACKGROUND Mizolastine is a novel histamine H1-antagonist registered in Europe for the management of allergic rhinitis and urticaria . OBJECTIVES To compare the clinical efficacy and safety of mizolastine with loratadine and placebo in patients with chronic idiopathic urticaria ( CIU ) . METHODS A multicentre , double-blind , parallel group study was designed in which 247 patients with CIU were randomised after a 1-week placebo run-in period to 10 mg daily mizolastine ( n = 88 ) , 10 mg daily loratadine ( n = 79 ) , or placebo ( n = 80 ) for a 4-week treatment period . RESULTS Mizolastine and loratadine both relieved symptoms of CIU . After 2 weeks ' treatment , the severity of pruritus ( visual analogue score ( VAS ) assessed by patients ) decreased significantly in both the mizolastine and loratadine groups compared with placebo ( mizolastine : -36.7 mm , P = 0.0001 ; loratadine : -29.8 , P = 0.0071 ; placebo : -16.3 ) ; this improvement with both active treatments was maintained throughout the treatment period , the difference being significant only for the mizolastine group ( P = 0.0090 ) . Both active treatments were also associated with reduced weekly episodes of urticaria compared with placebo , which was significant after 2 weeks ' treatment ( mizolastine : 7.9 episodes , P = 0.0061 ; loratadine : 8.3 , P = 0.0221 ; placebo : 13.3 ) . Angioedema was improved to a clinically significant extent with mizolastine , and loratadine compared with placebo in those patients who had this symptom before treatment . Overall tolerability of both treatments was similar to placebo , and there were no clinically relevant effects on cardiac repolarisation with either mizolastine or loratadine . CONCLUSION Mizolastine ( 10 mg daily ) is confirmed as an effective and well tolerated agent , comparable to loratadine and superior to placebo , for the management of CIU . Mizolastine acted as rapidly as loratadine in improving urticarial symptoms from the first day of treatment . Instructions: please typing these entity words according to sentence: Efficacy and safety, mizolastine, placebo - controlled, loratadine, chronic idiopathic urticaria, Mizolastine, mizolastine with loratadine, chronic idiopathic urticaria ( CIU ), 247, relieved symptoms of CIU, severity of pruritus ( visual analogue score ( VAS ) assessed by patients ), mizolastine and loratadine, episodes of urticaria, Angioedema, Overall tolerability, effects on cardiac repolarisation, mizolastine or loratadine, effective and well tolerated, urticarial symptoms Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O" ]
Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria : results of the MILOR Study . BACKGROUND Mizolastine is a novel histamine H1-antagonist registered in Europe for the management of allergic rhinitis and urticaria . OBJECTIVES To compare the clinical efficacy and safety of mizolastine with loratadine and placebo in patients with chronic idiopathic urticaria ( CIU ) . METHODS A multicentre , double-blind , parallel group study was designed in which 247 patients with CIU were randomised after a 1-week placebo run-in period to 10 mg daily mizolastine ( n = 88 ) , 10 mg daily loratadine ( n = 79 ) , or placebo ( n = 80 ) for a 4-week treatment period . RESULTS Mizolastine and loratadine both relieved symptoms of CIU . After 2 weeks ' treatment , the severity of pruritus ( visual analogue score ( VAS ) assessed by patients ) decreased significantly in both the mizolastine and loratadine groups compared with placebo ( mizolastine : -36.7 mm , P = 0.0001 ; loratadine : -29.8 , P = 0.0071 ; placebo : -16.3 ) ; this improvement with both active treatments was maintained throughout the treatment period , the difference being significant only for the mizolastine group ( P = 0.0090 ) . Both active treatments were also associated with reduced weekly episodes of urticaria compared with placebo , which was significant after 2 weeks ' treatment ( mizolastine : 7.9 episodes , P = 0.0061 ; loratadine : 8.3 , P = 0.0221 ; placebo : 13.3 ) . Angioedema was improved to a clinically significant extent with mizolastine , and loratadine compared with placebo in those patients who had this symptom before treatment . Overall tolerability of both treatments was similar to placebo , and there were no clinically relevant effects on cardiac repolarisation with either mizolastine or loratadine . CONCLUSION Mizolastine ( 10 mg daily ) is confirmed as an effective and well tolerated agent , comparable to loratadine and superior to placebo , for the management of CIU . Mizolastine acted as rapidly as loratadine in improving urticarial symptoms from the first day of treatment .
[ "Efficacy", "and", "safety", "of", "mizolastine", "10", "mg", "in", "a", "placebo", "-", "controlled", "comparison", "with", "loratadine", "in", "chronic", "idiopathic", "urticaria", ":", "results", "of", "the", "MILOR", "Study", ".", "BACKGROUND", "Mizolastine", "is", "a", "novel", "histamine", "H1-antagonist", "registered", "in", "Europe", "for", "the", "management", "of", "allergic", "rhinitis", "and", "urticaria", ".", "OBJECTIVES", "To", "compare", "the", "clinical", "efficacy", "and", "safety", "of", "mizolastine", "with", "loratadine", "and", "placebo", "in", "patients", "with", "chronic", "idiopathic", "urticaria", "(", "CIU", ")", ".", "METHODS", "A", "multicentre", ",", "double", "-", "blind", ",", "parallel", "group", "study", "was", "designed", "in", "which", "247", "patients", "with", "CIU", "were", "randomised", "after", "a", "1-week", "placebo", "run", "-", "in", "period", "to", "10", "mg", "daily", "mizolastine", "(", "n", "=", "88", ")", ",", "10", "mg", "daily", "loratadine", "(", "n", "=", "79", ")", ",", "or", "placebo", "(", "n", "=", "80", ")", "for", "a", "4-week", "treatment", "period", ".", "RESULTS", "Mizolastine", "and", "loratadine", "both", "relieved", "symptoms", "of", "CIU", ".", "After", "2", "weeks", "'", "treatment", ",", "the", "severity", "of", "pruritus", "(", "visual", "analogue", "score", "(", "VAS", ")", "assessed", "by", "patients", ")", "decreased", "significantly", "in", "both", "the", "mizolastine", "and", "loratadine", "groups", "compared", "with", "placebo", "(", "mizolastine", ":", "-36.7", "mm", ",", "P", "=", "0.0001", ";", "loratadine", ":", "-29.8", ",", "P", "=", "0.0071", ";", "placebo", ":", "-16.3", ")", ";", "this", "improvement", "with", "both", "active", "treatments", "was", "maintained", "throughout", "the", "treatment", "period", ",", "the", "difference", "being", "significant", "only", "for", "the", "mizolastine", "group", "(", "P", "=", "0.0090", ")", ".", "Both", "active", "treatments", "were", "also", "associated", "with", "reduced", "weekly", "episodes", "of", "urticaria", "compared", "with", "placebo", ",", "which", "was", "significant", "after", "2", "weeks", "'", "treatment", "(", "mizolastine", ":", "7.9", "episodes", ",", "P", "=", "0.0061", ";", "loratadine", ":", "8.3", ",", "P", "=", "0.0221", ";", "placebo", ":", "13.3", ")", ".", "Angioedema", "was", "improved", "to", "a", "clinically", "significant", "extent", "with", "mizolastine", ",", "and", "loratadine", "compared", "with", "placebo", "in", "those", "patients", "who", "had", "this", "symptom", "before", "treatment", ".", "Overall", "tolerability", "of", "both", "treatments", "was", "similar", "to", "placebo", ",", "and", "there", "were", "no", "clinically", "relevant", "effects", "on", "cardiac", "repolarisation", "with", "either", "mizolastine", "or", "loratadine", ".", "CONCLUSION", "Mizolastine", "(", "10", "mg", "daily", ")", "is", "confirmed", "as", "an", "effective", "and", "well", "tolerated", "agent", ",", "comparable", "to", "loratadine", "and", "superior", "to", "placebo", ",", "for", "the", "management", "of", "CIU", ".", "Mizolastine", "acted", "as", "rapidly", "as", "loratadine", "in", "improving", "urticarial", "symptoms", "from", "the", "first", "day", "of", "treatment", "." ]
[ "Outcome_Physical", "Participant_Condition", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]
Efficacy and safety, mizolastine, placebo - controlled, loratadine, chronic idiopathic urticaria, Mizolastine, mizolastine with loratadine, chronic idiopathic urticaria ( CIU ), 247, relieved symptoms of CIU, severity of pruritus ( visual analogue score ( VAS ) assessed by patients ), mizolastine and loratadine, episodes of urticaria, Angioedema, Overall tolerability, effects on cardiac repolarisation, mizolastine or loratadine, effective and well tolerated, urticarial symptoms
466_task2
Sentence: Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria : results of the MILOR Study . BACKGROUND Mizolastine is a novel histamine H1-antagonist registered in Europe for the management of allergic rhinitis and urticaria . OBJECTIVES To compare the clinical efficacy and safety of mizolastine with loratadine and placebo in patients with chronic idiopathic urticaria ( CIU ) . METHODS A multicentre , double-blind , parallel group study was designed in which 247 patients with CIU were randomised after a 1-week placebo run-in period to 10 mg daily mizolastine ( n = 88 ) , 10 mg daily loratadine ( n = 79 ) , or placebo ( n = 80 ) for a 4-week treatment period . RESULTS Mizolastine and loratadine both relieved symptoms of CIU . After 2 weeks ' treatment , the severity of pruritus ( visual analogue score ( VAS ) assessed by patients ) decreased significantly in both the mizolastine and loratadine groups compared with placebo ( mizolastine : -36.7 mm , P = 0.0001 ; loratadine : -29.8 , P = 0.0071 ; placebo : -16.3 ) ; this improvement with both active treatments was maintained throughout the treatment period , the difference being significant only for the mizolastine group ( P = 0.0090 ) . Both active treatments were also associated with reduced weekly episodes of urticaria compared with placebo , which was significant after 2 weeks ' treatment ( mizolastine : 7.9 episodes , P = 0.0061 ; loratadine : 8.3 , P = 0.0221 ; placebo : 13.3 ) . Angioedema was improved to a clinically significant extent with mizolastine , and loratadine compared with placebo in those patients who had this symptom before treatment . Overall tolerability of both treatments was similar to placebo , and there were no clinically relevant effects on cardiac repolarisation with either mizolastine or loratadine . CONCLUSION Mizolastine ( 10 mg daily ) is confirmed as an effective and well tolerated agent , comparable to loratadine and superior to placebo , for the management of CIU . Mizolastine acted as rapidly as loratadine in improving urticarial symptoms from the first day of treatment . Instructions: please extract entity words from the input sentence
[ "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O" ]
Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria : results of the MILOR Study . BACKGROUND Mizolastine is a novel histamine H1-antagonist registered in Europe for the management of allergic rhinitis and urticaria . OBJECTIVES To compare the clinical efficacy and safety of mizolastine with loratadine and placebo in patients with chronic idiopathic urticaria ( CIU ) . METHODS A multicentre , double-blind , parallel group study was designed in which 247 patients with CIU were randomised after a 1-week placebo run-in period to 10 mg daily mizolastine ( n = 88 ) , 10 mg daily loratadine ( n = 79 ) , or placebo ( n = 80 ) for a 4-week treatment period . RESULTS Mizolastine and loratadine both relieved symptoms of CIU . After 2 weeks ' treatment , the severity of pruritus ( visual analogue score ( VAS ) assessed by patients ) decreased significantly in both the mizolastine and loratadine groups compared with placebo ( mizolastine : -36.7 mm , P = 0.0001 ; loratadine : -29.8 , P = 0.0071 ; placebo : -16.3 ) ; this improvement with both active treatments was maintained throughout the treatment period , the difference being significant only for the mizolastine group ( P = 0.0090 ) . Both active treatments were also associated with reduced weekly episodes of urticaria compared with placebo , which was significant after 2 weeks ' treatment ( mizolastine : 7.9 episodes , P = 0.0061 ; loratadine : 8.3 , P = 0.0221 ; placebo : 13.3 ) . Angioedema was improved to a clinically significant extent with mizolastine , and loratadine compared with placebo in those patients who had this symptom before treatment . Overall tolerability of both treatments was similar to placebo , and there were no clinically relevant effects on cardiac repolarisation with either mizolastine or loratadine . CONCLUSION Mizolastine ( 10 mg daily ) is confirmed as an effective and well tolerated agent , comparable to loratadine and superior to placebo , for the management of CIU . Mizolastine acted as rapidly as loratadine in improving urticarial symptoms from the first day of treatment .
[ "Efficacy", "and", "safety", "of", "mizolastine", "10", "mg", "in", "a", "placebo", "-", "controlled", "comparison", "with", "loratadine", "in", "chronic", "idiopathic", "urticaria", ":", "results", "of", "the", "MILOR", "Study", ".", "BACKGROUND", "Mizolastine", "is", "a", "novel", "histamine", "H1-antagonist", "registered", "in", "Europe", "for", "the", "management", "of", "allergic", "rhinitis", "and", "urticaria", ".", "OBJECTIVES", "To", "compare", "the", "clinical", "efficacy", "and", "safety", "of", "mizolastine", "with", "loratadine", "and", "placebo", "in", "patients", "with", "chronic", "idiopathic", "urticaria", "(", "CIU", ")", ".", "METHODS", "A", "multicentre", ",", "double", "-", "blind", ",", "parallel", "group", "study", "was", "designed", "in", "which", "247", "patients", "with", "CIU", "were", "randomised", "after", "a", "1-week", "placebo", "run", "-", "in", "period", "to", "10", "mg", "daily", "mizolastine", "(", "n", "=", "88", ")", ",", "10", "mg", "daily", "loratadine", "(", "n", "=", "79", ")", ",", "or", "placebo", "(", "n", "=", "80", ")", "for", "a", "4-week", "treatment", "period", ".", "RESULTS", "Mizolastine", "and", "loratadine", "both", "relieved", "symptoms", "of", "CIU", ".", "After", "2", "weeks", "'", "treatment", ",", "the", "severity", "of", "pruritus", "(", "visual", "analogue", "score", "(", "VAS", ")", "assessed", "by", "patients", ")", "decreased", "significantly", "in", "both", "the", "mizolastine", "and", "loratadine", "groups", "compared", "with", "placebo", "(", "mizolastine", ":", "-36.7", "mm", ",", "P", "=", "0.0001", ";", "loratadine", ":", "-29.8", ",", "P", "=", "0.0071", ";", "placebo", ":", "-16.3", ")", ";", "this", "improvement", "with", "both", "active", "treatments", "was", "maintained", "throughout", "the", "treatment", "period", ",", "the", "difference", "being", "significant", "only", "for", "the", "mizolastine", "group", "(", "P", "=", "0.0090", ")", ".", "Both", "active", "treatments", "were", "also", "associated", "with", "reduced", "weekly", "episodes", "of", "urticaria", "compared", "with", "placebo", ",", "which", "was", "significant", "after", "2", "weeks", "'", "treatment", "(", "mizolastine", ":", "7.9", "episodes", ",", "P", "=", "0.0061", ";", "loratadine", ":", "8.3", ",", "P", "=", "0.0221", ";", "placebo", ":", "13.3", ")", ".", "Angioedema", "was", "improved", "to", "a", "clinically", "significant", "extent", "with", "mizolastine", ",", "and", "loratadine", "compared", "with", "placebo", "in", "those", "patients", "who", "had", "this", "symptom", "before", "treatment", ".", "Overall", "tolerability", "of", "both", "treatments", "was", "similar", "to", "placebo", ",", "and", "there", "were", "no", "clinically", "relevant", "effects", "on", "cardiac", "repolarisation", "with", "either", "mizolastine", "or", "loratadine", ".", "CONCLUSION", "Mizolastine", "(", "10", "mg", "daily", ")", "is", "confirmed", "as", "an", "effective", "and", "well", "tolerated", "agent", ",", "comparable", "to", "loratadine", "and", "superior", "to", "placebo", ",", "for", "the", "management", "of", "CIU", ".", "Mizolastine", "acted", "as", "rapidly", "as", "loratadine", "in", "improving", "urticarial", "symptoms", "from", "the", "first", "day", "of", "treatment", "." ]
[ "Outcome_Physical", "Participant_Condition", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]
histone is a Protein, Histone is a Protein, arginine is a Entity, lysine is a Entity, histones H3 is a Protein, H4 is a Protein, K9 is a Entity, histone H3 is a Protein, K20 is a Entity, histone H4 is a Protein, histone H3 is a Protein, K9 is a Entity, histone H4 is a Protein, K20 is a Entity, histone H4 is a Protein, K20 is a Entity, histone H3 is a Protein, H4 is a Protein, K9 is a Entity, histone H4 is a Protein, histone H4 is a Protein, K20 is a Entity, histone is a Protein, lysine is a Entity
142_task0
Sentence: Distinct dynamics and distribution of histone methyl-lysine derivatives in mouse development. Histone methylation acts as an epigenetic regulator of chromatin activity through the modification of arginine and lysine residues on histones H3 and H4. In the case of lysine, this includes the formation of mono-, di-, or trimethyl groups, each of which is presumed to represent a distinct functional state at the cellular level. To examine the potential developmental roles of these modifications, we determined the global patterns of lysine methylation involving K9 on histone H3 and K20 on histone H4 in midgestation mouse embryos. For each lysine target site, we observed distinct subnuclear distributions of the mono- and trimethyl versions in 10T1/2 cells that were conserved within primary cultures and within the 3D-tissue architecture of the embryo. Interestingly, three of these modifications, histone H3 trimethyl K9, histone H4 monomethyl K20, and histone H4 trimethyl K20 exhibited marked differences in their distribution within the neuroepithelium. Specifically, both histone H3 trimethyl K9 and H4 monomethyl K20 were elevated in proliferating cells of the neural tube, which in the case of the K9 modification was limited to mitotic cells on the luminal surface. In contrast, histone H4 trimethyl K20 was progressively lost from these medial regions and became enriched in differentiating neurons in the ventrolateral neural tube. The inverse relationship of histone H4 K20 methyl derivatives is even more striking during skeletal and cardiac myogenesis where the accumulation of the trimethyl modification in pericentromeric heterochromatin suggests a role in gene silencing in postmitotic muscle cells. Importantly, our results establish that histone lysine methylation occurs in a highly dynamic manner that is consistent with their function in an epigenetic program for cell division and differentiation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "I-Protein", "O", "B-Entity", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Entity", "O", "B-Protein", "I-Protein", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Distinct dynamics and distribution of histone methyl-lysine derivatives in mouse development. Histone methylation acts as an epigenetic regulator of chromatin activity through the modification of arginine and lysine residues on histones H3 and H4. In the case of lysine, this includes the formation of mono-, di-, or trimethyl groups, each of which is presumed to represent a distinct functional state at the cellular level. To examine the potential developmental roles of these modifications, we determined the global patterns of lysine methylation involving K9 on histone H3 and K20 on histone H4 in midgestation mouse embryos. For each lysine target site, we observed distinct subnuclear distributions of the mono- and trimethyl versions in 10T1/2 cells that were conserved within primary cultures and within the 3D-tissue architecture of the embryo. Interestingly, three of these modifications, histone H3 trimethyl K9, histone H4 monomethyl K20, and histone H4 trimethyl K20 exhibited marked differences in their distribution within the neuroepithelium. Specifically, both histone H3 trimethyl K9 and H4 monomethyl K20 were elevated in proliferating cells of the neural tube, which in the case of the K9 modification was limited to mitotic cells on the luminal surface. In contrast, histone H4 trimethyl K20 was progressively lost from these medial regions and became enriched in differentiating neurons in the ventrolateral neural tube. The inverse relationship of histone H4 K20 methyl derivatives is even more striking during skeletal and cardiac myogenesis where the accumulation of the trimethyl modification in pericentromeric heterochromatin suggests a role in gene silencing in postmitotic muscle cells. Importantly, our results establish that histone lysine methylation occurs in a highly dynamic manner that is consistent with their function in an epigenetic program for cell division and differentiation.
[ "Distinct", "dynamics", "and", "distribution", "of", "histone", "methyl", "-", "lysine", "derivatives", "in", "mouse", "development", ".", "\n", "Histone", "methylation", "acts", "as", "an", "epigenetic", "regulator", "of", "chromatin", "activity", "through", "the", "modification", "of", "arginine", "and", "lysine", "residues", "on", "histones", "H3", "and", "H4", ".", "In", "the", "case", "of", "lysine", ",", "this", "includes", "the", "formation", "of", "mono-", ",", "di-", ",", "or", "trimethyl", "groups", ",", "each", "of", "which", "is", "presumed", "to", "represent", "a", "distinct", "functional", "state", "at", "the", "cellular", "level", ".", "To", "examine", "the", "potential", "developmental", "roles", "of", "these", "modifications", ",", "we", "determined", "the", "global", "patterns", "of", "lysine", "methylation", "involving", "K9", "on", "histone", "H3", "and", "K20", "on", "histone", "H4", "in", "midgestation", "mouse", "embryos", ".", "For", "each", "lysine", "target", "site", ",", "we", "observed", "distinct", "subnuclear", "distributions", "of", "the", "mono-", "and", "trimethyl", "versions", "in", "10T1/2", "cells", "that", "were", "conserved", "within", "primary", "cultures", "and", "within", "the", "3D", "-", "tissue", "architecture", "of", "the", "embryo", ".", "Interestingly", ",", "three", "of", "these", "modifications", ",", "histone", "H3", "trimethyl", "K9", ",", "histone", "H4", "monomethyl", "K20", ",", "and", "histone", "H4", "trimethyl", "K20", "exhibited", "marked", "differences", "in", "their", "distribution", "within", "the", "neuroepithelium", ".", "Specifically", ",", "both", "histone", "H3", "trimethyl", "K9", "and", "H4", "monomethyl", "K20", "were", "elevated", "in", "proliferating", "cells", "of", "the", "neural", "tube", ",", "which", "in", "the", "case", "of", "the", "K9", "modification", "was", "limited", "to", "mitotic", "cells", "on", "the", "luminal", "surface", ".", "In", "contrast", ",", "histone", "H4", "trimethyl", "K20", "was", "progressively", "lost", "from", "these", "medial", "regions", "and", "became", "enriched", "in", "differentiating", "neurons", "in", "the", "ventrolateral", "neural", "tube", ".", "The", "inverse", "relationship", "of", "histone", "H4", "K20", "methyl", "derivatives", "is", "even", "more", "striking", "during", "skeletal", "and", "cardiac", "myogenesis", "where", "the", "accumulation", "of", "the", "trimethyl", "modification", "in", "pericentromeric", "heterochromatin", "suggests", "a", "role", "in", "gene", "silencing", "in", "postmitotic", "muscle", "cells", ".", "Importantly", ",", "our", "results", "establish", "that", "histone", "lysine", "methylation", "occurs", "in", "a", "highly", "dynamic", "manner", "that", "is", "consistent", "with", "their", "function", "in", "an", "epigenetic", "program", "for", "cell", "division", "and", "differentiation", ".", "\n" ]
[ "Protein", "Entity" ]
histone is a Protein, Histone is a Protein, arginine is a Entity, lysine is a Entity, histones H3 is a Protein, H4 is a Protein, K9 is a Entity, histone H3 is a Protein, K20 is a Entity, histone H4 is a Protein, histone H3 is a Protein, K9 is a Entity, histone H4 is a Protein, K20 is a Entity, histone H4 is a Protein, K20 is a Entity, histone H3 is a Protein, H4 is a Protein, K9 is a Entity, histone H4 is a Protein, histone H4 is a Protein, K20 is a Entity, histone is a Protein, lysine is a Entity
142_task1
Sentence: Distinct dynamics and distribution of histone methyl-lysine derivatives in mouse development. Histone methylation acts as an epigenetic regulator of chromatin activity through the modification of arginine and lysine residues on histones H3 and H4. In the case of lysine, this includes the formation of mono-, di-, or trimethyl groups, each of which is presumed to represent a distinct functional state at the cellular level. To examine the potential developmental roles of these modifications, we determined the global patterns of lysine methylation involving K9 on histone H3 and K20 on histone H4 in midgestation mouse embryos. For each lysine target site, we observed distinct subnuclear distributions of the mono- and trimethyl versions in 10T1/2 cells that were conserved within primary cultures and within the 3D-tissue architecture of the embryo. Interestingly, three of these modifications, histone H3 trimethyl K9, histone H4 monomethyl K20, and histone H4 trimethyl K20 exhibited marked differences in their distribution within the neuroepithelium. Specifically, both histone H3 trimethyl K9 and H4 monomethyl K20 were elevated in proliferating cells of the neural tube, which in the case of the K9 modification was limited to mitotic cells on the luminal surface. In contrast, histone H4 trimethyl K20 was progressively lost from these medial regions and became enriched in differentiating neurons in the ventrolateral neural tube. The inverse relationship of histone H4 K20 methyl derivatives is even more striking during skeletal and cardiac myogenesis where the accumulation of the trimethyl modification in pericentromeric heterochromatin suggests a role in gene silencing in postmitotic muscle cells. Importantly, our results establish that histone lysine methylation occurs in a highly dynamic manner that is consistent with their function in an epigenetic program for cell division and differentiation. Instructions: please typing these entity words according to sentence: histone, Histone, arginine, lysine, histones H3, H4, K9, histone H3, K20, histone H4, histone H3, K9, histone H4, K20, histone H4, K20, histone H3, H4, K9, histone H4, histone H4, K20, histone, lysine Options: Entity, Protein
[ "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "I-Protein", "O", "B-Entity", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Entity", "O", "B-Protein", "I-Protein", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Distinct dynamics and distribution of histone methyl-lysine derivatives in mouse development. Histone methylation acts as an epigenetic regulator of chromatin activity through the modification of arginine and lysine residues on histones H3 and H4. In the case of lysine, this includes the formation of mono-, di-, or trimethyl groups, each of which is presumed to represent a distinct functional state at the cellular level. To examine the potential developmental roles of these modifications, we determined the global patterns of lysine methylation involving K9 on histone H3 and K20 on histone H4 in midgestation mouse embryos. For each lysine target site, we observed distinct subnuclear distributions of the mono- and trimethyl versions in 10T1/2 cells that were conserved within primary cultures and within the 3D-tissue architecture of the embryo. Interestingly, three of these modifications, histone H3 trimethyl K9, histone H4 monomethyl K20, and histone H4 trimethyl K20 exhibited marked differences in their distribution within the neuroepithelium. Specifically, both histone H3 trimethyl K9 and H4 monomethyl K20 were elevated in proliferating cells of the neural tube, which in the case of the K9 modification was limited to mitotic cells on the luminal surface. In contrast, histone H4 trimethyl K20 was progressively lost from these medial regions and became enriched in differentiating neurons in the ventrolateral neural tube. The inverse relationship of histone H4 K20 methyl derivatives is even more striking during skeletal and cardiac myogenesis where the accumulation of the trimethyl modification in pericentromeric heterochromatin suggests a role in gene silencing in postmitotic muscle cells. Importantly, our results establish that histone lysine methylation occurs in a highly dynamic manner that is consistent with their function in an epigenetic program for cell division and differentiation.
[ "Distinct", "dynamics", "and", "distribution", "of", "histone", "methyl", "-", "lysine", "derivatives", "in", "mouse", "development", ".", "\n", "Histone", "methylation", "acts", "as", "an", "epigenetic", "regulator", "of", "chromatin", "activity", "through", "the", "modification", "of", "arginine", "and", "lysine", "residues", "on", "histones", "H3", "and", "H4", ".", "In", "the", "case", "of", "lysine", ",", "this", "includes", "the", "formation", "of", "mono-", ",", "di-", ",", "or", "trimethyl", "groups", ",", "each", "of", "which", "is", "presumed", "to", "represent", "a", "distinct", "functional", "state", "at", "the", "cellular", "level", ".", "To", "examine", "the", "potential", "developmental", "roles", "of", "these", "modifications", ",", "we", "determined", "the", "global", "patterns", "of", "lysine", "methylation", "involving", "K9", "on", "histone", "H3", "and", "K20", "on", "histone", "H4", "in", "midgestation", "mouse", "embryos", ".", "For", "each", "lysine", "target", "site", ",", "we", "observed", "distinct", "subnuclear", "distributions", "of", "the", "mono-", "and", "trimethyl", "versions", "in", "10T1/2", "cells", "that", "were", "conserved", "within", "primary", "cultures", "and", "within", "the", "3D", "-", "tissue", "architecture", "of", "the", "embryo", ".", "Interestingly", ",", "three", "of", "these", "modifications", ",", "histone", "H3", "trimethyl", "K9", ",", "histone", "H4", "monomethyl", "K20", ",", "and", "histone", "H4", "trimethyl", "K20", "exhibited", "marked", "differences", "in", "their", "distribution", "within", "the", "neuroepithelium", ".", "Specifically", ",", "both", "histone", "H3", "trimethyl", "K9", "and", "H4", "monomethyl", "K20", "were", "elevated", "in", "proliferating", "cells", "of", "the", "neural", "tube", ",", "which", "in", "the", "case", "of", "the", "K9", "modification", "was", "limited", "to", "mitotic", "cells", "on", "the", "luminal", "surface", ".", "In", "contrast", ",", "histone", "H4", "trimethyl", "K20", "was", "progressively", "lost", "from", "these", "medial", "regions", "and", "became", "enriched", "in", "differentiating", "neurons", "in", "the", "ventrolateral", "neural", "tube", ".", "The", "inverse", "relationship", "of", "histone", "H4", "K20", "methyl", "derivatives", "is", "even", "more", "striking", "during", "skeletal", "and", "cardiac", "myogenesis", "where", "the", "accumulation", "of", "the", "trimethyl", "modification", "in", "pericentromeric", "heterochromatin", "suggests", "a", "role", "in", "gene", "silencing", "in", "postmitotic", "muscle", "cells", ".", "Importantly", ",", "our", "results", "establish", "that", "histone", "lysine", "methylation", "occurs", "in", "a", "highly", "dynamic", "manner", "that", "is", "consistent", "with", "their", "function", "in", "an", "epigenetic", "program", "for", "cell", "division", "and", "differentiation", ".", "\n" ]
[ "Protein", "Entity" ]
histone, Histone, arginine, lysine, histones H3, H4, K9, histone H3, K20, histone H4, histone H3, K9, histone H4, K20, histone H4, K20, histone H3, H4, K9, histone H4, histone H4, K20, histone, lysine
142_task2
Sentence: Distinct dynamics and distribution of histone methyl-lysine derivatives in mouse development. Histone methylation acts as an epigenetic regulator of chromatin activity through the modification of arginine and lysine residues on histones H3 and H4. In the case of lysine, this includes the formation of mono-, di-, or trimethyl groups, each of which is presumed to represent a distinct functional state at the cellular level. To examine the potential developmental roles of these modifications, we determined the global patterns of lysine methylation involving K9 on histone H3 and K20 on histone H4 in midgestation mouse embryos. For each lysine target site, we observed distinct subnuclear distributions of the mono- and trimethyl versions in 10T1/2 cells that were conserved within primary cultures and within the 3D-tissue architecture of the embryo. Interestingly, three of these modifications, histone H3 trimethyl K9, histone H4 monomethyl K20, and histone H4 trimethyl K20 exhibited marked differences in their distribution within the neuroepithelium. Specifically, both histone H3 trimethyl K9 and H4 monomethyl K20 were elevated in proliferating cells of the neural tube, which in the case of the K9 modification was limited to mitotic cells on the luminal surface. In contrast, histone H4 trimethyl K20 was progressively lost from these medial regions and became enriched in differentiating neurons in the ventrolateral neural tube. The inverse relationship of histone H4 K20 methyl derivatives is even more striking during skeletal and cardiac myogenesis where the accumulation of the trimethyl modification in pericentromeric heterochromatin suggests a role in gene silencing in postmitotic muscle cells. Importantly, our results establish that histone lysine methylation occurs in a highly dynamic manner that is consistent with their function in an epigenetic program for cell division and differentiation. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "I-Protein", "O", "B-Entity", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Entity", "O", "B-Protein", "I-Protein", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Distinct dynamics and distribution of histone methyl-lysine derivatives in mouse development. Histone methylation acts as an epigenetic regulator of chromatin activity through the modification of arginine and lysine residues on histones H3 and H4. In the case of lysine, this includes the formation of mono-, di-, or trimethyl groups, each of which is presumed to represent a distinct functional state at the cellular level. To examine the potential developmental roles of these modifications, we determined the global patterns of lysine methylation involving K9 on histone H3 and K20 on histone H4 in midgestation mouse embryos. For each lysine target site, we observed distinct subnuclear distributions of the mono- and trimethyl versions in 10T1/2 cells that were conserved within primary cultures and within the 3D-tissue architecture of the embryo. Interestingly, three of these modifications, histone H3 trimethyl K9, histone H4 monomethyl K20, and histone H4 trimethyl K20 exhibited marked differences in their distribution within the neuroepithelium. Specifically, both histone H3 trimethyl K9 and H4 monomethyl K20 were elevated in proliferating cells of the neural tube, which in the case of the K9 modification was limited to mitotic cells on the luminal surface. In contrast, histone H4 trimethyl K20 was progressively lost from these medial regions and became enriched in differentiating neurons in the ventrolateral neural tube. The inverse relationship of histone H4 K20 methyl derivatives is even more striking during skeletal and cardiac myogenesis where the accumulation of the trimethyl modification in pericentromeric heterochromatin suggests a role in gene silencing in postmitotic muscle cells. Importantly, our results establish that histone lysine methylation occurs in a highly dynamic manner that is consistent with their function in an epigenetic program for cell division and differentiation.
[ "Distinct", "dynamics", "and", "distribution", "of", "histone", "methyl", "-", "lysine", "derivatives", "in", "mouse", "development", ".", "\n", "Histone", "methylation", "acts", "as", "an", "epigenetic", "regulator", "of", "chromatin", "activity", "through", "the", "modification", "of", "arginine", "and", "lysine", "residues", "on", "histones", "H3", "and", "H4", ".", "In", "the", "case", "of", "lysine", ",", "this", "includes", "the", "formation", "of", "mono-", ",", "di-", ",", "or", "trimethyl", "groups", ",", "each", "of", "which", "is", "presumed", "to", "represent", "a", "distinct", "functional", "state", "at", "the", "cellular", "level", ".", "To", "examine", "the", "potential", "developmental", "roles", "of", "these", "modifications", ",", "we", "determined", "the", "global", "patterns", "of", "lysine", "methylation", "involving", "K9", "on", "histone", "H3", "and", "K20", "on", "histone", "H4", "in", "midgestation", "mouse", "embryos", ".", "For", "each", "lysine", "target", "site", ",", "we", "observed", "distinct", "subnuclear", "distributions", "of", "the", "mono-", "and", "trimethyl", "versions", "in", "10T1/2", "cells", "that", "were", "conserved", "within", "primary", "cultures", "and", "within", "the", "3D", "-", "tissue", "architecture", "of", "the", "embryo", ".", "Interestingly", ",", "three", "of", "these", "modifications", ",", "histone", "H3", "trimethyl", "K9", ",", "histone", "H4", "monomethyl", "K20", ",", "and", "histone", "H4", "trimethyl", "K20", "exhibited", "marked", "differences", "in", "their", "distribution", "within", "the", "neuroepithelium", ".", "Specifically", ",", "both", "histone", "H3", "trimethyl", "K9", "and", "H4", "monomethyl", "K20", "were", "elevated", "in", "proliferating", "cells", "of", "the", "neural", "tube", ",", "which", "in", "the", "case", "of", "the", "K9", "modification", "was", "limited", "to", "mitotic", "cells", "on", "the", "luminal", "surface", ".", "In", "contrast", ",", "histone", "H4", "trimethyl", "K20", "was", "progressively", "lost", "from", "these", "medial", "regions", "and", "became", "enriched", "in", "differentiating", "neurons", "in", "the", "ventrolateral", "neural", "tube", ".", "The", "inverse", "relationship", "of", "histone", "H4", "K20", "methyl", "derivatives", "is", "even", "more", "striking", "during", "skeletal", "and", "cardiac", "myogenesis", "where", "the", "accumulation", "of", "the", "trimethyl", "modification", "in", "pericentromeric", "heterochromatin", "suggests", "a", "role", "in", "gene", "silencing", "in", "postmitotic", "muscle", "cells", ".", "Importantly", ",", "our", "results", "establish", "that", "histone", "lysine", "methylation", "occurs", "in", "a", "highly", "dynamic", "manner", "that", "is", "consistent", "with", "their", "function", "in", "an", "epigenetic", "program", "for", "cell", "division", "and", "differentiation", ".", "\n" ]
[ "Protein", "Entity" ]
GDAP1 is a GENE-Y
23628762_task0
Sentence: Charcot-Marie-Tooth disease-associated mutants of GDAP1 dissociate its roles in peroxisomal and mitochondrial fission. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Charcot-Marie-Tooth disease-associated mutants of GDAP1 dissociate its roles in peroxisomal and mitochondrial fission.
[ "Charcot", "-", "Marie", "-", "Tooth", "disease", "-", "associated", "mutants", "of", "GDAP1", "dissociate", "its", "roles", "in", "peroxisomal", "and", "mitochondrial", "fission", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
GDAP1 is a GENE-Y
23628762_task1
Sentence: Charcot-Marie-Tooth disease-associated mutants of GDAP1 dissociate its roles in peroxisomal and mitochondrial fission. Instructions: please typing these entity words according to sentence: GDAP1 Options: GENE-Y
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Charcot-Marie-Tooth disease-associated mutants of GDAP1 dissociate its roles in peroxisomal and mitochondrial fission.
[ "Charcot", "-", "Marie", "-", "Tooth", "disease", "-", "associated", "mutants", "of", "GDAP1", "dissociate", "its", "roles", "in", "peroxisomal", "and", "mitochondrial", "fission", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
GDAP1
23628762_task2
Sentence: Charcot-Marie-Tooth disease-associated mutants of GDAP1 dissociate its roles in peroxisomal and mitochondrial fission. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Charcot-Marie-Tooth disease-associated mutants of GDAP1 dissociate its roles in peroxisomal and mitochondrial fission.
[ "Charcot", "-", "Marie", "-", "Tooth", "disease", "-", "associated", "mutants", "of", "GDAP1", "dissociate", "its", "roles", "in", "peroxisomal", "and", "mitochondrial", "fission", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Candida is an umlsterm, human is an umlsterm, infection is an umlsterm, infections is an umlsterm, Candida is an umlsterm, spondylitis is an umlsterm, patient is an umlsterm, spondylitis is an umlsterm, adult is an umlsterm, Candida is an umlsterm, spondylitis is an umlsterm, occurrence is an umlsterm, candidiasis is an umlsterm, Spondylitis is an umlsterm, Amphotericin B is an umlsterm, candidiasis is an umlsterm, patients is an umlsterm, Spondylitis is an umlsterm, postoperative wound infection is an umlsterm, infection is an umlsterm, laboratory is an umlsterm, Candida is an umlsterm, diagnostic is an umlsterm, Diagnosis is an umlsterm, open is an umlsterm, biopsy is an umlsterm, needle is an umlsterm, aspiration is an umlsterm, therapeutic is an umlsterm, antifungal is an umlsterm, therapy is an umlsterm, Amphotericin B is an umlsterm, fluconazole is an umlsterm, surgical is an umlsterm, debridement is an umlsterm, instumentation is an umlsterm, spine is an umlsterm, spondylitis is an umlsterm, candidiasis is an umlsterm, infection is an umlsterm, humans is an umlsterm, patients is an umlsterm, Candida is an umlsterm, septicaemia is an umlsterm, septicaemia is an umlsterm, symptoms is an umlsterm, time is an umlsterm, diagnosis is an umlsterm
DerUnfallchirurg.81010955.eng.abstr_task0
Sentence: Candida species have emerged as important pathogens in human infection . Although a variety of deep-seated candidal infections have been reported , Candida spondylitis has rarely been described . One patient with candida tropicalis spondylitis L I and L II in combination with candida coxitis is presented , and the 31 adult cases with vertebral involvement previously reported are reviewed . Candida spondylitis is noted as a simultaneous occurrence or late manifestation of hematogenously disseminated candidiasis . Spondylitis may not be prevented by a course of Amphotericin B adequate to control the acute episode of disseminated candidiasis , particularly in immune suppressed patients . Spondylitis does not present as a postoperative wound infection . The insidious progression of infection , the nonspecificity of laboratory data , and the failure to recognise Candida as a potential pathogen may lead to diagnostic delay . Diagnosis can be made by either open biopsy or CT controlled needle aspiration . Successful therapeutic regimes have employed combinations of antifungal therapy ( Amphotericin B or fluconazole ) with radical surgical debridement . Ventral and facultatively dorsal instumentation is required to stabilize the spine . It is anticipated that the spondylitis will become a more commonly recognised manifestation of hematogenously disseminated candidiasis . A increasing significance of candida species as etiologic agents of infection immune compromised humans has been recognised in the recent years . In those patients whom an antecedent Candida septicaemia was documented , a striking delay of 3.3 months was found between the septicaemia and the onset of symptoms as well as the time of diagnosis . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
Candida species have emerged as important pathogens in human infection . Although a variety of deep-seated candidal infections have been reported , Candida spondylitis has rarely been described . One patient with candida tropicalis spondylitis L I and L II in combination with candida coxitis is presented , and the 31 adult cases with vertebral involvement previously reported are reviewed . Candida spondylitis is noted as a simultaneous occurrence or late manifestation of hematogenously disseminated candidiasis . Spondylitis may not be prevented by a course of Amphotericin B adequate to control the acute episode of disseminated candidiasis , particularly in immune suppressed patients . Spondylitis does not present as a postoperative wound infection . The insidious progression of infection , the nonspecificity of laboratory data , and the failure to recognise Candida as a potential pathogen may lead to diagnostic delay . Diagnosis can be made by either open biopsy or CT controlled needle aspiration . Successful therapeutic regimes have employed combinations of antifungal therapy ( Amphotericin B or fluconazole ) with radical surgical debridement . Ventral and facultatively dorsal instumentation is required to stabilize the spine . It is anticipated that the spondylitis will become a more commonly recognised manifestation of hematogenously disseminated candidiasis . A increasing significance of candida species as etiologic agents of infection immune compromised humans has been recognised in the recent years . In those patients whom an antecedent Candida septicaemia was documented , a striking delay of 3.3 months was found between the septicaemia and the onset of symptoms as well as the time of diagnosis .
[ "Candida", "species", "have", "emerged", "as", "important", "pathogens", "in", "human", "infection", ".", "Although", "a", "variety", "of", "deep", "-", "seated", "candidal", "infections", "have", "been", "reported", ",", "Candida", "spondylitis", "has", "rarely", "been", "described", ".", "One", "patient", "with", "candida", "tropicalis", "spondylitis", "L", "I", "and", "L", "II", "in", "combination", "with", "candida", "coxitis", "is", "presented", ",", "and", "the", "31", "adult", "cases", "with", "vertebral", "involvement", "previously", "reported", "are", "reviewed", ".", "Candida", "spondylitis", "is", "noted", "as", "a", "simultaneous", "occurrence", "or", "late", "manifestation", "of", "hematogenously", "disseminated", "candidiasis", ".", "Spondylitis", "may", "not", "be", "prevented", "by", "a", "course", "of", "Amphotericin", "B", "adequate", "to", "control", "the", "acute", "episode", "of", "disseminated", "candidiasis", ",", "particularly", "in", "immune", "suppressed", "patients", ".", "Spondylitis", "does", "not", "present", "as", "a", "postoperative", "wound", "infection", ".", "The", "insidious", "progression", "of", "infection", ",", "the", "nonspecificity", "of", "laboratory", "data", ",", "and", "the", "failure", "to", "recognise", "Candida", "as", "a", "potential", "pathogen", "may", "lead", "to", "diagnostic", "delay", ".", "Diagnosis", "can", "be", "made", "by", "either", "open", "biopsy", "or", "CT", "controlled", "needle", "aspiration", ".", "Successful", "therapeutic", "regimes", "have", "employed", "combinations", "of", "antifungal", "therapy", "(", "Amphotericin", "B", "or", "fluconazole", ")", "with", "radical", "surgical", "debridement", ".", "Ventral", "and", "facultatively", "dorsal", "instumentation", "is", "required", "to", "stabilize", "the", "spine", ".", "It", "is", "anticipated", "that", "the", "spondylitis", "will", "become", "a", "more", "commonly", "recognised", "manifestation", "of", "hematogenously", "disseminated", "candidiasis", ".", "A", "increasing", "significance", "of", "candida", "species", "as", "etiologic", "agents", "of", "infection", "immune", "compromised", "humans", "has", "been", "recognised", "in", "the", "recent", "years", ".", "In", "those", "patients", "whom", "an", "antecedent", "Candida", "septicaemia", "was", "documented", ",", "a", "striking", "delay", "of", "3.3", "months", "was", "found", "between", "the", "septicaemia", "and", "the", "onset", "of", "symptoms", "as", "well", "as", "the", "time", "of", "diagnosis", "." ]
[ "umlsterm" ]
Candida is an umlsterm, human is an umlsterm, infection is an umlsterm, infections is an umlsterm, Candida is an umlsterm, spondylitis is an umlsterm, patient is an umlsterm, spondylitis is an umlsterm, adult is an umlsterm, Candida is an umlsterm, spondylitis is an umlsterm, occurrence is an umlsterm, candidiasis is an umlsterm, Spondylitis is an umlsterm, Amphotericin B is an umlsterm, candidiasis is an umlsterm, patients is an umlsterm, Spondylitis is an umlsterm, postoperative wound infection is an umlsterm, infection is an umlsterm, laboratory is an umlsterm, Candida is an umlsterm, diagnostic is an umlsterm, Diagnosis is an umlsterm, open is an umlsterm, biopsy is an umlsterm, needle is an umlsterm, aspiration is an umlsterm, therapeutic is an umlsterm, antifungal is an umlsterm, therapy is an umlsterm, Amphotericin B is an umlsterm, fluconazole is an umlsterm, surgical is an umlsterm, debridement is an umlsterm, instumentation is an umlsterm, spine is an umlsterm, spondylitis is an umlsterm, candidiasis is an umlsterm, infection is an umlsterm, humans is an umlsterm, patients is an umlsterm, Candida is an umlsterm, septicaemia is an umlsterm, septicaemia is an umlsterm, symptoms is an umlsterm, time is an umlsterm, diagnosis is an umlsterm
DerUnfallchirurg.81010955.eng.abstr_task1
Sentence: Candida species have emerged as important pathogens in human infection . Although a variety of deep-seated candidal infections have been reported , Candida spondylitis has rarely been described . One patient with candida tropicalis spondylitis L I and L II in combination with candida coxitis is presented , and the 31 adult cases with vertebral involvement previously reported are reviewed . Candida spondylitis is noted as a simultaneous occurrence or late manifestation of hematogenously disseminated candidiasis . Spondylitis may not be prevented by a course of Amphotericin B adequate to control the acute episode of disseminated candidiasis , particularly in immune suppressed patients . Spondylitis does not present as a postoperative wound infection . The insidious progression of infection , the nonspecificity of laboratory data , and the failure to recognise Candida as a potential pathogen may lead to diagnostic delay . Diagnosis can be made by either open biopsy or CT controlled needle aspiration . Successful therapeutic regimes have employed combinations of antifungal therapy ( Amphotericin B or fluconazole ) with radical surgical debridement . Ventral and facultatively dorsal instumentation is required to stabilize the spine . It is anticipated that the spondylitis will become a more commonly recognised manifestation of hematogenously disseminated candidiasis . A increasing significance of candida species as etiologic agents of infection immune compromised humans has been recognised in the recent years . In those patients whom an antecedent Candida septicaemia was documented , a striking delay of 3.3 months was found between the septicaemia and the onset of symptoms as well as the time of diagnosis . Instructions: please typing these entity words according to sentence: Candida, human, infection, infections, Candida, spondylitis, patient, spondylitis, adult, Candida, spondylitis, occurrence, candidiasis, Spondylitis, Amphotericin B, candidiasis, patients, Spondylitis, postoperative wound infection, infection, laboratory, Candida, diagnostic, Diagnosis, open, biopsy, needle, aspiration, therapeutic, antifungal, therapy, Amphotericin B, fluconazole, surgical, debridement, instumentation, spine, spondylitis, candidiasis, infection, humans, patients, Candida, septicaemia, septicaemia, symptoms, time, diagnosis Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
Candida species have emerged as important pathogens in human infection . Although a variety of deep-seated candidal infections have been reported , Candida spondylitis has rarely been described . One patient with candida tropicalis spondylitis L I and L II in combination with candida coxitis is presented , and the 31 adult cases with vertebral involvement previously reported are reviewed . Candida spondylitis is noted as a simultaneous occurrence or late manifestation of hematogenously disseminated candidiasis . Spondylitis may not be prevented by a course of Amphotericin B adequate to control the acute episode of disseminated candidiasis , particularly in immune suppressed patients . Spondylitis does not present as a postoperative wound infection . The insidious progression of infection , the nonspecificity of laboratory data , and the failure to recognise Candida as a potential pathogen may lead to diagnostic delay . Diagnosis can be made by either open biopsy or CT controlled needle aspiration . Successful therapeutic regimes have employed combinations of antifungal therapy ( Amphotericin B or fluconazole ) with radical surgical debridement . Ventral and facultatively dorsal instumentation is required to stabilize the spine . It is anticipated that the spondylitis will become a more commonly recognised manifestation of hematogenously disseminated candidiasis . A increasing significance of candida species as etiologic agents of infection immune compromised humans has been recognised in the recent years . In those patients whom an antecedent Candida septicaemia was documented , a striking delay of 3.3 months was found between the septicaemia and the onset of symptoms as well as the time of diagnosis .
[ "Candida", "species", "have", "emerged", "as", "important", "pathogens", "in", "human", "infection", ".", "Although", "a", "variety", "of", "deep", "-", "seated", "candidal", "infections", "have", "been", "reported", ",", "Candida", "spondylitis", "has", "rarely", "been", "described", ".", "One", "patient", "with", "candida", "tropicalis", "spondylitis", "L", "I", "and", "L", "II", "in", "combination", "with", "candida", "coxitis", "is", "presented", ",", "and", "the", "31", "adult", "cases", "with", "vertebral", "involvement", "previously", "reported", "are", "reviewed", ".", "Candida", "spondylitis", "is", "noted", "as", "a", "simultaneous", "occurrence", "or", "late", "manifestation", "of", "hematogenously", "disseminated", "candidiasis", ".", "Spondylitis", "may", "not", "be", "prevented", "by", "a", "course", "of", "Amphotericin", "B", "adequate", "to", "control", "the", "acute", "episode", "of", "disseminated", "candidiasis", ",", "particularly", "in", "immune", "suppressed", "patients", ".", "Spondylitis", "does", "not", "present", "as", "a", "postoperative", "wound", "infection", ".", "The", "insidious", "progression", "of", "infection", ",", "the", "nonspecificity", "of", "laboratory", "data", ",", "and", "the", "failure", "to", "recognise", "Candida", "as", "a", "potential", "pathogen", "may", "lead", "to", "diagnostic", "delay", ".", "Diagnosis", "can", "be", "made", "by", "either", "open", "biopsy", "or", "CT", "controlled", "needle", "aspiration", ".", "Successful", "therapeutic", "regimes", "have", "employed", "combinations", "of", "antifungal", "therapy", "(", "Amphotericin", "B", "or", "fluconazole", ")", "with", "radical", "surgical", "debridement", ".", "Ventral", "and", "facultatively", "dorsal", "instumentation", "is", "required", "to", "stabilize", "the", "spine", ".", "It", "is", "anticipated", "that", "the", "spondylitis", "will", "become", "a", "more", "commonly", "recognised", "manifestation", "of", "hematogenously", "disseminated", "candidiasis", ".", "A", "increasing", "significance", "of", "candida", "species", "as", "etiologic", "agents", "of", "infection", "immune", "compromised", "humans", "has", "been", "recognised", "in", "the", "recent", "years", ".", "In", "those", "patients", "whom", "an", "antecedent", "Candida", "septicaemia", "was", "documented", ",", "a", "striking", "delay", "of", "3.3", "months", "was", "found", "between", "the", "septicaemia", "and", "the", "onset", "of", "symptoms", "as", "well", "as", "the", "time", "of", "diagnosis", "." ]
[ "umlsterm" ]
Candida, human, infection, infections, Candida, spondylitis, patient, spondylitis, adult, Candida, spondylitis, occurrence, candidiasis, Spondylitis, Amphotericin B, candidiasis, patients, Spondylitis, postoperative wound infection, infection, laboratory, Candida, diagnostic, Diagnosis, open, biopsy, needle, aspiration, therapeutic, antifungal, therapy, Amphotericin B, fluconazole, surgical, debridement, instumentation, spine, spondylitis, candidiasis, infection, humans, patients, Candida, septicaemia, septicaemia, symptoms, time, diagnosis
DerUnfallchirurg.81010955.eng.abstr_task2
Sentence: Candida species have emerged as important pathogens in human infection . Although a variety of deep-seated candidal infections have been reported , Candida spondylitis has rarely been described . One patient with candida tropicalis spondylitis L I and L II in combination with candida coxitis is presented , and the 31 adult cases with vertebral involvement previously reported are reviewed . Candida spondylitis is noted as a simultaneous occurrence or late manifestation of hematogenously disseminated candidiasis . Spondylitis may not be prevented by a course of Amphotericin B adequate to control the acute episode of disseminated candidiasis , particularly in immune suppressed patients . Spondylitis does not present as a postoperative wound infection . The insidious progression of infection , the nonspecificity of laboratory data , and the failure to recognise Candida as a potential pathogen may lead to diagnostic delay . Diagnosis can be made by either open biopsy or CT controlled needle aspiration . Successful therapeutic regimes have employed combinations of antifungal therapy ( Amphotericin B or fluconazole ) with radical surgical debridement . Ventral and facultatively dorsal instumentation is required to stabilize the spine . It is anticipated that the spondylitis will become a more commonly recognised manifestation of hematogenously disseminated candidiasis . A increasing significance of candida species as etiologic agents of infection immune compromised humans has been recognised in the recent years . In those patients whom an antecedent Candida septicaemia was documented , a striking delay of 3.3 months was found between the septicaemia and the onset of symptoms as well as the time of diagnosis . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
Candida species have emerged as important pathogens in human infection . Although a variety of deep-seated candidal infections have been reported , Candida spondylitis has rarely been described . One patient with candida tropicalis spondylitis L I and L II in combination with candida coxitis is presented , and the 31 adult cases with vertebral involvement previously reported are reviewed . Candida spondylitis is noted as a simultaneous occurrence or late manifestation of hematogenously disseminated candidiasis . Spondylitis may not be prevented by a course of Amphotericin B adequate to control the acute episode of disseminated candidiasis , particularly in immune suppressed patients . Spondylitis does not present as a postoperative wound infection . The insidious progression of infection , the nonspecificity of laboratory data , and the failure to recognise Candida as a potential pathogen may lead to diagnostic delay . Diagnosis can be made by either open biopsy or CT controlled needle aspiration . Successful therapeutic regimes have employed combinations of antifungal therapy ( Amphotericin B or fluconazole ) with radical surgical debridement . Ventral and facultatively dorsal instumentation is required to stabilize the spine . It is anticipated that the spondylitis will become a more commonly recognised manifestation of hematogenously disseminated candidiasis . A increasing significance of candida species as etiologic agents of infection immune compromised humans has been recognised in the recent years . In those patients whom an antecedent Candida septicaemia was documented , a striking delay of 3.3 months was found between the septicaemia and the onset of symptoms as well as the time of diagnosis .
[ "Candida", "species", "have", "emerged", "as", "important", "pathogens", "in", "human", "infection", ".", "Although", "a", "variety", "of", "deep", "-", "seated", "candidal", "infections", "have", "been", "reported", ",", "Candida", "spondylitis", "has", "rarely", "been", "described", ".", "One", "patient", "with", "candida", "tropicalis", "spondylitis", "L", "I", "and", "L", "II", "in", "combination", "with", "candida", "coxitis", "is", "presented", ",", "and", "the", "31", "adult", "cases", "with", "vertebral", "involvement", "previously", "reported", "are", "reviewed", ".", "Candida", "spondylitis", "is", "noted", "as", "a", "simultaneous", "occurrence", "or", "late", "manifestation", "of", "hematogenously", "disseminated", "candidiasis", ".", "Spondylitis", "may", "not", "be", "prevented", "by", "a", "course", "of", "Amphotericin", "B", "adequate", "to", "control", "the", "acute", "episode", "of", "disseminated", "candidiasis", ",", "particularly", "in", "immune", "suppressed", "patients", ".", "Spondylitis", "does", "not", "present", "as", "a", "postoperative", "wound", "infection", ".", "The", "insidious", "progression", "of", "infection", ",", "the", "nonspecificity", "of", "laboratory", "data", ",", "and", "the", "failure", "to", "recognise", "Candida", "as", "a", "potential", "pathogen", "may", "lead", "to", "diagnostic", "delay", ".", "Diagnosis", "can", "be", "made", "by", "either", "open", "biopsy", "or", "CT", "controlled", "needle", "aspiration", ".", "Successful", "therapeutic", "regimes", "have", "employed", "combinations", "of", "antifungal", "therapy", "(", "Amphotericin", "B", "or", "fluconazole", ")", "with", "radical", "surgical", "debridement", ".", "Ventral", "and", "facultatively", "dorsal", "instumentation", "is", "required", "to", "stabilize", "the", "spine", ".", "It", "is", "anticipated", "that", "the", "spondylitis", "will", "become", "a", "more", "commonly", "recognised", "manifestation", "of", "hematogenously", "disseminated", "candidiasis", ".", "A", "increasing", "significance", "of", "candida", "species", "as", "etiologic", "agents", "of", "infection", "immune", "compromised", "humans", "has", "been", "recognised", "in", "the", "recent", "years", ".", "In", "those", "patients", "whom", "an", "antecedent", "Candida", "septicaemia", "was", "documented", ",", "a", "striking", "delay", "of", "3.3", "months", "was", "found", "between", "the", "septicaemia", "and", "the", "onset", "of", "symptoms", "as", "well", "as", "the", "time", "of", "diagnosis", "." ]
[ "umlsterm" ]
car is an umlsterm, accidents is an umlsterm, persons is an umlsterm, car is an umlsterm, overall is an umlsterm, fractures is an umlsterm, foot is an umlsterm, role is an umlsterm, foot is an umlsterm, foot is an umlsterm, injuries is an umlsterm, single is an umlsterm, fractures is an umlsterm, forefoot is an umlsterm, ankle is an umlsterm, hindfoot is an umlsterm, open fractures is an umlsterm, ability is an umlsterm, foot injury is an umlsterm, ability is an umlsterm, evaluation is an umlsterm, foot is an umlsterm, injuries is an umlsterm, foot is an umlsterm, fractures is an umlsterm
DerUnfallchirurg.91020429.eng.abstr_task0
Sentence: During 1973 and 1989 , 6,378 car accidents with 8,931 injured persons were evaluated in the area of Hannover . 3,267 car drivers and passengers sustained fractures overall and 148 ( 4,5 % ) fractures of the foot . A major role in the ethiology of the foot fractures evolves from the deformation of the foot room . Driver and front seat passenger showed similar injuries . Among the 286 single fractures , the forefoot was affected most often ( 45 % ) , followed by ankle ( 38 % ) , midfoot ( 11 % ) and hindfoot ( 6 % ) . 5 % were open fractures . The long term results were estimated upon the limitation of working ability caused by the foot injury in relation to the entire working ability . The evaluation concludes that the foot fractures especially in combination with other injuries were frequently not recognized within the primary examination and therefore underestimated . The long-term outcome leaded to a high degree of impairment due to foot fractures . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]
During 1973 and 1989 , 6,378 car accidents with 8,931 injured persons were evaluated in the area of Hannover . 3,267 car drivers and passengers sustained fractures overall and 148 ( 4,5 % ) fractures of the foot . A major role in the ethiology of the foot fractures evolves from the deformation of the foot room . Driver and front seat passenger showed similar injuries . Among the 286 single fractures , the forefoot was affected most often ( 45 % ) , followed by ankle ( 38 % ) , midfoot ( 11 % ) and hindfoot ( 6 % ) . 5 % were open fractures . The long term results were estimated upon the limitation of working ability caused by the foot injury in relation to the entire working ability . The evaluation concludes that the foot fractures especially in combination with other injuries were frequently not recognized within the primary examination and therefore underestimated . The long-term outcome leaded to a high degree of impairment due to foot fractures .
[ "During", "1973", "and", "1989", ",", "6,378", "car", "accidents", "with", "8,931", "injured", "persons", "were", "evaluated", "in", "the", "area", "of", "Hannover", ".", "3,267", "car", "drivers", "and", "passengers", "sustained", "fractures", "overall", "and", "148", "(", "4,5", "%", ")", "fractures", "of", "the", "foot", ".", "A", "major", "role", "in", "the", "ethiology", "of", "the", "foot", "fractures", "evolves", "from", "the", "deformation", "of", "the", "foot", "room", ".", "Driver", "and", "front", "seat", "passenger", "showed", "similar", "injuries", ".", "Among", "the", "286", "single", "fractures", ",", "the", "forefoot", "was", "affected", "most", "often", "(", "45", "%", ")", ",", "followed", "by", "ankle", "(", "38", "%", ")", ",", "midfoot", "(", "11", "%", ")", "and", "hindfoot", "(", "6", "%", ")", ".", "5", "%", "were", "open", "fractures", ".", "The", "long", "term", "results", "were", "estimated", "upon", "the", "limitation", "of", "working", "ability", "caused", "by", "the", "foot", "injury", "in", "relation", "to", "the", "entire", "working", "ability", ".", "The", "evaluation", "concludes", "that", "the", "foot", "fractures", "especially", "in", "combination", "with", "other", "injuries", "were", "frequently", "not", "recognized", "within", "the", "primary", "examination", "and", "therefore", "underestimated", ".", "The", "long", "-", "term", "outcome", "leaded", "to", "a", "high", "degree", "of", "impairment", "due", "to", "foot", "fractures", "." ]
[ "umlsterm" ]
car is an umlsterm, accidents is an umlsterm, persons is an umlsterm, car is an umlsterm, overall is an umlsterm, fractures is an umlsterm, foot is an umlsterm, role is an umlsterm, foot is an umlsterm, foot is an umlsterm, injuries is an umlsterm, single is an umlsterm, fractures is an umlsterm, forefoot is an umlsterm, ankle is an umlsterm, hindfoot is an umlsterm, open fractures is an umlsterm, ability is an umlsterm, foot injury is an umlsterm, ability is an umlsterm, evaluation is an umlsterm, foot is an umlsterm, injuries is an umlsterm, foot is an umlsterm, fractures is an umlsterm
DerUnfallchirurg.91020429.eng.abstr_task1
Sentence: During 1973 and 1989 , 6,378 car accidents with 8,931 injured persons were evaluated in the area of Hannover . 3,267 car drivers and passengers sustained fractures overall and 148 ( 4,5 % ) fractures of the foot . A major role in the ethiology of the foot fractures evolves from the deformation of the foot room . Driver and front seat passenger showed similar injuries . Among the 286 single fractures , the forefoot was affected most often ( 45 % ) , followed by ankle ( 38 % ) , midfoot ( 11 % ) and hindfoot ( 6 % ) . 5 % were open fractures . The long term results were estimated upon the limitation of working ability caused by the foot injury in relation to the entire working ability . The evaluation concludes that the foot fractures especially in combination with other injuries were frequently not recognized within the primary examination and therefore underestimated . The long-term outcome leaded to a high degree of impairment due to foot fractures . Instructions: please typing these entity words according to sentence: car, accidents, persons, car, overall, fractures, foot, role, foot, foot, injuries, single, fractures, forefoot, ankle, hindfoot, open fractures, ability, foot injury, ability, evaluation, foot, injuries, foot, fractures Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]
During 1973 and 1989 , 6,378 car accidents with 8,931 injured persons were evaluated in the area of Hannover . 3,267 car drivers and passengers sustained fractures overall and 148 ( 4,5 % ) fractures of the foot . A major role in the ethiology of the foot fractures evolves from the deformation of the foot room . Driver and front seat passenger showed similar injuries . Among the 286 single fractures , the forefoot was affected most often ( 45 % ) , followed by ankle ( 38 % ) , midfoot ( 11 % ) and hindfoot ( 6 % ) . 5 % were open fractures . The long term results were estimated upon the limitation of working ability caused by the foot injury in relation to the entire working ability . The evaluation concludes that the foot fractures especially in combination with other injuries were frequently not recognized within the primary examination and therefore underestimated . The long-term outcome leaded to a high degree of impairment due to foot fractures .
[ "During", "1973", "and", "1989", ",", "6,378", "car", "accidents", "with", "8,931", "injured", "persons", "were", "evaluated", "in", "the", "area", "of", "Hannover", ".", "3,267", "car", "drivers", "and", "passengers", "sustained", "fractures", "overall", "and", "148", "(", "4,5", "%", ")", "fractures", "of", "the", "foot", ".", "A", "major", "role", "in", "the", "ethiology", "of", "the", "foot", "fractures", "evolves", "from", "the", "deformation", "of", "the", "foot", "room", ".", "Driver", "and", "front", "seat", "passenger", "showed", "similar", "injuries", ".", "Among", "the", "286", "single", "fractures", ",", "the", "forefoot", "was", "affected", "most", "often", "(", "45", "%", ")", ",", "followed", "by", "ankle", "(", "38", "%", ")", ",", "midfoot", "(", "11", "%", ")", "and", "hindfoot", "(", "6", "%", ")", ".", "5", "%", "were", "open", "fractures", ".", "The", "long", "term", "results", "were", "estimated", "upon", "the", "limitation", "of", "working", "ability", "caused", "by", "the", "foot", "injury", "in", "relation", "to", "the", "entire", "working", "ability", ".", "The", "evaluation", "concludes", "that", "the", "foot", "fractures", "especially", "in", "combination", "with", "other", "injuries", "were", "frequently", "not", "recognized", "within", "the", "primary", "examination", "and", "therefore", "underestimated", ".", "The", "long", "-", "term", "outcome", "leaded", "to", "a", "high", "degree", "of", "impairment", "due", "to", "foot", "fractures", "." ]
[ "umlsterm" ]
car, accidents, persons, car, overall, fractures, foot, role, foot, foot, injuries, single, fractures, forefoot, ankle, hindfoot, open fractures, ability, foot injury, ability, evaluation, foot, injuries, foot, fractures
DerUnfallchirurg.91020429.eng.abstr_task2
Sentence: During 1973 and 1989 , 6,378 car accidents with 8,931 injured persons were evaluated in the area of Hannover . 3,267 car drivers and passengers sustained fractures overall and 148 ( 4,5 % ) fractures of the foot . A major role in the ethiology of the foot fractures evolves from the deformation of the foot room . Driver and front seat passenger showed similar injuries . Among the 286 single fractures , the forefoot was affected most often ( 45 % ) , followed by ankle ( 38 % ) , midfoot ( 11 % ) and hindfoot ( 6 % ) . 5 % were open fractures . The long term results were estimated upon the limitation of working ability caused by the foot injury in relation to the entire working ability . The evaluation concludes that the foot fractures especially in combination with other injuries were frequently not recognized within the primary examination and therefore underestimated . The long-term outcome leaded to a high degree of impairment due to foot fractures . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]
During 1973 and 1989 , 6,378 car accidents with 8,931 injured persons were evaluated in the area of Hannover . 3,267 car drivers and passengers sustained fractures overall and 148 ( 4,5 % ) fractures of the foot . A major role in the ethiology of the foot fractures evolves from the deformation of the foot room . Driver and front seat passenger showed similar injuries . Among the 286 single fractures , the forefoot was affected most often ( 45 % ) , followed by ankle ( 38 % ) , midfoot ( 11 % ) and hindfoot ( 6 % ) . 5 % were open fractures . The long term results were estimated upon the limitation of working ability caused by the foot injury in relation to the entire working ability . The evaluation concludes that the foot fractures especially in combination with other injuries were frequently not recognized within the primary examination and therefore underestimated . The long-term outcome leaded to a high degree of impairment due to foot fractures .
[ "During", "1973", "and", "1989", ",", "6,378", "car", "accidents", "with", "8,931", "injured", "persons", "were", "evaluated", "in", "the", "area", "of", "Hannover", ".", "3,267", "car", "drivers", "and", "passengers", "sustained", "fractures", "overall", "and", "148", "(", "4,5", "%", ")", "fractures", "of", "the", "foot", ".", "A", "major", "role", "in", "the", "ethiology", "of", "the", "foot", "fractures", "evolves", "from", "the", "deformation", "of", "the", "foot", "room", ".", "Driver", "and", "front", "seat", "passenger", "showed", "similar", "injuries", ".", "Among", "the", "286", "single", "fractures", ",", "the", "forefoot", "was", "affected", "most", "often", "(", "45", "%", ")", ",", "followed", "by", "ankle", "(", "38", "%", ")", ",", "midfoot", "(", "11", "%", ")", "and", "hindfoot", "(", "6", "%", ")", ".", "5", "%", "were", "open", "fractures", ".", "The", "long", "term", "results", "were", "estimated", "upon", "the", "limitation", "of", "working", "ability", "caused", "by", "the", "foot", "injury", "in", "relation", "to", "the", "entire", "working", "ability", ".", "The", "evaluation", "concludes", "that", "the", "foot", "fractures", "especially", "in", "combination", "with", "other", "injuries", "were", "frequently", "not", "recognized", "within", "the", "primary", "examination", "and", "therefore", "underestimated", ".", "The", "long", "-", "term", "outcome", "leaded", "to", "a", "high", "degree", "of", "impairment", "due", "to", "foot", "fractures", "." ]
[ "umlsterm" ]
oncocytomas is an umlsterm, oncocytomas is an umlsterm, oncocytomatosis is an umlsterm, oncocytomatosis is an umlsterm, autopsy is an umlsterm, adenoma is an umlsterm, pheochromocytoma is an umlsterm, cicatrices is an umlsterm, large cell carcinoma is an umlsterm, lung is an umlsterm, renal tubules is an umlsterm, epithelial cells is an umlsterm, oncocytomas is an umlsterm, findings is an umlsterm, origin is an umlsterm, oncocytoma is an umlsterm, epithelium is an umlsterm, analysis is an umlsterm, tumors is an umlsterm, cytogenetic is an umlsterm, oncocytoma is an umlsterm, tumors is an umlsterm, oncocytomatosis is an umlsterm, tumors is an umlsterm
DerPathologe.90200189.eng.abstr_task0
Sentence: Multiple and bilateral oncocytomas are rare . There are only ten cases that have been previously described . Three of these displayed multiple and bilateral oncocytomas and microoncocytomas , a so-called oncocytomatosis . This report describes a case of renal oncocytomatosis found at autopsy . In addition , we found an adrenal adenoma , a pheochromocytoma and thoracic cicatrices 4 years after curatively resected large cell carcinoma of the lung . In the distal renal tubules we found oncocytic epithelial cells , with partial transition into microoncocytomas . Immunhistochemically , these and the main oncocytomas were CD 10 negative . These findings support the origin of oncocytoma from oncocytically transformed distal tubular epithelium . CGH analysis of the different tumors revealed no common cytogenetic changes . Coexistence of renal oncocytoma with other tumors is rare . Hitherto , coexistence of a renal oncocytomatosis with multiple tumors has not been described . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Multiple and bilateral oncocytomas are rare . There are only ten cases that have been previously described . Three of these displayed multiple and bilateral oncocytomas and microoncocytomas , a so-called oncocytomatosis . This report describes a case of renal oncocytomatosis found at autopsy . In addition , we found an adrenal adenoma , a pheochromocytoma and thoracic cicatrices 4 years after curatively resected large cell carcinoma of the lung . In the distal renal tubules we found oncocytic epithelial cells , with partial transition into microoncocytomas . Immunhistochemically , these and the main oncocytomas were CD 10 negative . These findings support the origin of oncocytoma from oncocytically transformed distal tubular epithelium . CGH analysis of the different tumors revealed no common cytogenetic changes . Coexistence of renal oncocytoma with other tumors is rare . Hitherto , coexistence of a renal oncocytomatosis with multiple tumors has not been described .
[ "Multiple", "and", "bilateral", "oncocytomas", "are", "rare", ".", "There", "are", "only", "ten", "cases", "that", "have", "been", "previously", "described", ".", "Three", "of", "these", "displayed", "multiple", "and", "bilateral", "oncocytomas", "and", "microoncocytomas", ",", "a", "so", "-", "called", "oncocytomatosis", ".", "This", "report", "describes", "a", "case", "of", "renal", "oncocytomatosis", "found", "at", "autopsy", ".", "In", "addition", ",", "we", "found", "an", "adrenal", "adenoma", ",", "a", "pheochromocytoma", "and", "thoracic", "cicatrices", "4", "years", "after", "curatively", "resected", "large", "cell", "carcinoma", "of", "the", "lung", ".", "In", "the", "distal", "renal", "tubules", "we", "found", "oncocytic", "epithelial", "cells", ",", "with", "partial", "transition", "into", "microoncocytomas", ".", "Immunhistochemically", ",", "these", "and", "the", "main", "oncocytomas", "were", "CD", "10", "negative", ".", "These", "findings", "support", "the", "origin", "of", "oncocytoma", "from", "oncocytically", "transformed", "distal", "tubular", "epithelium", ".", "CGH", "analysis", "of", "the", "different", "tumors", "revealed", "no", "common", "cytogenetic", "changes", ".", "Coexistence", "of", "renal", "oncocytoma", "with", "other", "tumors", "is", "rare", ".", "Hitherto", ",", "coexistence", "of", "a", "renal", "oncocytomatosis", "with", "multiple", "tumors", "has", "not", "been", "described", "." ]
[ "umlsterm" ]
oncocytomas is an umlsterm, oncocytomas is an umlsterm, oncocytomatosis is an umlsterm, oncocytomatosis is an umlsterm, autopsy is an umlsterm, adenoma is an umlsterm, pheochromocytoma is an umlsterm, cicatrices is an umlsterm, large cell carcinoma is an umlsterm, lung is an umlsterm, renal tubules is an umlsterm, epithelial cells is an umlsterm, oncocytomas is an umlsterm, findings is an umlsterm, origin is an umlsterm, oncocytoma is an umlsterm, epithelium is an umlsterm, analysis is an umlsterm, tumors is an umlsterm, cytogenetic is an umlsterm, oncocytoma is an umlsterm, tumors is an umlsterm, oncocytomatosis is an umlsterm, tumors is an umlsterm
DerPathologe.90200189.eng.abstr_task1
Sentence: Multiple and bilateral oncocytomas are rare . There are only ten cases that have been previously described . Three of these displayed multiple and bilateral oncocytomas and microoncocytomas , a so-called oncocytomatosis . This report describes a case of renal oncocytomatosis found at autopsy . In addition , we found an adrenal adenoma , a pheochromocytoma and thoracic cicatrices 4 years after curatively resected large cell carcinoma of the lung . In the distal renal tubules we found oncocytic epithelial cells , with partial transition into microoncocytomas . Immunhistochemically , these and the main oncocytomas were CD 10 negative . These findings support the origin of oncocytoma from oncocytically transformed distal tubular epithelium . CGH analysis of the different tumors revealed no common cytogenetic changes . Coexistence of renal oncocytoma with other tumors is rare . Hitherto , coexistence of a renal oncocytomatosis with multiple tumors has not been described . Instructions: please typing these entity words according to sentence: oncocytomas, oncocytomas, oncocytomatosis, oncocytomatosis, autopsy, adenoma, pheochromocytoma, cicatrices, large cell carcinoma, lung, renal tubules, epithelial cells, oncocytomas, findings, origin, oncocytoma, epithelium, analysis, tumors, cytogenetic, oncocytoma, tumors, oncocytomatosis, tumors Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Multiple and bilateral oncocytomas are rare . There are only ten cases that have been previously described . Three of these displayed multiple and bilateral oncocytomas and microoncocytomas , a so-called oncocytomatosis . This report describes a case of renal oncocytomatosis found at autopsy . In addition , we found an adrenal adenoma , a pheochromocytoma and thoracic cicatrices 4 years after curatively resected large cell carcinoma of the lung . In the distal renal tubules we found oncocytic epithelial cells , with partial transition into microoncocytomas . Immunhistochemically , these and the main oncocytomas were CD 10 negative . These findings support the origin of oncocytoma from oncocytically transformed distal tubular epithelium . CGH analysis of the different tumors revealed no common cytogenetic changes . Coexistence of renal oncocytoma with other tumors is rare . Hitherto , coexistence of a renal oncocytomatosis with multiple tumors has not been described .
[ "Multiple", "and", "bilateral", "oncocytomas", "are", "rare", ".", "There", "are", "only", "ten", "cases", "that", "have", "been", "previously", "described", ".", "Three", "of", "these", "displayed", "multiple", "and", "bilateral", "oncocytomas", "and", "microoncocytomas", ",", "a", "so", "-", "called", "oncocytomatosis", ".", "This", "report", "describes", "a", "case", "of", "renal", "oncocytomatosis", "found", "at", "autopsy", ".", "In", "addition", ",", "we", "found", "an", "adrenal", "adenoma", ",", "a", "pheochromocytoma", "and", "thoracic", "cicatrices", "4", "years", "after", "curatively", "resected", "large", "cell", "carcinoma", "of", "the", "lung", ".", "In", "the", "distal", "renal", "tubules", "we", "found", "oncocytic", "epithelial", "cells", ",", "with", "partial", "transition", "into", "microoncocytomas", ".", "Immunhistochemically", ",", "these", "and", "the", "main", "oncocytomas", "were", "CD", "10", "negative", ".", "These", "findings", "support", "the", "origin", "of", "oncocytoma", "from", "oncocytically", "transformed", "distal", "tubular", "epithelium", ".", "CGH", "analysis", "of", "the", "different", "tumors", "revealed", "no", "common", "cytogenetic", "changes", ".", "Coexistence", "of", "renal", "oncocytoma", "with", "other", "tumors", "is", "rare", ".", "Hitherto", ",", "coexistence", "of", "a", "renal", "oncocytomatosis", "with", "multiple", "tumors", "has", "not", "been", "described", "." ]
[ "umlsterm" ]
oncocytomas, oncocytomas, oncocytomatosis, oncocytomatosis, autopsy, adenoma, pheochromocytoma, cicatrices, large cell carcinoma, lung, renal tubules, epithelial cells, oncocytomas, findings, origin, oncocytoma, epithelium, analysis, tumors, cytogenetic, oncocytoma, tumors, oncocytomatosis, tumors
DerPathologe.90200189.eng.abstr_task2
Sentence: Multiple and bilateral oncocytomas are rare . There are only ten cases that have been previously described . Three of these displayed multiple and bilateral oncocytomas and microoncocytomas , a so-called oncocytomatosis . This report describes a case of renal oncocytomatosis found at autopsy . In addition , we found an adrenal adenoma , a pheochromocytoma and thoracic cicatrices 4 years after curatively resected large cell carcinoma of the lung . In the distal renal tubules we found oncocytic epithelial cells , with partial transition into microoncocytomas . Immunhistochemically , these and the main oncocytomas were CD 10 negative . These findings support the origin of oncocytoma from oncocytically transformed distal tubular epithelium . CGH analysis of the different tumors revealed no common cytogenetic changes . Coexistence of renal oncocytoma with other tumors is rare . Hitherto , coexistence of a renal oncocytomatosis with multiple tumors has not been described . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Multiple and bilateral oncocytomas are rare . There are only ten cases that have been previously described . Three of these displayed multiple and bilateral oncocytomas and microoncocytomas , a so-called oncocytomatosis . This report describes a case of renal oncocytomatosis found at autopsy . In addition , we found an adrenal adenoma , a pheochromocytoma and thoracic cicatrices 4 years after curatively resected large cell carcinoma of the lung . In the distal renal tubules we found oncocytic epithelial cells , with partial transition into microoncocytomas . Immunhistochemically , these and the main oncocytomas were CD 10 negative . These findings support the origin of oncocytoma from oncocytically transformed distal tubular epithelium . CGH analysis of the different tumors revealed no common cytogenetic changes . Coexistence of renal oncocytoma with other tumors is rare . Hitherto , coexistence of a renal oncocytomatosis with multiple tumors has not been described .
[ "Multiple", "and", "bilateral", "oncocytomas", "are", "rare", ".", "There", "are", "only", "ten", "cases", "that", "have", "been", "previously", "described", ".", "Three", "of", "these", "displayed", "multiple", "and", "bilateral", "oncocytomas", "and", "microoncocytomas", ",", "a", "so", "-", "called", "oncocytomatosis", ".", "This", "report", "describes", "a", "case", "of", "renal", "oncocytomatosis", "found", "at", "autopsy", ".", "In", "addition", ",", "we", "found", "an", "adrenal", "adenoma", ",", "a", "pheochromocytoma", "and", "thoracic", "cicatrices", "4", "years", "after", "curatively", "resected", "large", "cell", "carcinoma", "of", "the", "lung", ".", "In", "the", "distal", "renal", "tubules", "we", "found", "oncocytic", "epithelial", "cells", ",", "with", "partial", "transition", "into", "microoncocytomas", ".", "Immunhistochemically", ",", "these", "and", "the", "main", "oncocytomas", "were", "CD", "10", "negative", ".", "These", "findings", "support", "the", "origin", "of", "oncocytoma", "from", "oncocytically", "transformed", "distal", "tubular", "epithelium", ".", "CGH", "analysis", "of", "the", "different", "tumors", "revealed", "no", "common", "cytogenetic", "changes", ".", "Coexistence", "of", "renal", "oncocytoma", "with", "other", "tumors", "is", "rare", ".", "Hitherto", ",", "coexistence", "of", "a", "renal", "oncocytomatosis", "with", "multiple", "tumors", "has", "not", "been", "described", "." ]
[ "umlsterm" ]
rotigotine is a CHEMICAL
23165154_task0
Sentence: Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]
Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys.
[ "Three", "-", "month", "subchronic", "intramuscular", "toxicity", "study", "of", "rotigotine", "-", "loaded", "microspheres", "in", "Cynomolgus", "monkeys", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
rotigotine is a CHEMICAL
23165154_task1
Sentence: Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys. Instructions: please typing these entity words according to sentence: rotigotine Options: CHEMICAL
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]
Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys.
[ "Three", "-", "month", "subchronic", "intramuscular", "toxicity", "study", "of", "rotigotine", "-", "loaded", "microspheres", "in", "Cynomolgus", "monkeys", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
rotigotine
23165154_task2
Sentence: Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]
Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys.
[ "Three", "-", "month", "subchronic", "intramuscular", "toxicity", "study", "of", "rotigotine", "-", "loaded", "microspheres", "in", "Cynomolgus", "monkeys", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
tumor necrosis factor alpha is a Protein, NFATp is a Protein, ATF-2 is a Protein, / JUN is a Entity, tumor necrosis factor alpha is a Protein, TNF - alpha is a Protein, CD-40 is a Protein, TNF - alpha is a Protein, NFATp is a Protein, TNF - alpha is a Protein, promoter element kappa 3 is a Entity, ATF-2 is a Protein, cyclic AMP response element ( CRE ) site is a Entity, TNF - alpha is a Protein, TNF - alpha is a Protein, NFATp is a Protein, kappa 3 element is a Entity, ATF-2 is a Protein, composite kappa 3 / CRE site is a Entity, NFATp is a Protein, NFAT site is a Entity, -76 nucleotides is a Entity, TNF - alpha is a Protein, transcription start site is a Entity, TNF - alpha is a Protein, TNF - alpha is a Protein, promoter is a Entity, NFATp is a Protein, -76 site is a Entity, NFATp is a Protein, kappa 3 site is a Entity, NFATp is a Protein, - binding sites is a Entity, TNF - alpha is a Protein, promoter is a Entity, promoter element is a Entity, composite kappa 3 / CRE site is a Entity, TNF - alpha is a Protein
364_task0
Sentence: Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. The human tumor necrosis factor alpha (TNF-alpha) gene is one of the earliest genes transcribed after the stimulation of a B cell through its antigen receptor or via the CD-40 pathway. In both cases, induction of TNF-alpha gene transcription can be blocked by the immunosuppressants cyclosporin A and FK506, which suggested a role for the NFAT family of proteins in the regulation of the gene in B cells. Furthermore, in T cells, two molecules of NFATp bind to the TNF-alpha promoter element kappa 3 in association with ATF-2 and Jun proteins bound to an immediately adjacent cyclic AMP response element (CRE) site. Here, using the murine B-cell lymphoma cell line A20, we show that the TNF-alpha gene is regulated in a cell-type-specific manner. In A20 B cells, the TNF-alpha gene is not regulated by NFATp bound to the kappa 3 element. Instead, ATF-2 and Jun proteins bind to the composite kappa 3/CRE site and NFATp binds to a newly identified second NFAT site centered at -76 nucleotides relative to the TNF-alpha transcription start site. This new site plays a critical role in the calcium-mediated, cyclosporin A-sensitive induction of TNF-alpha in both A20 B cells and Ar-5 cells. Consistent with these results, quantitative DNase footprinting of the TNF-alpha promoter using increasing amounts of recombinant NFATp demonstrated that the -76 site binds to NFATp with a higher affinity than the kappa 3 site. Two other previously unrecognized NFATp-binding sites in the proximal TNF-alpha promoter were also identified by this analysis. Thus, through the differential use of the same promoter element, the composite kappa 3/CRE site, the TNF-alpha gene is regulated in a cell-type-specific manner in response to the same extracellular signal. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. The human tumor necrosis factor alpha (TNF-alpha) gene is one of the earliest genes transcribed after the stimulation of a B cell through its antigen receptor or via the CD-40 pathway. In both cases, induction of TNF-alpha gene transcription can be blocked by the immunosuppressants cyclosporin A and FK506, which suggested a role for the NFAT family of proteins in the regulation of the gene in B cells. Furthermore, in T cells, two molecules of NFATp bind to the TNF-alpha promoter element kappa 3 in association with ATF-2 and Jun proteins bound to an immediately adjacent cyclic AMP response element (CRE) site. Here, using the murine B-cell lymphoma cell line A20, we show that the TNF-alpha gene is regulated in a cell-type-specific manner. In A20 B cells, the TNF-alpha gene is not regulated by NFATp bound to the kappa 3 element. Instead, ATF-2 and Jun proteins bind to the composite kappa 3/CRE site and NFATp binds to a newly identified second NFAT site centered at -76 nucleotides relative to the TNF-alpha transcription start site. This new site plays a critical role in the calcium-mediated, cyclosporin A-sensitive induction of TNF-alpha in both A20 B cells and Ar-5 cells. Consistent with these results, quantitative DNase footprinting of the TNF-alpha promoter using increasing amounts of recombinant NFATp demonstrated that the -76 site binds to NFATp with a higher affinity than the kappa 3 site. Two other previously unrecognized NFATp-binding sites in the proximal TNF-alpha promoter were also identified by this analysis. Thus, through the differential use of the same promoter element, the composite kappa 3/CRE site, the TNF-alpha gene is regulated in a cell-type-specific manner in response to the same extracellular signal.
[ "Cell", "-", "type", "-", "specific", "regulation", "of", "the", "human", "tumor", "necrosis", "factor", "alpha", "gene", "in", "B", "cells", "and", "T", "cells", "by", "NFATp", "and", "ATF-2", "/", "JUN", ".", "\n", "The", "human", "tumor", "necrosis", "factor", "alpha", "(", "TNF", "-", "alpha", ")", "gene", "is", "one", "of", "the", "earliest", "genes", "transcribed", "after", "the", "stimulation", "of", "a", "B", "cell", "through", "its", "antigen", "receptor", "or", "via", "the", "CD-40", "pathway", ".", "In", "both", "cases", ",", "induction", "of", "TNF", "-", "alpha", "gene", "transcription", "can", "be", "blocked", "by", "the", "immunosuppressants", "cyclosporin", "A", "and", "FK506", ",", "which", "suggested", "a", "role", "for", "the", "NFAT", "family", "of", "proteins", "in", "the", "regulation", "of", "the", "gene", "in", "B", "cells", ".", "Furthermore", ",", "in", "T", "cells", ",", "two", "molecules", "of", "NFATp", "bind", "to", "the", "TNF", "-", "alpha", "promoter", "element", "kappa", "3", "in", "association", "with", "ATF-2", "and", "Jun", "proteins", "bound", "to", "an", "immediately", "adjacent", "cyclic", "AMP", "response", "element", "(", "CRE", ")", "site", ".", "Here", ",", "using", "the", "murine", "B", "-", "cell", "lymphoma", "cell", "line", "A20", ",", "we", "show", "that", "the", "TNF", "-", "alpha", "gene", "is", "regulated", "in", "a", "cell", "-", "type", "-", "specific", "manner", ".", "In", "A20", "B", "cells", ",", "the", "TNF", "-", "alpha", "gene", "is", "not", "regulated", "by", "NFATp", "bound", "to", "the", "kappa", "3", "element", ".", "Instead", ",", "ATF-2", "and", "Jun", "proteins", "bind", "to", "the", "composite", "kappa", "3", "/", "CRE", "site", "and", "NFATp", "binds", "to", "a", "newly", "identified", "second", "NFAT", "site", "centered", "at", "-76", "nucleotides", "relative", "to", "the", "TNF", "-", "alpha", "transcription", "start", "site", ".", "This", "new", "site", "plays", "a", "critical", "role", "in", "the", "calcium", "-", "mediated", ",", "cyclosporin", "A", "-", "sensitive", "induction", "of", "TNF", "-", "alpha", "in", "both", "A20", "B", "cells", "and", "Ar-5", "cells", ".", "Consistent", "with", "these", "results", ",", "quantitative", "DNase", "footprinting", "of", "the", "TNF", "-", "alpha", "promoter", "using", "increasing", "amounts", "of", "recombinant", "NFATp", "demonstrated", "that", "the", "-76", "site", "binds", "to", "NFATp", "with", "a", "higher", "affinity", "than", "the", "kappa", "3", "site", ".", "Two", "other", "previously", "unrecognized", "NFATp", "-", "binding", "sites", "in", "the", "proximal", "TNF", "-", "alpha", "promoter", "were", "also", "identified", "by", "this", "analysis", ".", "Thus", ",", "through", "the", "differential", "use", "of", "the", "same", "promoter", "element", ",", "the", "composite", "kappa", "3", "/", "CRE", "site", ",", "the", "TNF", "-", "alpha", "gene", "is", "regulated", "in", "a", "cell", "-", "type", "-", "specific", "manner", "in", "response", "to", "the", "same", "extracellular", "signal", ".", "\n" ]
[ "Entity", "Protein" ]
tumor necrosis factor alpha is a Protein, NFATp is a Protein, ATF-2 is a Protein, / JUN is a Entity, tumor necrosis factor alpha is a Protein, TNF - alpha is a Protein, CD-40 is a Protein, TNF - alpha is a Protein, NFATp is a Protein, TNF - alpha is a Protein, promoter element kappa 3 is a Entity, ATF-2 is a Protein, cyclic AMP response element ( CRE ) site is a Entity, TNF - alpha is a Protein, TNF - alpha is a Protein, NFATp is a Protein, kappa 3 element is a Entity, ATF-2 is a Protein, composite kappa 3 / CRE site is a Entity, NFATp is a Protein, NFAT site is a Entity, -76 nucleotides is a Entity, TNF - alpha is a Protein, transcription start site is a Entity, TNF - alpha is a Protein, TNF - alpha is a Protein, promoter is a Entity, NFATp is a Protein, -76 site is a Entity, NFATp is a Protein, kappa 3 site is a Entity, NFATp is a Protein, - binding sites is a Entity, TNF - alpha is a Protein, promoter is a Entity, promoter element is a Entity, composite kappa 3 / CRE site is a Entity, TNF - alpha is a Protein
364_task1
Sentence: Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. The human tumor necrosis factor alpha (TNF-alpha) gene is one of the earliest genes transcribed after the stimulation of a B cell through its antigen receptor or via the CD-40 pathway. In both cases, induction of TNF-alpha gene transcription can be blocked by the immunosuppressants cyclosporin A and FK506, which suggested a role for the NFAT family of proteins in the regulation of the gene in B cells. Furthermore, in T cells, two molecules of NFATp bind to the TNF-alpha promoter element kappa 3 in association with ATF-2 and Jun proteins bound to an immediately adjacent cyclic AMP response element (CRE) site. Here, using the murine B-cell lymphoma cell line A20, we show that the TNF-alpha gene is regulated in a cell-type-specific manner. In A20 B cells, the TNF-alpha gene is not regulated by NFATp bound to the kappa 3 element. Instead, ATF-2 and Jun proteins bind to the composite kappa 3/CRE site and NFATp binds to a newly identified second NFAT site centered at -76 nucleotides relative to the TNF-alpha transcription start site. This new site plays a critical role in the calcium-mediated, cyclosporin A-sensitive induction of TNF-alpha in both A20 B cells and Ar-5 cells. Consistent with these results, quantitative DNase footprinting of the TNF-alpha promoter using increasing amounts of recombinant NFATp demonstrated that the -76 site binds to NFATp with a higher affinity than the kappa 3 site. Two other previously unrecognized NFATp-binding sites in the proximal TNF-alpha promoter were also identified by this analysis. Thus, through the differential use of the same promoter element, the composite kappa 3/CRE site, the TNF-alpha gene is regulated in a cell-type-specific manner in response to the same extracellular signal. Instructions: please typing these entity words according to sentence: tumor necrosis factor alpha, NFATp, ATF-2, / JUN, tumor necrosis factor alpha, TNF - alpha, CD-40, TNF - alpha, NFATp, TNF - alpha, promoter element kappa 3, ATF-2, cyclic AMP response element ( CRE ) site, TNF - alpha, TNF - alpha, NFATp, kappa 3 element, ATF-2, composite kappa 3 / CRE site, NFATp, NFAT site, -76 nucleotides, TNF - alpha, transcription start site, TNF - alpha, TNF - alpha, promoter, NFATp, -76 site, NFATp, kappa 3 site, NFATp, - binding sites, TNF - alpha, promoter, promoter element, composite kappa 3 / CRE site, TNF - alpha Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. The human tumor necrosis factor alpha (TNF-alpha) gene is one of the earliest genes transcribed after the stimulation of a B cell through its antigen receptor or via the CD-40 pathway. In both cases, induction of TNF-alpha gene transcription can be blocked by the immunosuppressants cyclosporin A and FK506, which suggested a role for the NFAT family of proteins in the regulation of the gene in B cells. Furthermore, in T cells, two molecules of NFATp bind to the TNF-alpha promoter element kappa 3 in association with ATF-2 and Jun proteins bound to an immediately adjacent cyclic AMP response element (CRE) site. Here, using the murine B-cell lymphoma cell line A20, we show that the TNF-alpha gene is regulated in a cell-type-specific manner. In A20 B cells, the TNF-alpha gene is not regulated by NFATp bound to the kappa 3 element. Instead, ATF-2 and Jun proteins bind to the composite kappa 3/CRE site and NFATp binds to a newly identified second NFAT site centered at -76 nucleotides relative to the TNF-alpha transcription start site. This new site plays a critical role in the calcium-mediated, cyclosporin A-sensitive induction of TNF-alpha in both A20 B cells and Ar-5 cells. Consistent with these results, quantitative DNase footprinting of the TNF-alpha promoter using increasing amounts of recombinant NFATp demonstrated that the -76 site binds to NFATp with a higher affinity than the kappa 3 site. Two other previously unrecognized NFATp-binding sites in the proximal TNF-alpha promoter were also identified by this analysis. Thus, through the differential use of the same promoter element, the composite kappa 3/CRE site, the TNF-alpha gene is regulated in a cell-type-specific manner in response to the same extracellular signal.
[ "Cell", "-", "type", "-", "specific", "regulation", "of", "the", "human", "tumor", "necrosis", "factor", "alpha", "gene", "in", "B", "cells", "and", "T", "cells", "by", "NFATp", "and", "ATF-2", "/", "JUN", ".", "\n", "The", "human", "tumor", "necrosis", "factor", "alpha", "(", "TNF", "-", "alpha", ")", "gene", "is", "one", "of", "the", "earliest", "genes", "transcribed", "after", "the", "stimulation", "of", "a", "B", "cell", "through", "its", "antigen", "receptor", "or", "via", "the", "CD-40", "pathway", ".", "In", "both", "cases", ",", "induction", "of", "TNF", "-", "alpha", "gene", "transcription", "can", "be", "blocked", "by", "the", "immunosuppressants", "cyclosporin", "A", "and", "FK506", ",", "which", "suggested", "a", "role", "for", "the", "NFAT", "family", "of", "proteins", "in", "the", "regulation", "of", "the", "gene", "in", "B", "cells", ".", "Furthermore", ",", "in", "T", "cells", ",", "two", "molecules", "of", "NFATp", "bind", "to", "the", "TNF", "-", "alpha", "promoter", "element", "kappa", "3", "in", "association", "with", "ATF-2", "and", "Jun", "proteins", "bound", "to", "an", "immediately", "adjacent", "cyclic", "AMP", "response", "element", "(", "CRE", ")", "site", ".", "Here", ",", "using", "the", "murine", "B", "-", "cell", "lymphoma", "cell", "line", "A20", ",", "we", "show", "that", "the", "TNF", "-", "alpha", "gene", "is", "regulated", "in", "a", "cell", "-", "type", "-", "specific", "manner", ".", "In", "A20", "B", "cells", ",", "the", "TNF", "-", "alpha", "gene", "is", "not", "regulated", "by", "NFATp", "bound", "to", "the", "kappa", "3", "element", ".", "Instead", ",", "ATF-2", "and", "Jun", "proteins", "bind", "to", "the", "composite", "kappa", "3", "/", "CRE", "site", "and", "NFATp", "binds", "to", "a", "newly", "identified", "second", "NFAT", "site", "centered", "at", "-76", "nucleotides", "relative", "to", "the", "TNF", "-", "alpha", "transcription", "start", "site", ".", "This", "new", "site", "plays", "a", "critical", "role", "in", "the", "calcium", "-", "mediated", ",", "cyclosporin", "A", "-", "sensitive", "induction", "of", "TNF", "-", "alpha", "in", "both", "A20", "B", "cells", "and", "Ar-5", "cells", ".", "Consistent", "with", "these", "results", ",", "quantitative", "DNase", "footprinting", "of", "the", "TNF", "-", "alpha", "promoter", "using", "increasing", "amounts", "of", "recombinant", "NFATp", "demonstrated", "that", "the", "-76", "site", "binds", "to", "NFATp", "with", "a", "higher", "affinity", "than", "the", "kappa", "3", "site", ".", "Two", "other", "previously", "unrecognized", "NFATp", "-", "binding", "sites", "in", "the", "proximal", "TNF", "-", "alpha", "promoter", "were", "also", "identified", "by", "this", "analysis", ".", "Thus", ",", "through", "the", "differential", "use", "of", "the", "same", "promoter", "element", ",", "the", "composite", "kappa", "3", "/", "CRE", "site", ",", "the", "TNF", "-", "alpha", "gene", "is", "regulated", "in", "a", "cell", "-", "type", "-", "specific", "manner", "in", "response", "to", "the", "same", "extracellular", "signal", ".", "\n" ]
[ "Entity", "Protein" ]
tumor necrosis factor alpha, NFATp, ATF-2, / JUN, tumor necrosis factor alpha, TNF - alpha, CD-40, TNF - alpha, NFATp, TNF - alpha, promoter element kappa 3, ATF-2, cyclic AMP response element ( CRE ) site, TNF - alpha, TNF - alpha, NFATp, kappa 3 element, ATF-2, composite kappa 3 / CRE site, NFATp, NFAT site, -76 nucleotides, TNF - alpha, transcription start site, TNF - alpha, TNF - alpha, promoter, NFATp, -76 site, NFATp, kappa 3 site, NFATp, - binding sites, TNF - alpha, promoter, promoter element, composite kappa 3 / CRE site, TNF - alpha
364_task2
Sentence: Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. The human tumor necrosis factor alpha (TNF-alpha) gene is one of the earliest genes transcribed after the stimulation of a B cell through its antigen receptor or via the CD-40 pathway. In both cases, induction of TNF-alpha gene transcription can be blocked by the immunosuppressants cyclosporin A and FK506, which suggested a role for the NFAT family of proteins in the regulation of the gene in B cells. Furthermore, in T cells, two molecules of NFATp bind to the TNF-alpha promoter element kappa 3 in association with ATF-2 and Jun proteins bound to an immediately adjacent cyclic AMP response element (CRE) site. Here, using the murine B-cell lymphoma cell line A20, we show that the TNF-alpha gene is regulated in a cell-type-specific manner. In A20 B cells, the TNF-alpha gene is not regulated by NFATp bound to the kappa 3 element. Instead, ATF-2 and Jun proteins bind to the composite kappa 3/CRE site and NFATp binds to a newly identified second NFAT site centered at -76 nucleotides relative to the TNF-alpha transcription start site. This new site plays a critical role in the calcium-mediated, cyclosporin A-sensitive induction of TNF-alpha in both A20 B cells and Ar-5 cells. Consistent with these results, quantitative DNase footprinting of the TNF-alpha promoter using increasing amounts of recombinant NFATp demonstrated that the -76 site binds to NFATp with a higher affinity than the kappa 3 site. Two other previously unrecognized NFATp-binding sites in the proximal TNF-alpha promoter were also identified by this analysis. Thus, through the differential use of the same promoter element, the composite kappa 3/CRE site, the TNF-alpha gene is regulated in a cell-type-specific manner in response to the same extracellular signal. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. The human tumor necrosis factor alpha (TNF-alpha) gene is one of the earliest genes transcribed after the stimulation of a B cell through its antigen receptor or via the CD-40 pathway. In both cases, induction of TNF-alpha gene transcription can be blocked by the immunosuppressants cyclosporin A and FK506, which suggested a role for the NFAT family of proteins in the regulation of the gene in B cells. Furthermore, in T cells, two molecules of NFATp bind to the TNF-alpha promoter element kappa 3 in association with ATF-2 and Jun proteins bound to an immediately adjacent cyclic AMP response element (CRE) site. Here, using the murine B-cell lymphoma cell line A20, we show that the TNF-alpha gene is regulated in a cell-type-specific manner. In A20 B cells, the TNF-alpha gene is not regulated by NFATp bound to the kappa 3 element. Instead, ATF-2 and Jun proteins bind to the composite kappa 3/CRE site and NFATp binds to a newly identified second NFAT site centered at -76 nucleotides relative to the TNF-alpha transcription start site. This new site plays a critical role in the calcium-mediated, cyclosporin A-sensitive induction of TNF-alpha in both A20 B cells and Ar-5 cells. Consistent with these results, quantitative DNase footprinting of the TNF-alpha promoter using increasing amounts of recombinant NFATp demonstrated that the -76 site binds to NFATp with a higher affinity than the kappa 3 site. Two other previously unrecognized NFATp-binding sites in the proximal TNF-alpha promoter were also identified by this analysis. Thus, through the differential use of the same promoter element, the composite kappa 3/CRE site, the TNF-alpha gene is regulated in a cell-type-specific manner in response to the same extracellular signal.
[ "Cell", "-", "type", "-", "specific", "regulation", "of", "the", "human", "tumor", "necrosis", "factor", "alpha", "gene", "in", "B", "cells", "and", "T", "cells", "by", "NFATp", "and", "ATF-2", "/", "JUN", ".", "\n", "The", "human", "tumor", "necrosis", "factor", "alpha", "(", "TNF", "-", "alpha", ")", "gene", "is", "one", "of", "the", "earliest", "genes", "transcribed", "after", "the", "stimulation", "of", "a", "B", "cell", "through", "its", "antigen", "receptor", "or", "via", "the", "CD-40", "pathway", ".", "In", "both", "cases", ",", "induction", "of", "TNF", "-", "alpha", "gene", "transcription", "can", "be", "blocked", "by", "the", "immunosuppressants", "cyclosporin", "A", "and", "FK506", ",", "which", "suggested", "a", "role", "for", "the", "NFAT", "family", "of", "proteins", "in", "the", "regulation", "of", "the", "gene", "in", "B", "cells", ".", "Furthermore", ",", "in", "T", "cells", ",", "two", "molecules", "of", "NFATp", "bind", "to", "the", "TNF", "-", "alpha", "promoter", "element", "kappa", "3", "in", "association", "with", "ATF-2", "and", "Jun", "proteins", "bound", "to", "an", "immediately", "adjacent", "cyclic", "AMP", "response", "element", "(", "CRE", ")", "site", ".", "Here", ",", "using", "the", "murine", "B", "-", "cell", "lymphoma", "cell", "line", "A20", ",", "we", "show", "that", "the", "TNF", "-", "alpha", "gene", "is", "regulated", "in", "a", "cell", "-", "type", "-", "specific", "manner", ".", "In", "A20", "B", "cells", ",", "the", "TNF", "-", "alpha", "gene", "is", "not", "regulated", "by", "NFATp", "bound", "to", "the", "kappa", "3", "element", ".", "Instead", ",", "ATF-2", "and", "Jun", "proteins", "bind", "to", "the", "composite", "kappa", "3", "/", "CRE", "site", "and", "NFATp", "binds", "to", "a", "newly", "identified", "second", "NFAT", "site", "centered", "at", "-76", "nucleotides", "relative", "to", "the", "TNF", "-", "alpha", "transcription", "start", "site", ".", "This", "new", "site", "plays", "a", "critical", "role", "in", "the", "calcium", "-", "mediated", ",", "cyclosporin", "A", "-", "sensitive", "induction", "of", "TNF", "-", "alpha", "in", "both", "A20", "B", "cells", "and", "Ar-5", "cells", ".", "Consistent", "with", "these", "results", ",", "quantitative", "DNase", "footprinting", "of", "the", "TNF", "-", "alpha", "promoter", "using", "increasing", "amounts", "of", "recombinant", "NFATp", "demonstrated", "that", "the", "-76", "site", "binds", "to", "NFATp", "with", "a", "higher", "affinity", "than", "the", "kappa", "3", "site", ".", "Two", "other", "previously", "unrecognized", "NFATp", "-", "binding", "sites", "in", "the", "proximal", "TNF", "-", "alpha", "promoter", "were", "also", "identified", "by", "this", "analysis", ".", "Thus", ",", "through", "the", "differential", "use", "of", "the", "same", "promoter", "element", ",", "the", "composite", "kappa", "3", "/", "CRE", "site", ",", "the", "TNF", "-", "alpha", "gene", "is", "regulated", "in", "a", "cell", "-", "type", "-", "specific", "manner", "in", "response", "to", "the", "same", "extracellular", "signal", ".", "\n" ]
[ "Entity", "Protein" ]
methylthioadenosine phosphorylase is a GENE-Y, pemetrexed is a CHEMICAL
17041099_task0
Sentence: The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "O", "O" ]
The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity.
[ "The", "effect", "of", "a", "novel", "transition", "state", "inhibitor", "of", "methylthioadenosine", "phosphorylase", "on", "pemetrexed", "activity", "." ]
[ "GENE-Y", "CHEMICAL" ]
methylthioadenosine phosphorylase is a GENE-Y, pemetrexed is a CHEMICAL
17041099_task1
Sentence: The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity. Instructions: please typing these entity words according to sentence: methylthioadenosine phosphorylase, pemetrexed Options: GENE-Y, CHEMICAL
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "O", "O" ]
The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity.
[ "The", "effect", "of", "a", "novel", "transition", "state", "inhibitor", "of", "methylthioadenosine", "phosphorylase", "on", "pemetrexed", "activity", "." ]
[ "GENE-Y", "CHEMICAL" ]
methylthioadenosine phosphorylase, pemetrexed
17041099_task2
Sentence: The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "O", "O" ]
The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity.
[ "The", "effect", "of", "a", "novel", "transition", "state", "inhibitor", "of", "methylthioadenosine", "phosphorylase", "on", "pemetrexed", "activity", "." ]
[ "GENE-Y", "CHEMICAL" ]
Dopamine transporter is a GENE-Y, amphetamine is a CHEMICAL
15602501_task0
Sentence: Dopamine transporter gene associated with diminished subjective response to amphetamine. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL
[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O" ]
Dopamine transporter gene associated with diminished subjective response to amphetamine.
[ "Dopamine", "transporter", "gene", "associated", "with", "diminished", "subjective", "response", "to", "amphetamine", "." ]
[ "GENE-Y", "CHEMICAL" ]
Dopamine transporter is a GENE-Y, amphetamine is a CHEMICAL
15602501_task1
Sentence: Dopamine transporter gene associated with diminished subjective response to amphetamine. Instructions: please typing these entity words according to sentence: Dopamine transporter, amphetamine Options: GENE-Y, CHEMICAL
[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O" ]
Dopamine transporter gene associated with diminished subjective response to amphetamine.
[ "Dopamine", "transporter", "gene", "associated", "with", "diminished", "subjective", "response", "to", "amphetamine", "." ]
[ "GENE-Y", "CHEMICAL" ]
Dopamine transporter, amphetamine
15602501_task2
Sentence: Dopamine transporter gene associated with diminished subjective response to amphetamine. Instructions: please extract entity words from the input sentence
[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O" ]
Dopamine transporter gene associated with diminished subjective response to amphetamine.
[ "Dopamine", "transporter", "gene", "associated", "with", "diminished", "subjective", "response", "to", "amphetamine", "." ]
[ "GENE-Y", "CHEMICAL" ]
Antioxidants is an other_organic_compound, monocyte adhesion is an other_name, nuclear factor - kappa B mobilization is an other_name, vascular cell adhesion molecule-1 is a protein_molecule, endothelial cells is a cell_type, radicals is an inorganic
10920_task0
Sentence: Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kappa B mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: inorganic, other_organic_compound, cell_type, other_name, protein_molecule
[ "B-other_organic_compound", "O", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O", "O", "O", "B-inorganic", "O" ]
Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kappa B mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals.
[ "Antioxidants", "inhibit", "monocyte", "adhesion", "by", "suppressing", "nuclear", "factor", "-", "kappa", "B", "mobilization", "and", "induction", "of", "vascular", "cell", "adhesion", "molecule-1", "in", "endothelial", "cells", "stimulated", "to", "generate", "radicals", "." ]
[ "DNA_domain_or_region", "cell_line", "cell_type", "protein_molecule", "other_name", "other_organic_compound", "protein_family_or_group", "inorganic" ]
Antioxidants is an other_organic_compound, monocyte adhesion is an other_name, nuclear factor - kappa B mobilization is an other_name, vascular cell adhesion molecule-1 is a protein_molecule, endothelial cells is a cell_type, radicals is an inorganic
10920_task1
Sentence: Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kappa B mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. Instructions: please typing these entity words according to sentence: Antioxidants, monocyte adhesion, nuclear factor - kappa B mobilization, vascular cell adhesion molecule-1, endothelial cells, radicals Options: inorganic, other_organic_compound, cell_type, other_name, protein_molecule
[ "B-other_organic_compound", "O", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O", "O", "O", "B-inorganic", "O" ]
Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kappa B mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals.
[ "Antioxidants", "inhibit", "monocyte", "adhesion", "by", "suppressing", "nuclear", "factor", "-", "kappa", "B", "mobilization", "and", "induction", "of", "vascular", "cell", "adhesion", "molecule-1", "in", "endothelial", "cells", "stimulated", "to", "generate", "radicals", "." ]
[ "DNA_domain_or_region", "cell_line", "cell_type", "protein_molecule", "other_name", "other_organic_compound", "protein_family_or_group", "inorganic" ]
Antioxidants, monocyte adhesion, nuclear factor - kappa B mobilization, vascular cell adhesion molecule-1, endothelial cells, radicals
10920_task2
Sentence: Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kappa B mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. Instructions: please extract entity words from the input sentence
[ "B-other_organic_compound", "O", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O", "O", "O", "B-inorganic", "O" ]
Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kappa B mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals.
[ "Antioxidants", "inhibit", "monocyte", "adhesion", "by", "suppressing", "nuclear", "factor", "-", "kappa", "B", "mobilization", "and", "induction", "of", "vascular", "cell", "adhesion", "molecule-1", "in", "endothelial", "cells", "stimulated", "to", "generate", "radicals", "." ]
[ "DNA_domain_or_region", "cell_line", "cell_type", "protein_molecule", "other_name", "other_organic_compound", "protein_family_or_group", "inorganic" ]
breast cancer is a Cancer, breast cancer is a Cancer, breast cancer is a Cancer, breast cancer is a Cancer, breast cancer tissues is a Tissue, tissues is a Tissue, breast cancer is a Cancer, breast tissues is a Tissue, cell membranes is a Cellular_component, cancer is a Cancer, tissues is a Tissue, cell membrane is a Cellular_component, cytoplasm is a Organism_substance, cancer tissues is a Tissue, cell membranes is a Cellular_component, carcinoma tissues is a Tissue, breast tissues is a Tissue, cellular is a Cell, lymph node is a Multi-tissue_structure, breast is a Organism_subdivision
PMID-22105864_task0
Sentence: Aquaporins in human breast cancer: identification and involvement in carcinogenesis of breast cancer. BACKGROUND AND OBJECTIVES: Aquaporins (AQPs) play important roles in water and glycerol transport. Recently, the role of AQPs in human carcinogenesis has become an area of great interest. However, little is known about the function of AQPs in human breast cancer. The aim of this study was to investigate the expression profile of AQPs in human breast cancer and its significance. METHODS: In this study, we screened the expression profile of AQP0-12 in breast cancer tissues and corresponding normal tissues by RT-PCR, Western blotting and immunohistochemistry. RESULTS: AQP1, 3-5, and 10-12 were expressed in human breast cancer and/or normal breast tissues, and AQP1 and 3-5 exhibited differential expression. AQP1 was expressed in cell membranes and its expression was higher in cancer than that in normal tissues. AQP4 was expressed in the cell membrane and cytoplasm and was detected markedly stronger in normal than in cancer tissues. AQP5 was expressed mainly in cell membranes in carcinoma tissues, but was almost absent in normal breast tissues. Expression of AQP5 was associated with cellular differentiation, lymph node invasion, and clinicopathological staging. CONCLUSIONS: These observations suggested that several subtypes of the AQP family play a role in human breast carcinogenesis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Multi-tissue_structure, Tissue, Organism_substance, Organism_subdivision, Cancer, Cellular_component, Cell
[ "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O" ]
Aquaporins in human breast cancer: identification and involvement in carcinogenesis of breast cancer. BACKGROUND AND OBJECTIVES: Aquaporins (AQPs) play important roles in water and glycerol transport. Recently, the role of AQPs in human carcinogenesis has become an area of great interest. However, little is known about the function of AQPs in human breast cancer. The aim of this study was to investigate the expression profile of AQPs in human breast cancer and its significance. METHODS: In this study, we screened the expression profile of AQP0-12 in breast cancer tissues and corresponding normal tissues by RT-PCR, Western blotting and immunohistochemistry. RESULTS: AQP1, 3-5, and 10-12 were expressed in human breast cancer and/or normal breast tissues, and AQP1 and 3-5 exhibited differential expression. AQP1 was expressed in cell membranes and its expression was higher in cancer than that in normal tissues. AQP4 was expressed in the cell membrane and cytoplasm and was detected markedly stronger in normal than in cancer tissues. AQP5 was expressed mainly in cell membranes in carcinoma tissues, but was almost absent in normal breast tissues. Expression of AQP5 was associated with cellular differentiation, lymph node invasion, and clinicopathological staging. CONCLUSIONS: These observations suggested that several subtypes of the AQP family play a role in human breast carcinogenesis.
[ "Aquaporins", "in", "human", "breast", "cancer", ":", "identification", "and", "involvement", "in", "carcinogenesis", "of", "breast", "cancer", ".", "\n", "BACKGROUND", "AND", "OBJECTIVES", ":", "Aquaporins", "(", "AQPs", ")", "play", "important", "roles", "in", "water", "and", "glycerol", "transport", ".", "Recently", ",", "the", "role", "of", "AQPs", "in", "human", "carcinogenesis", "has", "become", "an", "area", "of", "great", "interest", ".", "However", ",", "little", "is", "known", "about", "the", "function", "of", "AQPs", "in", "human", "breast", "cancer", ".", "The", "aim", "of", "this", "study", "was", "to", "investigate", "the", "expression", "profile", "of", "AQPs", "in", "human", "breast", "cancer", "and", "its", "significance", ".", "METHODS", ":", "In", "this", "study", ",", "we", "screened", "the", "expression", "profile", "of", "AQP0", "-", "12", "in", "breast", "cancer", "tissues", "and", "corresponding", "normal", "tissues", "by", "RT", "-", "PCR", ",", "Western", "blotting", "and", "immunohistochemistry", ".", "RESULTS", ":", "AQP1", ",", "3", "-", "5", ",", "and", "10", "-", "12", "were", "expressed", "in", "human", "breast", "cancer", "and", "/", "or", "normal", "breast", "tissues", ",", "and", "AQP1", "and", "3", "-", "5", "exhibited", "differential", "expression", ".", "AQP1", "was", "expressed", "in", "cell", "membranes", "and", "its", "expression", "was", "higher", "in", "cancer", "than", "that", "in", "normal", "tissues", ".", "AQP4", "was", "expressed", "in", "the", "cell", "membrane", "and", "cytoplasm", "and", "was", "detected", "markedly", "stronger", "in", "normal", "than", "in", "cancer", "tissues", ".", "AQP5", "was", "expressed", "mainly", "in", "cell", "membranes", "in", "carcinoma", "tissues", ",", "but", "was", "almost", "absent", "in", "normal", "breast", "tissues", ".", "Expression", "of", "AQP5", "was", "associated", "with", "cellular", "differentiation", ",", "lymph", "node", "invasion", ",", "and", "clinicopathological", "staging", ".", "CONCLUSIONS", ":", "These", "observations", "suggested", "that", "several", "subtypes", "of", "the", "AQP", "family", "play", "a", "role", "in", "human", "breast", "carcinogenesis", ".", "\n" ]
[ "Tissue", "Cellular_component", "Cancer", "Multi-tissue_structure", "Organism_substance", "Cell", "Organism_subdivision" ]
breast cancer is a Cancer, breast cancer is a Cancer, breast cancer is a Cancer, breast cancer is a Cancer, breast cancer tissues is a Tissue, tissues is a Tissue, breast cancer is a Cancer, breast tissues is a Tissue, cell membranes is a Cellular_component, cancer is a Cancer, tissues is a Tissue, cell membrane is a Cellular_component, cytoplasm is a Organism_substance, cancer tissues is a Tissue, cell membranes is a Cellular_component, carcinoma tissues is a Tissue, breast tissues is a Tissue, cellular is a Cell, lymph node is a Multi-tissue_structure, breast is a Organism_subdivision
PMID-22105864_task1
Sentence: Aquaporins in human breast cancer: identification and involvement in carcinogenesis of breast cancer. BACKGROUND AND OBJECTIVES: Aquaporins (AQPs) play important roles in water and glycerol transport. Recently, the role of AQPs in human carcinogenesis has become an area of great interest. However, little is known about the function of AQPs in human breast cancer. The aim of this study was to investigate the expression profile of AQPs in human breast cancer and its significance. METHODS: In this study, we screened the expression profile of AQP0-12 in breast cancer tissues and corresponding normal tissues by RT-PCR, Western blotting and immunohistochemistry. RESULTS: AQP1, 3-5, and 10-12 were expressed in human breast cancer and/or normal breast tissues, and AQP1 and 3-5 exhibited differential expression. AQP1 was expressed in cell membranes and its expression was higher in cancer than that in normal tissues. AQP4 was expressed in the cell membrane and cytoplasm and was detected markedly stronger in normal than in cancer tissues. AQP5 was expressed mainly in cell membranes in carcinoma tissues, but was almost absent in normal breast tissues. Expression of AQP5 was associated with cellular differentiation, lymph node invasion, and clinicopathological staging. CONCLUSIONS: These observations suggested that several subtypes of the AQP family play a role in human breast carcinogenesis. Instructions: please typing these entity words according to sentence: breast cancer, breast cancer, breast cancer, breast cancer, breast cancer tissues, tissues, breast cancer, breast tissues, cell membranes, cancer, tissues, cell membrane, cytoplasm, cancer tissues, cell membranes, carcinoma tissues, breast tissues, cellular, lymph node, breast Options: Multi-tissue_structure, Tissue, Organism_substance, Organism_subdivision, Cancer, Cellular_component, Cell
[ "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O" ]
Aquaporins in human breast cancer: identification and involvement in carcinogenesis of breast cancer. BACKGROUND AND OBJECTIVES: Aquaporins (AQPs) play important roles in water and glycerol transport. Recently, the role of AQPs in human carcinogenesis has become an area of great interest. However, little is known about the function of AQPs in human breast cancer. The aim of this study was to investigate the expression profile of AQPs in human breast cancer and its significance. METHODS: In this study, we screened the expression profile of AQP0-12 in breast cancer tissues and corresponding normal tissues by RT-PCR, Western blotting and immunohistochemistry. RESULTS: AQP1, 3-5, and 10-12 were expressed in human breast cancer and/or normal breast tissues, and AQP1 and 3-5 exhibited differential expression. AQP1 was expressed in cell membranes and its expression was higher in cancer than that in normal tissues. AQP4 was expressed in the cell membrane and cytoplasm and was detected markedly stronger in normal than in cancer tissues. AQP5 was expressed mainly in cell membranes in carcinoma tissues, but was almost absent in normal breast tissues. Expression of AQP5 was associated with cellular differentiation, lymph node invasion, and clinicopathological staging. CONCLUSIONS: These observations suggested that several subtypes of the AQP family play a role in human breast carcinogenesis.
[ "Aquaporins", "in", "human", "breast", "cancer", ":", "identification", "and", "involvement", "in", "carcinogenesis", "of", "breast", "cancer", ".", "\n", "BACKGROUND", "AND", "OBJECTIVES", ":", "Aquaporins", "(", "AQPs", ")", "play", "important", "roles", "in", "water", "and", "glycerol", "transport", ".", "Recently", ",", "the", "role", "of", "AQPs", "in", "human", "carcinogenesis", "has", "become", "an", "area", "of", "great", "interest", ".", "However", ",", "little", "is", "known", "about", "the", "function", "of", "AQPs", "in", "human", "breast", "cancer", ".", "The", "aim", "of", "this", "study", "was", "to", "investigate", "the", "expression", "profile", "of", "AQPs", "in", "human", "breast", "cancer", "and", "its", "significance", ".", "METHODS", ":", "In", "this", "study", ",", "we", "screened", "the", "expression", "profile", "of", "AQP0", "-", "12", "in", "breast", "cancer", "tissues", "and", "corresponding", "normal", "tissues", "by", "RT", "-", "PCR", ",", "Western", "blotting", "and", "immunohistochemistry", ".", "RESULTS", ":", "AQP1", ",", "3", "-", "5", ",", "and", "10", "-", "12", "were", "expressed", "in", "human", "breast", "cancer", "and", "/", "or", "normal", "breast", "tissues", ",", "and", "AQP1", "and", "3", "-", "5", "exhibited", "differential", "expression", ".", "AQP1", "was", "expressed", "in", "cell", "membranes", "and", "its", "expression", "was", "higher", "in", "cancer", "than", "that", "in", "normal", "tissues", ".", "AQP4", "was", "expressed", "in", "the", "cell", "membrane", "and", "cytoplasm", "and", "was", "detected", "markedly", "stronger", "in", "normal", "than", "in", "cancer", "tissues", ".", "AQP5", "was", "expressed", "mainly", "in", "cell", "membranes", "in", "carcinoma", "tissues", ",", "but", "was", "almost", "absent", "in", "normal", "breast", "tissues", ".", "Expression", "of", "AQP5", "was", "associated", "with", "cellular", "differentiation", ",", "lymph", "node", "invasion", ",", "and", "clinicopathological", "staging", ".", "CONCLUSIONS", ":", "These", "observations", "suggested", "that", "several", "subtypes", "of", "the", "AQP", "family", "play", "a", "role", "in", "human", "breast", "carcinogenesis", ".", "\n" ]
[ "Tissue", "Cellular_component", "Cancer", "Multi-tissue_structure", "Organism_substance", "Cell", "Organism_subdivision" ]
breast cancer, breast cancer, breast cancer, breast cancer, breast cancer tissues, tissues, breast cancer, breast tissues, cell membranes, cancer, tissues, cell membrane, cytoplasm, cancer tissues, cell membranes, carcinoma tissues, breast tissues, cellular, lymph node, breast
PMID-22105864_task2
Sentence: Aquaporins in human breast cancer: identification and involvement in carcinogenesis of breast cancer. BACKGROUND AND OBJECTIVES: Aquaporins (AQPs) play important roles in water and glycerol transport. Recently, the role of AQPs in human carcinogenesis has become an area of great interest. However, little is known about the function of AQPs in human breast cancer. The aim of this study was to investigate the expression profile of AQPs in human breast cancer and its significance. METHODS: In this study, we screened the expression profile of AQP0-12 in breast cancer tissues and corresponding normal tissues by RT-PCR, Western blotting and immunohistochemistry. RESULTS: AQP1, 3-5, and 10-12 were expressed in human breast cancer and/or normal breast tissues, and AQP1 and 3-5 exhibited differential expression. AQP1 was expressed in cell membranes and its expression was higher in cancer than that in normal tissues. AQP4 was expressed in the cell membrane and cytoplasm and was detected markedly stronger in normal than in cancer tissues. AQP5 was expressed mainly in cell membranes in carcinoma tissues, but was almost absent in normal breast tissues. Expression of AQP5 was associated with cellular differentiation, lymph node invasion, and clinicopathological staging. CONCLUSIONS: These observations suggested that several subtypes of the AQP family play a role in human breast carcinogenesis. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O" ]
Aquaporins in human breast cancer: identification and involvement in carcinogenesis of breast cancer. BACKGROUND AND OBJECTIVES: Aquaporins (AQPs) play important roles in water and glycerol transport. Recently, the role of AQPs in human carcinogenesis has become an area of great interest. However, little is known about the function of AQPs in human breast cancer. The aim of this study was to investigate the expression profile of AQPs in human breast cancer and its significance. METHODS: In this study, we screened the expression profile of AQP0-12 in breast cancer tissues and corresponding normal tissues by RT-PCR, Western blotting and immunohistochemistry. RESULTS: AQP1, 3-5, and 10-12 were expressed in human breast cancer and/or normal breast tissues, and AQP1 and 3-5 exhibited differential expression. AQP1 was expressed in cell membranes and its expression was higher in cancer than that in normal tissues. AQP4 was expressed in the cell membrane and cytoplasm and was detected markedly stronger in normal than in cancer tissues. AQP5 was expressed mainly in cell membranes in carcinoma tissues, but was almost absent in normal breast tissues. Expression of AQP5 was associated with cellular differentiation, lymph node invasion, and clinicopathological staging. CONCLUSIONS: These observations suggested that several subtypes of the AQP family play a role in human breast carcinogenesis.
[ "Aquaporins", "in", "human", "breast", "cancer", ":", "identification", "and", "involvement", "in", "carcinogenesis", "of", "breast", "cancer", ".", "\n", "BACKGROUND", "AND", "OBJECTIVES", ":", "Aquaporins", "(", "AQPs", ")", "play", "important", "roles", "in", "water", "and", "glycerol", "transport", ".", "Recently", ",", "the", "role", "of", "AQPs", "in", "human", "carcinogenesis", "has", "become", "an", "area", "of", "great", "interest", ".", "However", ",", "little", "is", "known", "about", "the", "function", "of", "AQPs", "in", "human", "breast", "cancer", ".", "The", "aim", "of", "this", "study", "was", "to", "investigate", "the", "expression", "profile", "of", "AQPs", "in", "human", "breast", "cancer", "and", "its", "significance", ".", "METHODS", ":", "In", "this", "study", ",", "we", "screened", "the", "expression", "profile", "of", "AQP0", "-", "12", "in", "breast", "cancer", "tissues", "and", "corresponding", "normal", "tissues", "by", "RT", "-", "PCR", ",", "Western", "blotting", "and", "immunohistochemistry", ".", "RESULTS", ":", "AQP1", ",", "3", "-", "5", ",", "and", "10", "-", "12", "were", "expressed", "in", "human", "breast", "cancer", "and", "/", "or", "normal", "breast", "tissues", ",", "and", "AQP1", "and", "3", "-", "5", "exhibited", "differential", "expression", ".", "AQP1", "was", "expressed", "in", "cell", "membranes", "and", "its", "expression", "was", "higher", "in", "cancer", "than", "that", "in", "normal", "tissues", ".", "AQP4", "was", "expressed", "in", "the", "cell", "membrane", "and", "cytoplasm", "and", "was", "detected", "markedly", "stronger", "in", "normal", "than", "in", "cancer", "tissues", ".", "AQP5", "was", "expressed", "mainly", "in", "cell", "membranes", "in", "carcinoma", "tissues", ",", "but", "was", "almost", "absent", "in", "normal", "breast", "tissues", ".", "Expression", "of", "AQP5", "was", "associated", "with", "cellular", "differentiation", ",", "lymph", "node", "invasion", ",", "and", "clinicopathological", "staging", ".", "CONCLUSIONS", ":", "These", "observations", "suggested", "that", "several", "subtypes", "of", "the", "AQP", "family", "play", "a", "role", "in", "human", "breast", "carcinogenesis", ".", "\n" ]
[ "Tissue", "Cellular_component", "Cancer", "Multi-tissue_structure", "Organism_substance", "Cell", "Organism_subdivision" ]
Therapie is an umlsterm, Glaukom is an umlsterm, Goniotomie is an umlsterm
DerOpthalmologe.00970623.ger.abstr_task0
Sentence: Fragestellung . Die Wirksamkeit der Trabekulotomie ( TO ) als primaere operative Therapie bei kongenitalem Glaukom wurde mit der Wirksamkeit der Goniotomie ( GO ) verglichen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Fragestellung . Die Wirksamkeit der Trabekulotomie ( TO ) als primaere operative Therapie bei kongenitalem Glaukom wurde mit der Wirksamkeit der Goniotomie ( GO ) verglichen .
[ "Fragestellung", ".", "Die", "Wirksamkeit", "der", "Trabekulotomie", "(", "TO", ")", "als", "primaere", "operative", "Therapie", "bei", "kongenitalem", "Glaukom", "wurde", "mit", "der", "Wirksamkeit", "der", "Goniotomie", "(", "GO", ")", "verglichen", "." ]
[ "umlsterm" ]
Therapie is an umlsterm, Glaukom is an umlsterm, Goniotomie is an umlsterm
DerOpthalmologe.00970623.ger.abstr_task1
Sentence: Fragestellung . Die Wirksamkeit der Trabekulotomie ( TO ) als primaere operative Therapie bei kongenitalem Glaukom wurde mit der Wirksamkeit der Goniotomie ( GO ) verglichen . Instructions: please typing these entity words according to sentence: Therapie, Glaukom, Goniotomie Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Fragestellung . Die Wirksamkeit der Trabekulotomie ( TO ) als primaere operative Therapie bei kongenitalem Glaukom wurde mit der Wirksamkeit der Goniotomie ( GO ) verglichen .
[ "Fragestellung", ".", "Die", "Wirksamkeit", "der", "Trabekulotomie", "(", "TO", ")", "als", "primaere", "operative", "Therapie", "bei", "kongenitalem", "Glaukom", "wurde", "mit", "der", "Wirksamkeit", "der", "Goniotomie", "(", "GO", ")", "verglichen", "." ]
[ "umlsterm" ]
Therapie, Glaukom, Goniotomie
DerOpthalmologe.00970623.ger.abstr_task2
Sentence: Fragestellung . Die Wirksamkeit der Trabekulotomie ( TO ) als primaere operative Therapie bei kongenitalem Glaukom wurde mit der Wirksamkeit der Goniotomie ( GO ) verglichen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Fragestellung . Die Wirksamkeit der Trabekulotomie ( TO ) als primaere operative Therapie bei kongenitalem Glaukom wurde mit der Wirksamkeit der Goniotomie ( GO ) verglichen .
[ "Fragestellung", ".", "Die", "Wirksamkeit", "der", "Trabekulotomie", "(", "TO", ")", "als", "primaere", "operative", "Therapie", "bei", "kongenitalem", "Glaukom", "wurde", "mit", "der", "Wirksamkeit", "der", "Goniotomie", "(", "GO", ")", "verglichen", "." ]
[ "umlsterm" ]
Infektionskrankheiten is an umlsterm, Menschen is an umlsterm, Infektionsschutzgesetz is an umlsterm, uebertragbaren Krankheiten is an umlsterm, Deutschland is an umlsterm, Infektion is an umlsterm, Diagnosen is an umlsterm
Bundesgesundheitsblatt.00430839.ger.abstr_task0
Sentence: Mit Einfuehrung des Gesetzes zur Verhuetung und Bekaempfung von Infektionskrankheiten beim Menschen ( Infektionsschutzgesetz IfSG ) werden erstmals gemaess § 4 ( 2 ) Falldefinitionen zur routinemaessigen Uebermittlung der meldepflichtigen uebertragbaren Krankheiten in Deutschland in verbindlicher Form eingefuehrt . Mit Hilfe der Falldefinitionen werden Krankheitsbezeichnungen mit einer definierten Beschreibung der Erkrankung in Verbindung gebracht . Die damit einhergehende Abstraktion fuehrt zur Schaffung " nosologischer Entitaeten " . Die gemaess IfSG vom Robert Koch-Institut erstellten Falldefinitionen versetzen die Gesundheitsaemter in die Lage , die ihnen gemeldeten Erkrankungs- oder Todesfaelle sowie die Nachweise von Krankheitserregern nach einheitlichen Kriterien zu bewerten und ueber die Landesgesundheitsbehoerden der Bundeslaender an das Robert Koch-Institut ( RKI ) zu uebermitteln . Durch die Einfuehrung der Falldefinitionen wird die Qualitaet der Meldedaten deutlich verbessert , da jede gemeldete Erkrankung/ Infektion definierte Kriterien erfuellt und somit unklare Erkrankungsfaelle oder Diagnosen nicht mit gesicherten vermischt werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Mit Einfuehrung des Gesetzes zur Verhuetung und Bekaempfung von Infektionskrankheiten beim Menschen ( Infektionsschutzgesetz IfSG ) werden erstmals gemaess § 4 ( 2 ) Falldefinitionen zur routinemaessigen Uebermittlung der meldepflichtigen uebertragbaren Krankheiten in Deutschland in verbindlicher Form eingefuehrt . Mit Hilfe der Falldefinitionen werden Krankheitsbezeichnungen mit einer definierten Beschreibung der Erkrankung in Verbindung gebracht . Die damit einhergehende Abstraktion fuehrt zur Schaffung " nosologischer Entitaeten " . Die gemaess IfSG vom Robert Koch-Institut erstellten Falldefinitionen versetzen die Gesundheitsaemter in die Lage , die ihnen gemeldeten Erkrankungs- oder Todesfaelle sowie die Nachweise von Krankheitserregern nach einheitlichen Kriterien zu bewerten und ueber die Landesgesundheitsbehoerden der Bundeslaender an das Robert Koch-Institut ( RKI ) zu uebermitteln . Durch die Einfuehrung der Falldefinitionen wird die Qualitaet der Meldedaten deutlich verbessert , da jede gemeldete Erkrankung/ Infektion definierte Kriterien erfuellt und somit unklare Erkrankungsfaelle oder Diagnosen nicht mit gesicherten vermischt werden .
[ "Mit", "Einfuehrung", "des", "Gesetzes", "zur", "Verhuetung", "und", "Bekaempfung", "von", "Infektionskrankheiten", "beim", "Menschen", "(", "Infektionsschutzgesetz", "IfSG", ")", "werden", "erstmals", "gemaess", "§", "4", "(", "2", ")", "Falldefinitionen", "zur", "routinemaessigen", "Uebermittlung", "der", "meldepflichtigen", "uebertragbaren", "Krankheiten", "in", "Deutschland", "in", "verbindlicher", "Form", "eingefuehrt", ".", "Mit", "Hilfe", "der", "Falldefinitionen", "werden", "Krankheitsbezeichnungen", "mit", "einer", "definierten", "Beschreibung", "der", "Erkrankung", "in", "Verbindung", "gebracht", ".", "Die", "damit", "einhergehende", "Abstraktion", "fuehrt", "zur", "Schaffung", "\"", "nosologischer", "Entitaeten", "\"", ".", "Die", "gemaess", "IfSG", "vom", "Robert", "Koch", "-", "Institut", "erstellten", "Falldefinitionen", "versetzen", "die", "Gesundheitsaemter", "in", "die", "Lage", ",", "die", "ihnen", "gemeldeten", "Erkrankungs-", "oder", "Todesfaelle", "sowie", "die", "Nachweise", "von", "Krankheitserregern", "nach", "einheitlichen", "Kriterien", "zu", "bewerten", "und", "ueber", "die", "Landesgesundheitsbehoerden", "der", "Bundeslaender", "an", "das", "Robert", "Koch", "-", "Institut", "(", "RKI", ")", "zu", "uebermitteln", ".", "Durch", "die", "Einfuehrung", "der", "Falldefinitionen", "wird", "die", "Qualitaet", "der", "Meldedaten", "deutlich", "verbessert", ",", "da", "jede", "gemeldete", "Erkrankung/", "Infektion", "definierte", "Kriterien", "erfuellt", "und", "somit", "unklare", "Erkrankungsfaelle", "oder", "Diagnosen", "nicht", "mit", "gesicherten", "vermischt", "werden", "." ]
[ "umlsterm" ]
Infektionskrankheiten is an umlsterm, Menschen is an umlsterm, Infektionsschutzgesetz is an umlsterm, uebertragbaren Krankheiten is an umlsterm, Deutschland is an umlsterm, Infektion is an umlsterm, Diagnosen is an umlsterm
Bundesgesundheitsblatt.00430839.ger.abstr_task1
Sentence: Mit Einfuehrung des Gesetzes zur Verhuetung und Bekaempfung von Infektionskrankheiten beim Menschen ( Infektionsschutzgesetz IfSG ) werden erstmals gemaess § 4 ( 2 ) Falldefinitionen zur routinemaessigen Uebermittlung der meldepflichtigen uebertragbaren Krankheiten in Deutschland in verbindlicher Form eingefuehrt . Mit Hilfe der Falldefinitionen werden Krankheitsbezeichnungen mit einer definierten Beschreibung der Erkrankung in Verbindung gebracht . Die damit einhergehende Abstraktion fuehrt zur Schaffung " nosologischer Entitaeten " . Die gemaess IfSG vom Robert Koch-Institut erstellten Falldefinitionen versetzen die Gesundheitsaemter in die Lage , die ihnen gemeldeten Erkrankungs- oder Todesfaelle sowie die Nachweise von Krankheitserregern nach einheitlichen Kriterien zu bewerten und ueber die Landesgesundheitsbehoerden der Bundeslaender an das Robert Koch-Institut ( RKI ) zu uebermitteln . Durch die Einfuehrung der Falldefinitionen wird die Qualitaet der Meldedaten deutlich verbessert , da jede gemeldete Erkrankung/ Infektion definierte Kriterien erfuellt und somit unklare Erkrankungsfaelle oder Diagnosen nicht mit gesicherten vermischt werden . Instructions: please typing these entity words according to sentence: Infektionskrankheiten, Menschen, Infektionsschutzgesetz, uebertragbaren Krankheiten, Deutschland, Infektion, Diagnosen Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Mit Einfuehrung des Gesetzes zur Verhuetung und Bekaempfung von Infektionskrankheiten beim Menschen ( Infektionsschutzgesetz IfSG ) werden erstmals gemaess § 4 ( 2 ) Falldefinitionen zur routinemaessigen Uebermittlung der meldepflichtigen uebertragbaren Krankheiten in Deutschland in verbindlicher Form eingefuehrt . Mit Hilfe der Falldefinitionen werden Krankheitsbezeichnungen mit einer definierten Beschreibung der Erkrankung in Verbindung gebracht . Die damit einhergehende Abstraktion fuehrt zur Schaffung " nosologischer Entitaeten " . Die gemaess IfSG vom Robert Koch-Institut erstellten Falldefinitionen versetzen die Gesundheitsaemter in die Lage , die ihnen gemeldeten Erkrankungs- oder Todesfaelle sowie die Nachweise von Krankheitserregern nach einheitlichen Kriterien zu bewerten und ueber die Landesgesundheitsbehoerden der Bundeslaender an das Robert Koch-Institut ( RKI ) zu uebermitteln . Durch die Einfuehrung der Falldefinitionen wird die Qualitaet der Meldedaten deutlich verbessert , da jede gemeldete Erkrankung/ Infektion definierte Kriterien erfuellt und somit unklare Erkrankungsfaelle oder Diagnosen nicht mit gesicherten vermischt werden .
[ "Mit", "Einfuehrung", "des", "Gesetzes", "zur", "Verhuetung", "und", "Bekaempfung", "von", "Infektionskrankheiten", "beim", "Menschen", "(", "Infektionsschutzgesetz", "IfSG", ")", "werden", "erstmals", "gemaess", "§", "4", "(", "2", ")", "Falldefinitionen", "zur", "routinemaessigen", "Uebermittlung", "der", "meldepflichtigen", "uebertragbaren", "Krankheiten", "in", "Deutschland", "in", "verbindlicher", "Form", "eingefuehrt", ".", "Mit", "Hilfe", "der", "Falldefinitionen", "werden", "Krankheitsbezeichnungen", "mit", "einer", "definierten", "Beschreibung", "der", "Erkrankung", "in", "Verbindung", "gebracht", ".", "Die", "damit", "einhergehende", "Abstraktion", "fuehrt", "zur", "Schaffung", "\"", "nosologischer", "Entitaeten", "\"", ".", "Die", "gemaess", "IfSG", "vom", "Robert", "Koch", "-", "Institut", "erstellten", "Falldefinitionen", "versetzen", "die", "Gesundheitsaemter", "in", "die", "Lage", ",", "die", "ihnen", "gemeldeten", "Erkrankungs-", "oder", "Todesfaelle", "sowie", "die", "Nachweise", "von", "Krankheitserregern", "nach", "einheitlichen", "Kriterien", "zu", "bewerten", "und", "ueber", "die", "Landesgesundheitsbehoerden", "der", "Bundeslaender", "an", "das", "Robert", "Koch", "-", "Institut", "(", "RKI", ")", "zu", "uebermitteln", ".", "Durch", "die", "Einfuehrung", "der", "Falldefinitionen", "wird", "die", "Qualitaet", "der", "Meldedaten", "deutlich", "verbessert", ",", "da", "jede", "gemeldete", "Erkrankung/", "Infektion", "definierte", "Kriterien", "erfuellt", "und", "somit", "unklare", "Erkrankungsfaelle", "oder", "Diagnosen", "nicht", "mit", "gesicherten", "vermischt", "werden", "." ]
[ "umlsterm" ]
Infektionskrankheiten, Menschen, Infektionsschutzgesetz, uebertragbaren Krankheiten, Deutschland, Infektion, Diagnosen
Bundesgesundheitsblatt.00430839.ger.abstr_task2
Sentence: Mit Einfuehrung des Gesetzes zur Verhuetung und Bekaempfung von Infektionskrankheiten beim Menschen ( Infektionsschutzgesetz IfSG ) werden erstmals gemaess § 4 ( 2 ) Falldefinitionen zur routinemaessigen Uebermittlung der meldepflichtigen uebertragbaren Krankheiten in Deutschland in verbindlicher Form eingefuehrt . Mit Hilfe der Falldefinitionen werden Krankheitsbezeichnungen mit einer definierten Beschreibung der Erkrankung in Verbindung gebracht . Die damit einhergehende Abstraktion fuehrt zur Schaffung " nosologischer Entitaeten " . Die gemaess IfSG vom Robert Koch-Institut erstellten Falldefinitionen versetzen die Gesundheitsaemter in die Lage , die ihnen gemeldeten Erkrankungs- oder Todesfaelle sowie die Nachweise von Krankheitserregern nach einheitlichen Kriterien zu bewerten und ueber die Landesgesundheitsbehoerden der Bundeslaender an das Robert Koch-Institut ( RKI ) zu uebermitteln . Durch die Einfuehrung der Falldefinitionen wird die Qualitaet der Meldedaten deutlich verbessert , da jede gemeldete Erkrankung/ Infektion definierte Kriterien erfuellt und somit unklare Erkrankungsfaelle oder Diagnosen nicht mit gesicherten vermischt werden . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Mit Einfuehrung des Gesetzes zur Verhuetung und Bekaempfung von Infektionskrankheiten beim Menschen ( Infektionsschutzgesetz IfSG ) werden erstmals gemaess § 4 ( 2 ) Falldefinitionen zur routinemaessigen Uebermittlung der meldepflichtigen uebertragbaren Krankheiten in Deutschland in verbindlicher Form eingefuehrt . Mit Hilfe der Falldefinitionen werden Krankheitsbezeichnungen mit einer definierten Beschreibung der Erkrankung in Verbindung gebracht . Die damit einhergehende Abstraktion fuehrt zur Schaffung " nosologischer Entitaeten " . Die gemaess IfSG vom Robert Koch-Institut erstellten Falldefinitionen versetzen die Gesundheitsaemter in die Lage , die ihnen gemeldeten Erkrankungs- oder Todesfaelle sowie die Nachweise von Krankheitserregern nach einheitlichen Kriterien zu bewerten und ueber die Landesgesundheitsbehoerden der Bundeslaender an das Robert Koch-Institut ( RKI ) zu uebermitteln . Durch die Einfuehrung der Falldefinitionen wird die Qualitaet der Meldedaten deutlich verbessert , da jede gemeldete Erkrankung/ Infektion definierte Kriterien erfuellt und somit unklare Erkrankungsfaelle oder Diagnosen nicht mit gesicherten vermischt werden .
[ "Mit", "Einfuehrung", "des", "Gesetzes", "zur", "Verhuetung", "und", "Bekaempfung", "von", "Infektionskrankheiten", "beim", "Menschen", "(", "Infektionsschutzgesetz", "IfSG", ")", "werden", "erstmals", "gemaess", "§", "4", "(", "2", ")", "Falldefinitionen", "zur", "routinemaessigen", "Uebermittlung", "der", "meldepflichtigen", "uebertragbaren", "Krankheiten", "in", "Deutschland", "in", "verbindlicher", "Form", "eingefuehrt", ".", "Mit", "Hilfe", "der", "Falldefinitionen", "werden", "Krankheitsbezeichnungen", "mit", "einer", "definierten", "Beschreibung", "der", "Erkrankung", "in", "Verbindung", "gebracht", ".", "Die", "damit", "einhergehende", "Abstraktion", "fuehrt", "zur", "Schaffung", "\"", "nosologischer", "Entitaeten", "\"", ".", "Die", "gemaess", "IfSG", "vom", "Robert", "Koch", "-", "Institut", "erstellten", "Falldefinitionen", "versetzen", "die", "Gesundheitsaemter", "in", "die", "Lage", ",", "die", "ihnen", "gemeldeten", "Erkrankungs-", "oder", "Todesfaelle", "sowie", "die", "Nachweise", "von", "Krankheitserregern", "nach", "einheitlichen", "Kriterien", "zu", "bewerten", "und", "ueber", "die", "Landesgesundheitsbehoerden", "der", "Bundeslaender", "an", "das", "Robert", "Koch", "-", "Institut", "(", "RKI", ")", "zu", "uebermitteln", ".", "Durch", "die", "Einfuehrung", "der", "Falldefinitionen", "wird", "die", "Qualitaet", "der", "Meldedaten", "deutlich", "verbessert", ",", "da", "jede", "gemeldete", "Erkrankung/", "Infektion", "definierte", "Kriterien", "erfuellt", "und", "somit", "unklare", "Erkrankungsfaelle", "oder", "Diagnosen", "nicht", "mit", "gesicherten", "vermischt", "werden", "." ]
[ "umlsterm" ]
Kehlkopfmaske is an umlsterm, methodenimmanente is an umlsterm, Risiken is an umlsterm, Technik is an umlsterm, Halsbeschwerden is an umlsterm, Patientenkomforts is an umlsterm, Kehlkopfmaske is an umlsterm, Intubation is an umlsterm, Kehlkopfmaske is an umlsterm, Kehlkopfmaske is an umlsterm, Heiserkeit is an umlsterm, Intubation is an umlsterm
DerAnaesthesist.90480904.ger.abstr_task0
Sentence: Funktionelle und strukturelle Stoerungen bei Anwendung der Kehlkopfmaske sind methodenimmanente Risiken . Sie koennen nicht eliminiert , durch Erfahrung , umsichtige Technik und Vorbereitung jedoch reduziert werden . Geringfuegige Halsbeschwerden ( " minor laryngeal morbidity " ) - eine nicht unwesentliche Determinante des Patientenkomforts - treten nach Einsatz der Kehlkopfmaske annaehernd so haeufig auf wie nach endotrachealer Intubation . Es gibt Hinweise dafuer , dass das Beschwerdebild sich nach Kehlkopfmaske und Endotrachealtubus unterscheidet : nach Kehlkopfmaske stehen Schluckbeschwerden im Vordergrund , waehrend sich Heiserkeit signifikant haeufiger nach endotrachealer Intubation findet . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Funktionelle und strukturelle Stoerungen bei Anwendung der Kehlkopfmaske sind methodenimmanente Risiken . Sie koennen nicht eliminiert , durch Erfahrung , umsichtige Technik und Vorbereitung jedoch reduziert werden . Geringfuegige Halsbeschwerden ( " minor laryngeal morbidity " ) - eine nicht unwesentliche Determinante des Patientenkomforts - treten nach Einsatz der Kehlkopfmaske annaehernd so haeufig auf wie nach endotrachealer Intubation . Es gibt Hinweise dafuer , dass das Beschwerdebild sich nach Kehlkopfmaske und Endotrachealtubus unterscheidet : nach Kehlkopfmaske stehen Schluckbeschwerden im Vordergrund , waehrend sich Heiserkeit signifikant haeufiger nach endotrachealer Intubation findet .
[ "Funktionelle", "und", "strukturelle", "Stoerungen", "bei", "Anwendung", "der", "Kehlkopfmaske", "sind", "methodenimmanente", "Risiken", ".", "Sie", "koennen", "nicht", "eliminiert", ",", "durch", "Erfahrung", ",", "umsichtige", "Technik", "und", "Vorbereitung", "jedoch", "reduziert", "werden", ".", "Geringfuegige", "Halsbeschwerden", "(", "\"", "minor", "laryngeal", "morbidity", "\"", ")", "-", "eine", "nicht", "unwesentliche", "Determinante", "des", "Patientenkomforts", "-", "treten", "nach", "Einsatz", "der", "Kehlkopfmaske", "annaehernd", "so", "haeufig", "auf", "wie", "nach", "endotrachealer", "Intubation", ".", "Es", "gibt", "Hinweise", "dafuer", ",", "dass", "das", "Beschwerdebild", "sich", "nach", "Kehlkopfmaske", "und", "Endotrachealtubus", "unterscheidet", ":", "nach", "Kehlkopfmaske", "stehen", "Schluckbeschwerden", "im", "Vordergrund", ",", "waehrend", "sich", "Heiserkeit", "signifikant", "haeufiger", "nach", "endotrachealer", "Intubation", "findet", "." ]
[ "umlsterm" ]
Kehlkopfmaske is an umlsterm, methodenimmanente is an umlsterm, Risiken is an umlsterm, Technik is an umlsterm, Halsbeschwerden is an umlsterm, Patientenkomforts is an umlsterm, Kehlkopfmaske is an umlsterm, Intubation is an umlsterm, Kehlkopfmaske is an umlsterm, Kehlkopfmaske is an umlsterm, Heiserkeit is an umlsterm, Intubation is an umlsterm
DerAnaesthesist.90480904.ger.abstr_task1
Sentence: Funktionelle und strukturelle Stoerungen bei Anwendung der Kehlkopfmaske sind methodenimmanente Risiken . Sie koennen nicht eliminiert , durch Erfahrung , umsichtige Technik und Vorbereitung jedoch reduziert werden . Geringfuegige Halsbeschwerden ( " minor laryngeal morbidity " ) - eine nicht unwesentliche Determinante des Patientenkomforts - treten nach Einsatz der Kehlkopfmaske annaehernd so haeufig auf wie nach endotrachealer Intubation . Es gibt Hinweise dafuer , dass das Beschwerdebild sich nach Kehlkopfmaske und Endotrachealtubus unterscheidet : nach Kehlkopfmaske stehen Schluckbeschwerden im Vordergrund , waehrend sich Heiserkeit signifikant haeufiger nach endotrachealer Intubation findet . Instructions: please typing these entity words according to sentence: Kehlkopfmaske, methodenimmanente, Risiken, Technik, Halsbeschwerden, Patientenkomforts, Kehlkopfmaske, Intubation, Kehlkopfmaske, Kehlkopfmaske, Heiserkeit, Intubation Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Funktionelle und strukturelle Stoerungen bei Anwendung der Kehlkopfmaske sind methodenimmanente Risiken . Sie koennen nicht eliminiert , durch Erfahrung , umsichtige Technik und Vorbereitung jedoch reduziert werden . Geringfuegige Halsbeschwerden ( " minor laryngeal morbidity " ) - eine nicht unwesentliche Determinante des Patientenkomforts - treten nach Einsatz der Kehlkopfmaske annaehernd so haeufig auf wie nach endotrachealer Intubation . Es gibt Hinweise dafuer , dass das Beschwerdebild sich nach Kehlkopfmaske und Endotrachealtubus unterscheidet : nach Kehlkopfmaske stehen Schluckbeschwerden im Vordergrund , waehrend sich Heiserkeit signifikant haeufiger nach endotrachealer Intubation findet .
[ "Funktionelle", "und", "strukturelle", "Stoerungen", "bei", "Anwendung", "der", "Kehlkopfmaske", "sind", "methodenimmanente", "Risiken", ".", "Sie", "koennen", "nicht", "eliminiert", ",", "durch", "Erfahrung", ",", "umsichtige", "Technik", "und", "Vorbereitung", "jedoch", "reduziert", "werden", ".", "Geringfuegige", "Halsbeschwerden", "(", "\"", "minor", "laryngeal", "morbidity", "\"", ")", "-", "eine", "nicht", "unwesentliche", "Determinante", "des", "Patientenkomforts", "-", "treten", "nach", "Einsatz", "der", "Kehlkopfmaske", "annaehernd", "so", "haeufig", "auf", "wie", "nach", "endotrachealer", "Intubation", ".", "Es", "gibt", "Hinweise", "dafuer", ",", "dass", "das", "Beschwerdebild", "sich", "nach", "Kehlkopfmaske", "und", "Endotrachealtubus", "unterscheidet", ":", "nach", "Kehlkopfmaske", "stehen", "Schluckbeschwerden", "im", "Vordergrund", ",", "waehrend", "sich", "Heiserkeit", "signifikant", "haeufiger", "nach", "endotrachealer", "Intubation", "findet", "." ]
[ "umlsterm" ]
Kehlkopfmaske, methodenimmanente, Risiken, Technik, Halsbeschwerden, Patientenkomforts, Kehlkopfmaske, Intubation, Kehlkopfmaske, Kehlkopfmaske, Heiserkeit, Intubation
DerAnaesthesist.90480904.ger.abstr_task2
Sentence: Funktionelle und strukturelle Stoerungen bei Anwendung der Kehlkopfmaske sind methodenimmanente Risiken . Sie koennen nicht eliminiert , durch Erfahrung , umsichtige Technik und Vorbereitung jedoch reduziert werden . Geringfuegige Halsbeschwerden ( " minor laryngeal morbidity " ) - eine nicht unwesentliche Determinante des Patientenkomforts - treten nach Einsatz der Kehlkopfmaske annaehernd so haeufig auf wie nach endotrachealer Intubation . Es gibt Hinweise dafuer , dass das Beschwerdebild sich nach Kehlkopfmaske und Endotrachealtubus unterscheidet : nach Kehlkopfmaske stehen Schluckbeschwerden im Vordergrund , waehrend sich Heiserkeit signifikant haeufiger nach endotrachealer Intubation findet . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Funktionelle und strukturelle Stoerungen bei Anwendung der Kehlkopfmaske sind methodenimmanente Risiken . Sie koennen nicht eliminiert , durch Erfahrung , umsichtige Technik und Vorbereitung jedoch reduziert werden . Geringfuegige Halsbeschwerden ( " minor laryngeal morbidity " ) - eine nicht unwesentliche Determinante des Patientenkomforts - treten nach Einsatz der Kehlkopfmaske annaehernd so haeufig auf wie nach endotrachealer Intubation . Es gibt Hinweise dafuer , dass das Beschwerdebild sich nach Kehlkopfmaske und Endotrachealtubus unterscheidet : nach Kehlkopfmaske stehen Schluckbeschwerden im Vordergrund , waehrend sich Heiserkeit signifikant haeufiger nach endotrachealer Intubation findet .
[ "Funktionelle", "und", "strukturelle", "Stoerungen", "bei", "Anwendung", "der", "Kehlkopfmaske", "sind", "methodenimmanente", "Risiken", ".", "Sie", "koennen", "nicht", "eliminiert", ",", "durch", "Erfahrung", ",", "umsichtige", "Technik", "und", "Vorbereitung", "jedoch", "reduziert", "werden", ".", "Geringfuegige", "Halsbeschwerden", "(", "\"", "minor", "laryngeal", "morbidity", "\"", ")", "-", "eine", "nicht", "unwesentliche", "Determinante", "des", "Patientenkomforts", "-", "treten", "nach", "Einsatz", "der", "Kehlkopfmaske", "annaehernd", "so", "haeufig", "auf", "wie", "nach", "endotrachealer", "Intubation", ".", "Es", "gibt", "Hinweise", "dafuer", ",", "dass", "das", "Beschwerdebild", "sich", "nach", "Kehlkopfmaske", "und", "Endotrachealtubus", "unterscheidet", ":", "nach", "Kehlkopfmaske", "stehen", "Schluckbeschwerden", "im", "Vordergrund", ",", "waehrend", "sich", "Heiserkeit", "signifikant", "haeufiger", "nach", "endotrachealer", "Intubation", "findet", "." ]
[ "umlsterm" ]
Iodine is a DRUG, iodine is a DRUG, Carbimazole is a DRUG, iodine is a DRUG, Carbimazole is a DRUG, digoxin is a DRUG, digitoxin is a DRUG, antithyroid agents is a GROUP, Antithyroid agents is a GROUP, sodium iodide I131 is a DRUG, Carbimazole is a DRUG, anticoagulants is a GROUP, anticoagulant is a GROUP
Carbimazole_ddi_task0
Sentence: Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole. Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents. A decrease of the dosage may be necessary when patient becomes euthyroid. Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole. Patients response to oral anticoagulants may be affected by his/her thyroid and metabolic status. An evaluation of prothrombin time and an adjustment of anticoagulant dosage are recommended Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG
[ "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O" ]
Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole. Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents. A decrease of the dosage may be necessary when patient becomes euthyroid. Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole. Patients response to oral anticoagulants may be affected by his/her thyroid and metabolic status. An evaluation of prothrombin time and an adjustment of anticoagulant dosage are recommended
[ "Iodine", "or", "iodine", "excess", "may", "decrease", "the", "effect", "of", "Carbimazole", ",", "and", "an", "iodine", "deficiency", "can", "increase", "the", "effect", "of", "Carbimazole", ".", "Serum", "concentration", "of", "digoxin", "and", "digitoxin", "may", "increase", "when", "patients", "take", "antithyroid", "agents", ".", "A", "decrease", "of", "the", "dosage", "may", "be", "necessary", "when", "patient", "becomes", "euthyroid", ".", "Antithyroid", "agents", "may", "decrease", "thyroidal", "uptake", "of", "sodium", "iodide", "I131", ",", "a", "rebound", "in", "uptake", "may", "occur", "up", "to", "5", "days", "after", "sudden", "withdrawal", "of", "Carbimazole", ".", "Patients", "response", "to", "oral", "anticoagulants", "may", "be", "affected", "by", "his", "/", "her", "thyroid", "and", "metabolic", "status", ".", "An", "evaluation", "of", "prothrombin", "time", "and", "an", "adjustment", "of", "anticoagulant", "dosage", "are", "recommended" ]
[ "GROUP", "DRUG" ]
Iodine is a DRUG, iodine is a DRUG, Carbimazole is a DRUG, iodine is a DRUG, Carbimazole is a DRUG, digoxin is a DRUG, digitoxin is a DRUG, antithyroid agents is a GROUP, Antithyroid agents is a GROUP, sodium iodide I131 is a DRUG, Carbimazole is a DRUG, anticoagulants is a GROUP, anticoagulant is a GROUP
Carbimazole_ddi_task1
Sentence: Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole. Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents. A decrease of the dosage may be necessary when patient becomes euthyroid. Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole. Patients response to oral anticoagulants may be affected by his/her thyroid and metabolic status. An evaluation of prothrombin time and an adjustment of anticoagulant dosage are recommended Instructions: please typing these entity words according to sentence: Iodine, iodine, Carbimazole, iodine, Carbimazole, digoxin, digitoxin, antithyroid agents, Antithyroid agents, sodium iodide I131, Carbimazole, anticoagulants, anticoagulant Options: GROUP, DRUG
[ "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O" ]
Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole. Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents. A decrease of the dosage may be necessary when patient becomes euthyroid. Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole. Patients response to oral anticoagulants may be affected by his/her thyroid and metabolic status. An evaluation of prothrombin time and an adjustment of anticoagulant dosage are recommended
[ "Iodine", "or", "iodine", "excess", "may", "decrease", "the", "effect", "of", "Carbimazole", ",", "and", "an", "iodine", "deficiency", "can", "increase", "the", "effect", "of", "Carbimazole", ".", "Serum", "concentration", "of", "digoxin", "and", "digitoxin", "may", "increase", "when", "patients", "take", "antithyroid", "agents", ".", "A", "decrease", "of", "the", "dosage", "may", "be", "necessary", "when", "patient", "becomes", "euthyroid", ".", "Antithyroid", "agents", "may", "decrease", "thyroidal", "uptake", "of", "sodium", "iodide", "I131", ",", "a", "rebound", "in", "uptake", "may", "occur", "up", "to", "5", "days", "after", "sudden", "withdrawal", "of", "Carbimazole", ".", "Patients", "response", "to", "oral", "anticoagulants", "may", "be", "affected", "by", "his", "/", "her", "thyroid", "and", "metabolic", "status", ".", "An", "evaluation", "of", "prothrombin", "time", "and", "an", "adjustment", "of", "anticoagulant", "dosage", "are", "recommended" ]
[ "GROUP", "DRUG" ]
Iodine, iodine, Carbimazole, iodine, Carbimazole, digoxin, digitoxin, antithyroid agents, Antithyroid agents, sodium iodide I131, Carbimazole, anticoagulants, anticoagulant
Carbimazole_ddi_task2
Sentence: Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole. Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents. A decrease of the dosage may be necessary when patient becomes euthyroid. Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole. Patients response to oral anticoagulants may be affected by his/her thyroid and metabolic status. An evaluation of prothrombin time and an adjustment of anticoagulant dosage are recommended Instructions: please extract entity words from the input sentence
[ "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O" ]
Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole. Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents. A decrease of the dosage may be necessary when patient becomes euthyroid. Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole. Patients response to oral anticoagulants may be affected by his/her thyroid and metabolic status. An evaluation of prothrombin time and an adjustment of anticoagulant dosage are recommended
[ "Iodine", "or", "iodine", "excess", "may", "decrease", "the", "effect", "of", "Carbimazole", ",", "and", "an", "iodine", "deficiency", "can", "increase", "the", "effect", "of", "Carbimazole", ".", "Serum", "concentration", "of", "digoxin", "and", "digitoxin", "may", "increase", "when", "patients", "take", "antithyroid", "agents", ".", "A", "decrease", "of", "the", "dosage", "may", "be", "necessary", "when", "patient", "becomes", "euthyroid", ".", "Antithyroid", "agents", "may", "decrease", "thyroidal", "uptake", "of", "sodium", "iodide", "I131", ",", "a", "rebound", "in", "uptake", "may", "occur", "up", "to", "5", "days", "after", "sudden", "withdrawal", "of", "Carbimazole", ".", "Patients", "response", "to", "oral", "anticoagulants", "may", "be", "affected", "by", "his", "/", "her", "thyroid", "and", "metabolic", "status", ".", "An", "evaluation", "of", "prothrombin", "time", "and", "an", "adjustment", "of", "anticoagulant", "dosage", "are", "recommended" ]
[ "GROUP", "DRUG" ]
BNP is a protein, oxygen is a compound
DS.d470_task0
Sentence: Diastolic function and BNP changes during exercise predict oxygen consumption in chronic heart failure patients. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein
[ "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O" ]
Diastolic function and BNP changes during exercise predict oxygen consumption in chronic heart failure patients.
[ "Diastolic", "function", "and", "BNP", "changes", "during", "exercise", "predict", "oxygen", "consumption", "in", "chronic", "heart", "failure", "patients", "." ]
[ "compound", "protein" ]
BNP is a protein, oxygen is a compound
DS.d470_task1
Sentence: Diastolic function and BNP changes during exercise predict oxygen consumption in chronic heart failure patients. Instructions: please typing these entity words according to sentence: BNP, oxygen Options: compound, protein
[ "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O" ]
Diastolic function and BNP changes during exercise predict oxygen consumption in chronic heart failure patients.
[ "Diastolic", "function", "and", "BNP", "changes", "during", "exercise", "predict", "oxygen", "consumption", "in", "chronic", "heart", "failure", "patients", "." ]
[ "compound", "protein" ]
BNP, oxygen
DS.d470_task2
Sentence: Diastolic function and BNP changes during exercise predict oxygen consumption in chronic heart failure patients. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O" ]
Diastolic function and BNP changes during exercise predict oxygen consumption in chronic heart failure patients.
[ "Diastolic", "function", "and", "BNP", "changes", "during", "exercise", "predict", "oxygen", "consumption", "in", "chronic", "heart", "failure", "patients", "." ]
[ "compound", "protein" ]
NO is a CHEMICAL, cytokines is a GENE-N, allicin is a CHEMICAL, cytokine is a GENE-N, TNF - α is a GENE-Y, IL-1β is a GENE-Y, IL-6 is a GENE-Y, NO is a CHEMICAL, HO-1 is a GENE-Y, allicin is a CHEMICAL, Allicin is a CHEMICAL, cytokines is a GENE-N, NO is a CHEMICAL, HO-1 is a GENE-Y, NO is a CHEMICAL, cytokines is a GENE-N, HO-1 is a GENE-Y, allicin is a CHEMICAL, allicin is a CHEMICAL
5017_task0
Sentence: Short-term heating reduces the anti-inflammatory effects of fresh raw garlic extracts on the LPS-induced production of NO and pro-inflammatory cytokines by downregulating allicin activity in RAW 264.7 macrophages. Garlic has a variety of biologic activities, including anti-inflammatory properties. Although garlic has several biologic activities, some people dislike eating fresh raw garlic because of its strong taste and smell. Therefore, garlic formulations involving heating procedures have been developed. In this study, we investigated whether short-term heating affects the anti-inflammatory properties of garlic. Fresh and heated raw garlic extracts (FRGE and HRGE) were prepared with incubation at 25°C and 95°C, respectively, for 2h. Treatment with FRGE and HRGE significantly reduced the LPS-induced increase in the pro-inflammatory cytokine concentration (TNF-α, IL-1β, and IL-6) and NO through HO-1 upregulation in RAW 264.7 macrophages. The anti-inflammatory effect was greater in FRGE than in HRGE. The allicin concentration was higher in FRGE than in HRGE. Allicin treatment showed reduced production of pro-inflammatory cytokines and NO and increased HO-1 activity. The results show that the decrease in LPS-induced NO and pro-inflammatory cytokines in RAW 264.7 macrophages through HO-1 induction was greater for FRGE compared with HRGE. Additionally, the results indicate that allicin is responsible for the anti-inflammatory effect of FRGE. Our results suggest a potential therapeutic use of allicin in the treatment of chronic inflammatory disease. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]
Short-term heating reduces the anti-inflammatory effects of fresh raw garlic extracts on the LPS-induced production of NO and pro-inflammatory cytokines by downregulating allicin activity in RAW 264.7 macrophages. Garlic has a variety of biologic activities, including anti-inflammatory properties. Although garlic has several biologic activities, some people dislike eating fresh raw garlic because of its strong taste and smell. Therefore, garlic formulations involving heating procedures have been developed. In this study, we investigated whether short-term heating affects the anti-inflammatory properties of garlic. Fresh and heated raw garlic extracts (FRGE and HRGE) were prepared with incubation at 25°C and 95°C, respectively, for 2h. Treatment with FRGE and HRGE significantly reduced the LPS-induced increase in the pro-inflammatory cytokine concentration (TNF-α, IL-1β, and IL-6) and NO through HO-1 upregulation in RAW 264.7 macrophages. The anti-inflammatory effect was greater in FRGE than in HRGE. The allicin concentration was higher in FRGE than in HRGE. Allicin treatment showed reduced production of pro-inflammatory cytokines and NO and increased HO-1 activity. The results show that the decrease in LPS-induced NO and pro-inflammatory cytokines in RAW 264.7 macrophages through HO-1 induction was greater for FRGE compared with HRGE. Additionally, the results indicate that allicin is responsible for the anti-inflammatory effect of FRGE. Our results suggest a potential therapeutic use of allicin in the treatment of chronic inflammatory disease.
[ "Short", "-", "term", "heating", "reduces", "the", "anti", "-", "inflammatory", "effects", "of", "fresh", "raw", "garlic", "extracts", "on", "the", "LPS", "-", "induced", "production", "of", "NO", "and", "pro", "-", "inflammatory", "cytokines", "by", "downregulating", "allicin", "activity", "in", "RAW", "264.7", "macrophages", ".", "\n", "Garlic", "has", "a", "variety", "of", "biologic", "activities", ",", "including", "anti", "-", "inflammatory", "properties", ".", "Although", "garlic", "has", "several", "biologic", "activities", ",", "some", "people", "dislike", "eating", "fresh", "raw", "garlic", "because", "of", "its", "strong", "taste", "and", "smell", ".", "Therefore", ",", "garlic", "formulations", "involving", "heating", "procedures", "have", "been", "developed", ".", "In", "this", "study", ",", "we", "investigated", "whether", "short", "-", "term", "heating", "affects", "the", "anti", "-", "inflammatory", "properties", "of", "garlic", ".", "Fresh", "and", "heated", "raw", "garlic", "extracts", "(", "FRGE", "and", "HRGE", ")", "were", "prepared", "with", "incubation", "at", "25", "°", "C", "and", "95", "°", "C", ",", "respectively", ",", "for", "2h", ".", "Treatment", "with", "FRGE", "and", "HRGE", "significantly", "reduced", "the", "LPS", "-", "induced", "increase", "in", "the", "pro", "-", "inflammatory", "cytokine", "concentration", "(", "TNF", "-", "α", ",", "IL-1β", ",", "and", "IL-6", ")", "and", "NO", "through", "HO-1", "upregulation", "in", "RAW", "264.7", "macrophages", ".", "The", "anti", "-", "inflammatory", "effect", "was", "greater", "in", "FRGE", "than", "in", "HRGE", ".", "The", "allicin", "concentration", "was", "higher", "in", "FRGE", "than", "in", "HRGE", ".", "Allicin", "treatment", "showed", "reduced", "production", "of", "pro", "-", "inflammatory", "cytokines", "and", "NO", "and", "increased", "HO-1", "activity", ".", "The", "results", "show", "that", "the", "decrease", "in", "LPS", "-", "induced", "NO", "and", "pro", "-", "inflammatory", "cytokines", "in", "RAW", "264.7", "macrophages", "through", "HO-1", "induction", "was", "greater", "for", "FRGE", "compared", "with", "HRGE", ".", "Additionally", ",", "the", "results", "indicate", "that", "allicin", "is", "responsible", "for", "the", "anti", "-", "inflammatory", "effect", "of", "FRGE", ".", "Our", "results", "suggest", "a", "potential", "therapeutic", "use", "of", "allicin", "in", "the", "treatment", "of", "chronic", "inflammatory", "disease", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
NO is a CHEMICAL, cytokines is a GENE-N, allicin is a CHEMICAL, cytokine is a GENE-N, TNF - α is a GENE-Y, IL-1β is a GENE-Y, IL-6 is a GENE-Y, NO is a CHEMICAL, HO-1 is a GENE-Y, allicin is a CHEMICAL, Allicin is a CHEMICAL, cytokines is a GENE-N, NO is a CHEMICAL, HO-1 is a GENE-Y, NO is a CHEMICAL, cytokines is a GENE-N, HO-1 is a GENE-Y, allicin is a CHEMICAL, allicin is a CHEMICAL
5017_task1
Sentence: Short-term heating reduces the anti-inflammatory effects of fresh raw garlic extracts on the LPS-induced production of NO and pro-inflammatory cytokines by downregulating allicin activity in RAW 264.7 macrophages. Garlic has a variety of biologic activities, including anti-inflammatory properties. Although garlic has several biologic activities, some people dislike eating fresh raw garlic because of its strong taste and smell. Therefore, garlic formulations involving heating procedures have been developed. In this study, we investigated whether short-term heating affects the anti-inflammatory properties of garlic. Fresh and heated raw garlic extracts (FRGE and HRGE) were prepared with incubation at 25°C and 95°C, respectively, for 2h. Treatment with FRGE and HRGE significantly reduced the LPS-induced increase in the pro-inflammatory cytokine concentration (TNF-α, IL-1β, and IL-6) and NO through HO-1 upregulation in RAW 264.7 macrophages. The anti-inflammatory effect was greater in FRGE than in HRGE. The allicin concentration was higher in FRGE than in HRGE. Allicin treatment showed reduced production of pro-inflammatory cytokines and NO and increased HO-1 activity. The results show that the decrease in LPS-induced NO and pro-inflammatory cytokines in RAW 264.7 macrophages through HO-1 induction was greater for FRGE compared with HRGE. Additionally, the results indicate that allicin is responsible for the anti-inflammatory effect of FRGE. Our results suggest a potential therapeutic use of allicin in the treatment of chronic inflammatory disease. Instructions: please typing these entity words according to sentence: NO, cytokines, allicin, cytokine, TNF - α, IL-1β, IL-6, NO, HO-1, allicin, Allicin, cytokines, NO, HO-1, NO, cytokines, HO-1, allicin, allicin Options: GENE-Y, GENE-N, CHEMICAL
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]
Short-term heating reduces the anti-inflammatory effects of fresh raw garlic extracts on the LPS-induced production of NO and pro-inflammatory cytokines by downregulating allicin activity in RAW 264.7 macrophages. Garlic has a variety of biologic activities, including anti-inflammatory properties. Although garlic has several biologic activities, some people dislike eating fresh raw garlic because of its strong taste and smell. Therefore, garlic formulations involving heating procedures have been developed. In this study, we investigated whether short-term heating affects the anti-inflammatory properties of garlic. Fresh and heated raw garlic extracts (FRGE and HRGE) were prepared with incubation at 25°C and 95°C, respectively, for 2h. Treatment with FRGE and HRGE significantly reduced the LPS-induced increase in the pro-inflammatory cytokine concentration (TNF-α, IL-1β, and IL-6) and NO through HO-1 upregulation in RAW 264.7 macrophages. The anti-inflammatory effect was greater in FRGE than in HRGE. The allicin concentration was higher in FRGE than in HRGE. Allicin treatment showed reduced production of pro-inflammatory cytokines and NO and increased HO-1 activity. The results show that the decrease in LPS-induced NO and pro-inflammatory cytokines in RAW 264.7 macrophages through HO-1 induction was greater for FRGE compared with HRGE. Additionally, the results indicate that allicin is responsible for the anti-inflammatory effect of FRGE. Our results suggest a potential therapeutic use of allicin in the treatment of chronic inflammatory disease.
[ "Short", "-", "term", "heating", "reduces", "the", "anti", "-", "inflammatory", "effects", "of", "fresh", "raw", "garlic", "extracts", "on", "the", "LPS", "-", "induced", "production", "of", "NO", "and", "pro", "-", "inflammatory", "cytokines", "by", "downregulating", "allicin", "activity", "in", "RAW", "264.7", "macrophages", ".", "\n", "Garlic", "has", "a", "variety", "of", "biologic", "activities", ",", "including", "anti", "-", "inflammatory", "properties", ".", "Although", "garlic", "has", "several", "biologic", "activities", ",", "some", "people", "dislike", "eating", "fresh", "raw", "garlic", "because", "of", "its", "strong", "taste", "and", "smell", ".", "Therefore", ",", "garlic", "formulations", "involving", "heating", "procedures", "have", "been", "developed", ".", "In", "this", "study", ",", "we", "investigated", "whether", "short", "-", "term", "heating", "affects", "the", "anti", "-", "inflammatory", "properties", "of", "garlic", ".", "Fresh", "and", "heated", "raw", "garlic", "extracts", "(", "FRGE", "and", "HRGE", ")", "were", "prepared", "with", "incubation", "at", "25", "°", "C", "and", "95", "°", "C", ",", "respectively", ",", "for", "2h", ".", "Treatment", "with", "FRGE", "and", "HRGE", "significantly", "reduced", "the", "LPS", "-", "induced", "increase", "in", "the", "pro", "-", "inflammatory", "cytokine", "concentration", "(", "TNF", "-", "α", ",", "IL-1β", ",", "and", "IL-6", ")", "and", "NO", "through", "HO-1", "upregulation", "in", "RAW", "264.7", "macrophages", ".", "The", "anti", "-", "inflammatory", "effect", "was", "greater", "in", "FRGE", "than", "in", "HRGE", ".", "The", "allicin", "concentration", "was", "higher", "in", "FRGE", "than", "in", "HRGE", ".", "Allicin", "treatment", "showed", "reduced", "production", "of", "pro", "-", "inflammatory", "cytokines", "and", "NO", "and", "increased", "HO-1", "activity", ".", "The", "results", "show", "that", "the", "decrease", "in", "LPS", "-", "induced", "NO", "and", "pro", "-", "inflammatory", "cytokines", "in", "RAW", "264.7", "macrophages", "through", "HO-1", "induction", "was", "greater", "for", "FRGE", "compared", "with", "HRGE", ".", "Additionally", ",", "the", "results", "indicate", "that", "allicin", "is", "responsible", "for", "the", "anti", "-", "inflammatory", "effect", "of", "FRGE", ".", "Our", "results", "suggest", "a", "potential", "therapeutic", "use", "of", "allicin", "in", "the", "treatment", "of", "chronic", "inflammatory", "disease", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
NO, cytokines, allicin, cytokine, TNF - α, IL-1β, IL-6, NO, HO-1, allicin, Allicin, cytokines, NO, HO-1, NO, cytokines, HO-1, allicin, allicin
5017_task2
Sentence: Short-term heating reduces the anti-inflammatory effects of fresh raw garlic extracts on the LPS-induced production of NO and pro-inflammatory cytokines by downregulating allicin activity in RAW 264.7 macrophages. Garlic has a variety of biologic activities, including anti-inflammatory properties. Although garlic has several biologic activities, some people dislike eating fresh raw garlic because of its strong taste and smell. Therefore, garlic formulations involving heating procedures have been developed. In this study, we investigated whether short-term heating affects the anti-inflammatory properties of garlic. Fresh and heated raw garlic extracts (FRGE and HRGE) were prepared with incubation at 25°C and 95°C, respectively, for 2h. Treatment with FRGE and HRGE significantly reduced the LPS-induced increase in the pro-inflammatory cytokine concentration (TNF-α, IL-1β, and IL-6) and NO through HO-1 upregulation in RAW 264.7 macrophages. The anti-inflammatory effect was greater in FRGE than in HRGE. The allicin concentration was higher in FRGE than in HRGE. Allicin treatment showed reduced production of pro-inflammatory cytokines and NO and increased HO-1 activity. The results show that the decrease in LPS-induced NO and pro-inflammatory cytokines in RAW 264.7 macrophages through HO-1 induction was greater for FRGE compared with HRGE. Additionally, the results indicate that allicin is responsible for the anti-inflammatory effect of FRGE. Our results suggest a potential therapeutic use of allicin in the treatment of chronic inflammatory disease. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]
Short-term heating reduces the anti-inflammatory effects of fresh raw garlic extracts on the LPS-induced production of NO and pro-inflammatory cytokines by downregulating allicin activity in RAW 264.7 macrophages. Garlic has a variety of biologic activities, including anti-inflammatory properties. Although garlic has several biologic activities, some people dislike eating fresh raw garlic because of its strong taste and smell. Therefore, garlic formulations involving heating procedures have been developed. In this study, we investigated whether short-term heating affects the anti-inflammatory properties of garlic. Fresh and heated raw garlic extracts (FRGE and HRGE) were prepared with incubation at 25°C and 95°C, respectively, for 2h. Treatment with FRGE and HRGE significantly reduced the LPS-induced increase in the pro-inflammatory cytokine concentration (TNF-α, IL-1β, and IL-6) and NO through HO-1 upregulation in RAW 264.7 macrophages. The anti-inflammatory effect was greater in FRGE than in HRGE. The allicin concentration was higher in FRGE than in HRGE. Allicin treatment showed reduced production of pro-inflammatory cytokines and NO and increased HO-1 activity. The results show that the decrease in LPS-induced NO and pro-inflammatory cytokines in RAW 264.7 macrophages through HO-1 induction was greater for FRGE compared with HRGE. Additionally, the results indicate that allicin is responsible for the anti-inflammatory effect of FRGE. Our results suggest a potential therapeutic use of allicin in the treatment of chronic inflammatory disease.
[ "Short", "-", "term", "heating", "reduces", "the", "anti", "-", "inflammatory", "effects", "of", "fresh", "raw", "garlic", "extracts", "on", "the", "LPS", "-", "induced", "production", "of", "NO", "and", "pro", "-", "inflammatory", "cytokines", "by", "downregulating", "allicin", "activity", "in", "RAW", "264.7", "macrophages", ".", "\n", "Garlic", "has", "a", "variety", "of", "biologic", "activities", ",", "including", "anti", "-", "inflammatory", "properties", ".", "Although", "garlic", "has", "several", "biologic", "activities", ",", "some", "people", "dislike", "eating", "fresh", "raw", "garlic", "because", "of", "its", "strong", "taste", "and", "smell", ".", "Therefore", ",", "garlic", "formulations", "involving", "heating", "procedures", "have", "been", "developed", ".", "In", "this", "study", ",", "we", "investigated", "whether", "short", "-", "term", "heating", "affects", "the", "anti", "-", "inflammatory", "properties", "of", "garlic", ".", "Fresh", "and", "heated", "raw", "garlic", "extracts", "(", "FRGE", "and", "HRGE", ")", "were", "prepared", "with", "incubation", "at", "25", "°", "C", "and", "95", "°", "C", ",", "respectively", ",", "for", "2h", ".", "Treatment", "with", "FRGE", "and", "HRGE", "significantly", "reduced", "the", "LPS", "-", "induced", "increase", "in", "the", "pro", "-", "inflammatory", "cytokine", "concentration", "(", "TNF", "-", "α", ",", "IL-1β", ",", "and", "IL-6", ")", "and", "NO", "through", "HO-1", "upregulation", "in", "RAW", "264.7", "macrophages", ".", "The", "anti", "-", "inflammatory", "effect", "was", "greater", "in", "FRGE", "than", "in", "HRGE", ".", "The", "allicin", "concentration", "was", "higher", "in", "FRGE", "than", "in", "HRGE", ".", "Allicin", "treatment", "showed", "reduced", "production", "of", "pro", "-", "inflammatory", "cytokines", "and", "NO", "and", "increased", "HO-1", "activity", ".", "The", "results", "show", "that", "the", "decrease", "in", "LPS", "-", "induced", "NO", "and", "pro", "-", "inflammatory", "cytokines", "in", "RAW", "264.7", "macrophages", "through", "HO-1", "induction", "was", "greater", "for", "FRGE", "compared", "with", "HRGE", ".", "Additionally", ",", "the", "results", "indicate", "that", "allicin", "is", "responsible", "for", "the", "anti", "-", "inflammatory", "effect", "of", "FRGE", ".", "Our", "results", "suggest", "a", "potential", "therapeutic", "use", "of", "allicin", "in", "the", "treatment", "of", "chronic", "inflammatory", "disease", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
methods is an umlsterm, capillary resistance is an umlsterm, measure is an umlsterm, vessel is an umlsterm, method is an umlsterm, procedure is an umlsterm, objective is an umlsterm, measurement is an umlsterm, petechiae is an umlsterm, capillary resistance is an umlsterm, persons is an umlsterm
DerHautarzt.60470276.eng.abstr_task0
Sentence: For over 100 years many different methods have been used to determine capillary resistance as a measure of small vessel fragility . There is still no firm agreement as to the most suitable method ; the procedure is not standardized and an objective system for measurement is lacking . We have developed a computerized system that makes it possible to count petechiae and determine their area without the results varying with different examiners . Although we tried to keep the conditions for our examinations constant , we found a wide individual spread . In spite of this , the capillary resistance of atopic subjects was significantly lower than that of healthy persons . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
For over 100 years many different methods have been used to determine capillary resistance as a measure of small vessel fragility . There is still no firm agreement as to the most suitable method ; the procedure is not standardized and an objective system for measurement is lacking . We have developed a computerized system that makes it possible to count petechiae and determine their area without the results varying with different examiners . Although we tried to keep the conditions for our examinations constant , we found a wide individual spread . In spite of this , the capillary resistance of atopic subjects was significantly lower than that of healthy persons .
[ "For", "over", "100", "years", "many", "different", "methods", "have", "been", "used", "to", "determine", "capillary", "resistance", "as", "a", "measure", "of", "small", "vessel", "fragility", ".", "There", "is", "still", "no", "firm", "agreement", "as", "to", "the", "most", "suitable", "method", ";", "the", "procedure", "is", "not", "standardized", "and", "an", "objective", "system", "for", "measurement", "is", "lacking", ".", "We", "have", "developed", "a", "computerized", "system", "that", "makes", "it", "possible", "to", "count", "petechiae", "and", "determine", "their", "area", "without", "the", "results", "varying", "with", "different", "examiners", ".", "Although", "we", "tried", "to", "keep", "the", "conditions", "for", "our", "examinations", "constant", ",", "we", "found", "a", "wide", "individual", "spread", ".", "In", "spite", "of", "this", ",", "the", "capillary", "resistance", "of", "atopic", "subjects", "was", "significantly", "lower", "than", "that", "of", "healthy", "persons", "." ]
[ "umlsterm" ]
methods is an umlsterm, capillary resistance is an umlsterm, measure is an umlsterm, vessel is an umlsterm, method is an umlsterm, procedure is an umlsterm, objective is an umlsterm, measurement is an umlsterm, petechiae is an umlsterm, capillary resistance is an umlsterm, persons is an umlsterm
DerHautarzt.60470276.eng.abstr_task1
Sentence: For over 100 years many different methods have been used to determine capillary resistance as a measure of small vessel fragility . There is still no firm agreement as to the most suitable method ; the procedure is not standardized and an objective system for measurement is lacking . We have developed a computerized system that makes it possible to count petechiae and determine their area without the results varying with different examiners . Although we tried to keep the conditions for our examinations constant , we found a wide individual spread . In spite of this , the capillary resistance of atopic subjects was significantly lower than that of healthy persons . Instructions: please typing these entity words according to sentence: methods, capillary resistance, measure, vessel, method, procedure, objective, measurement, petechiae, capillary resistance, persons Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
For over 100 years many different methods have been used to determine capillary resistance as a measure of small vessel fragility . There is still no firm agreement as to the most suitable method ; the procedure is not standardized and an objective system for measurement is lacking . We have developed a computerized system that makes it possible to count petechiae and determine their area without the results varying with different examiners . Although we tried to keep the conditions for our examinations constant , we found a wide individual spread . In spite of this , the capillary resistance of atopic subjects was significantly lower than that of healthy persons .
[ "For", "over", "100", "years", "many", "different", "methods", "have", "been", "used", "to", "determine", "capillary", "resistance", "as", "a", "measure", "of", "small", "vessel", "fragility", ".", "There", "is", "still", "no", "firm", "agreement", "as", "to", "the", "most", "suitable", "method", ";", "the", "procedure", "is", "not", "standardized", "and", "an", "objective", "system", "for", "measurement", "is", "lacking", ".", "We", "have", "developed", "a", "computerized", "system", "that", "makes", "it", "possible", "to", "count", "petechiae", "and", "determine", "their", "area", "without", "the", "results", "varying", "with", "different", "examiners", ".", "Although", "we", "tried", "to", "keep", "the", "conditions", "for", "our", "examinations", "constant", ",", "we", "found", "a", "wide", "individual", "spread", ".", "In", "spite", "of", "this", ",", "the", "capillary", "resistance", "of", "atopic", "subjects", "was", "significantly", "lower", "than", "that", "of", "healthy", "persons", "." ]
[ "umlsterm" ]
methods, capillary resistance, measure, vessel, method, procedure, objective, measurement, petechiae, capillary resistance, persons
DerHautarzt.60470276.eng.abstr_task2
Sentence: For over 100 years many different methods have been used to determine capillary resistance as a measure of small vessel fragility . There is still no firm agreement as to the most suitable method ; the procedure is not standardized and an objective system for measurement is lacking . We have developed a computerized system that makes it possible to count petechiae and determine their area without the results varying with different examiners . Although we tried to keep the conditions for our examinations constant , we found a wide individual spread . In spite of this , the capillary resistance of atopic subjects was significantly lower than that of healthy persons . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
For over 100 years many different methods have been used to determine capillary resistance as a measure of small vessel fragility . There is still no firm agreement as to the most suitable method ; the procedure is not standardized and an objective system for measurement is lacking . We have developed a computerized system that makes it possible to count petechiae and determine their area without the results varying with different examiners . Although we tried to keep the conditions for our examinations constant , we found a wide individual spread . In spite of this , the capillary resistance of atopic subjects was significantly lower than that of healthy persons .
[ "For", "over", "100", "years", "many", "different", "methods", "have", "been", "used", "to", "determine", "capillary", "resistance", "as", "a", "measure", "of", "small", "vessel", "fragility", ".", "There", "is", "still", "no", "firm", "agreement", "as", "to", "the", "most", "suitable", "method", ";", "the", "procedure", "is", "not", "standardized", "and", "an", "objective", "system", "for", "measurement", "is", "lacking", ".", "We", "have", "developed", "a", "computerized", "system", "that", "makes", "it", "possible", "to", "count", "petechiae", "and", "determine", "their", "area", "without", "the", "results", "varying", "with", "different", "examiners", ".", "Although", "we", "tried", "to", "keep", "the", "conditions", "for", "our", "examinations", "constant", ",", "we", "found", "a", "wide", "individual", "spread", ".", "In", "spite", "of", "this", ",", "the", "capillary", "resistance", "of", "atopic", "subjects", "was", "significantly", "lower", "than", "that", "of", "healthy", "persons", "." ]
[ "umlsterm" ]